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Abstract 
Historically, plant natural products and their derivatives have been invaluable 
sources of therapeutic agents to enhance human health and to treat disease. 
Angiogenesis is a complex and highly regulated process of generating new capillary 
networks from mature blood vessels. Failure to grow blood vessels has been reported to 
be associated with diseases including stroke, cardiovascular disorders and wound 
healing. However, pro-angiogenic drugs are less researched than anti-angiogenic drugs. 
Soybean is a source of nutrition and it contains a number of small metabolites that 
confer many beneficial health effects. Some of these metabolites have been found to 
modulate angiogenesis in animal tissue. Therefore, soybean-derived secondary 
metabolites and their potential therapeutic applications were the focus of this thesis. 
In chapter 3, a bioassay-directed discovery approach utilising size exclusion and 
liquid chromatography enabled the isolation and purification of a number of bioactive 
fractions from soybean xylem sap. Using high resolution accurate mass spectrometry 
and NMR, the structure of two pro-angiogenic molecules were elucidated and shown to 
be erylhro-guaiacylglycerol-8-0-4'-coniferyl alcohol (FKJ) , and threo-
guaiacylglycerol-8-0-4'-coniferyl alcohol (FK2). Independently sourced samples of 
FKI and FK2 exhibited comparable pro-angiogenic activity to the soybean molecules. 
The mode of action of these molecules was investigated in chapter 4 by studying 
their effect on endothelial cell proliferation, migration, tube formation and adhesion to 
the extracellular matrix (ECM) components, fibronectin and vitronectin. These 
compounds enhanced endothelial cell proliferation and endothelial cell tube formation 
on an artificial ECM, Matrigel, but did not affect endothelial cell migration or adhesion 
to fibronectin and vitronectin. It is proposed that FKJ and FK2 might enhance 
angiogenesis via potentiating the potent mitogen, bFGF, and/or its downstream 
signalling in endothelial cells. 
Flavonoids are implicated in positively influencing a number of human conditions 
and disease by their anti-tumour, anti-inflammatory and anti-oxidant activities. 
However, the bioactivities of these compounds have been mostly studied at high 
concentrations (> I µM) in in vitro and if! vivo experiments and at these concentrations 
are physiologically irrelevant. Chapter 5 examined the potential pro-angiogenic activity 
XI 
of a series of eighteen flavonoids at serum concentrations resulting from a normal diet. 
Seven flavonoids including genistein and naringenin showed significant promotion of 
angiogenesis at sub-µM concentrations while genistein inhibited angiogenesis at high 
µM concentrations. By examining structure-activity relationships we found that pro-
angiogenic molecules lack a C2-C3 double bond. 
ln conclusion, we have explored the potential of plant-derived secondary metabolites 
to promote angiogenesis in mammals. With novel bioactivity and a possible novel 
mechanism of action, FKJ and FK2 may have the potential to be developed for the 
therapeutic treatment of aberrant angiogenesis-related conditions such as cardiovascular 
disease, ischemia, stroke, chronic wounds and hypertension. Moreover, pro-angiogenic 
activity of dietary flavonoids, genistein and naringenin, at physiological concentrations 
has given some insight into the importance of measuring the bioactivity of natural-
derived compounds at their physiological concentrations. 
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Chapter 1 
General Introduction 
Chapter 1 
1.1. Natural products as a source for drug discovery 
Natural bioactive products are chemical substances derived from animals, plants or 
micro-organisms that exert a biological effect on other organisms. These molecules are 
mostly secondary metabolites and represent large and diverse classes of compounds 
including macrolides, terpenes, opiates, alkaloids and phenolic acids (Pezzuto 1997; 
Wase and Wright 2008; Li and Vederas 2009). 
Natural products and their derivatives have been an invaluable source of compounds 
for the pharmaceutical industry. Over 200 years ago (1804), the first pharmaceutically 
active pure compound, morphine, was isolated from a plant (Papaver somniferum) and 
commercially sold by Merck in 1827 (Hamilton and Baskett 2000) . This initiated an era 
in which drugs came to be identified and isolated from natural sources and later 
administrated in precise dosage. Later, the discovery of penicillin as an antibacterial 
filtrate, from the fungi , Penicillium rubens, by Fleming in 1928 and its development as 
a therapeutic by Florey, Chain and Heatley in 1940, revolutionised pharmaceutical 
research and led to the discovery of other new antibiotics (e.g., tetracyclin and 
erythromycin) (Li and Vederas 2009), anti-parasitics (e.g., avennecin), anti-malarials 
(e.g., quinine, artemisinin), lipid control agents (e.g., lovastatin and analogs), immune-
suppressants for organ transplants . (e.g., cyclosporine, rapamycins) and anti-cancer 
drugs (e.g., paclitaxel, irrinotecan) (Harvey 2008; Katiyar, Gupta et al. 2012) . 
A comprehensive review of pharmaceuticals developed over the last 30 years found 
that 50% of new drugs and 33% of small-molecule drugs were based on natural 
products or their derivatives (Newman and Cragg 2007; Newman 2008; Newman and 
Cragg 2012). With respect to anti-cancer and anti-infective agents this proportion is 
even hi&her and reaches 60% and· 75%, respectively (McChesney, Venkataraman et al. 
2007) . Indeed, natural products continue to provide a source of diverse and unique 
bioactive compounds that promote human health and contribute to the treatment of 
human disease (Kingston 2011) and in many ways the potential for discovering new 
compounds with pharmaceutical activity is largely unexplored (Njuguna, 
Masimirembwa et al. 2012). 
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1.2. Plant natural products: Botanical therapeutics 
Plants in particular have a long history as a source of therapeutics. The 
approximately 250,000 living plant species contain a much greater diversity ofbioactive 
compounds than any chemical library made by humans (Raskin, Ribnicky et al. 2002). 
Plant chemicals can be found in all parts of a plant, including the most accessible and 
abundant organs, the roots, shoots, seeds and leaves (Battle, Kyd et al. 2012). In the 
early 1900s, before the "Synthetic Era", 80% of all medicines were obtained directly 
from roots, barks and leaves (McChesney, Venkataraman et al. 2007). For example, the 
bark of the willow tree (Salix sp.) contains salicylic acid and was used by the ancient 
Greeks and native Americans to treat a wide range of ailments (Rishton 2008). 
Salicylic acid is the precursor of aspirin, a common over-the-counter analgesic that can 
also be used as an anti-inflammatory treatment and to inhibit platelet aggregation 
(Schafer 1995). More recently, the Pacific yew tree (Taxus brevifolia) (Wani, Taylor et 
al. 1971) and the French lilac (Galega ojjicianalis) have been the source of the active 
compounds in the drugs paclitaxel (Taxol®) and the biguanide class of antidiabetic, 
respectively, used in the treatment of breast cancer (Witters 2001). Other plant derived 
anticancer drugs include vincristine (Oncovin®) and vinblastine from the Madagascar 
periwinkle (Catharanthus roseus), and camptothecin from the Happy tree (Camptotheca 
acuminata) (Pezzuto 1997). It has been shown that some 25% of all modem active 
pharmaceutical compounds are from plant or plant derived natural products (Battle, Kyd 
et al. 2012). 
The success of plant compounds for therapeutic applications is remarkable but 
probably not unexpected given that plants produce a wide range of chemicals to deter 
herbivores ranging from small insects to large grazing mammals (Battle, Kyd et al. 
2012). ~oreover, plants and animals were derived from a common ancestor and have 
many common biosynthetic pathways, regulatory mechanisms, metabolites and 
signalling molecules (Kushiro, Nambara et al. 2003). Positive selection during 
evolution has resulted in plants producing a vast array of secondary metabolites to 
overcome environmental stress and to defend themselves against predation (Benderoth, 
Textor et al. 2006). These secondary metabolites are usually non-essential for growth 
and development but important for long term survival (Howitz and Sinclair 2008). 
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There are many examples of functional conservation between secondary metabolites 
in plants and animals. The carotenoids, lutein (Fig. 1.lA) and zeaxanthin (Fig. 1.lB) 
(Mourao, Santana et al. 2009), function in animals to protect the eye from harmful short 
wave radiation and in plants to protect their photosynthetic machinery from oxidative 
damage (Demmig-Adams and Adams 2002). These pigments may have evolved from a 
common biochemical ancestor that played a role in cellular photochemistry (Demmig-
Adams and Adams 2002). An additional example of chemical structure conservation is 
the indole ring found in the regulatory systems of both animals, as melatonin (Fig. 1.1 C) 
(Mourao, Santana et al. 2009) and plants, as auxin (Fig. 1. ID) (Pandi-Perumal, 
Srinivasan et al. 2006). Auxin is a plant hormone and essential for plant growth. In 
plants it is involved in processes such as light and gravity responses in root and shoot 
architecture and vascular development. In animals, auxin has been found to prevent 
carcinogen induced damage by preventing the down-regulation of anti-oxidant enzymes 
and the fragmentation of DNA (Mourao, Santana et al. 2009). Melatonin is an animal 
hormone and is part of apoptotic (programmed cell death) signalling pathways as an 
anti-oxidant compound. Melatonin has also been found to possess bioactivity in plants 
by preventing oxidative damage (Pandi-Perumal, Srinivasan et al. 2006). 
1.3. General strategies for natural product drug discovery 
Historically, drugs have been developed from traditional or folk medicines (Holt and 
Chandra 2002). These may consist of fresh or dry plant material or even simple 
aqueous or alcoholic extracts. This approach of building on traditional or folk 
knowledg_e has enhanced the rate of success in drug discovery in addition to saving time 
and money (Katiyar, Gupta et al. 2012). 
Howeyer, in the absence of ·guidance from traditional practices the key to a 
successful drug discovery lies in the researchers' ability to identify bioactivity (Piggott 
and Karuso 2004; Littleton, Rogers et al. 2005; Potterat and Hamburger 2006; 
Rollinger, Langer et al. 2006). During recent years, many specific and selective 
bioassays have been developed by which natural products can be evaluated quickly and 
economically (McChesney, Venkataraman et al. 2007). 
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Figure 1.1. Examples of the structurally related secondary metabolites between 
plants and animals. 
Lutein (A), zeaxanthin (B), melatonin (C), auxin (D). 
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The most efficient method for discovering drugs with novel chemical structure with 
possibly unique mechanisms of action is bioactivity-guided fractionation (Pezzuto 1997; 
Kingston 2011) . Although in recent years major improvements have been made to 
improve bioassays it is still necessary to subject extracts to some form of fractionation 
as crude extracts contain a huge complexity of compounds which may have opposing 
effects. For example, a crude extract may contain chemicals that inhibit and others that 
promote particular processes. In addition, there are the added complexities of chemical 
stability and solubility (McChesney, Venkataraman et al. 2007; Kingston 2011). 
Bioassays are used to identify active fractions following one or more orthogonal 
chromatographic separations targeting properties such as size, solubility, 
hydrophobicity and ionisation at different pH (Bickerton, Paolini et al. 2012). In a 
complex mixture, the early passes through the various chromatographic steps will yield 
active fractions that still represent mixtures of compounds. Ultimately, the purification 
process must be taken to the point where the active fraction only contains one bioactive 
compound (Fig. 1.2) (Cordell , Beecher et al. 1991; Pezzuto 1997; Koehn and Carter 
2005; Li and Vederas 2009). 
The presence of more than one component will create ambiguity as to the 
identification of the bioactive component. Thus chemical purity must be monitored by 
additional analyses (e.g., HPLC, GC/MS or LC/MS) until the analyst is certain that 
structural elucidation can be carried out on the bioactive molecule alone (Butler 2004; 
Koehn and Carter 2005). The mode of action of the active compound can be studied at 
this stage but without knowing the structure, it will be a limited investigation. Today, 
de nova structure elucidation is largely based on mass spectrometry (MS) and high field 
nuclear magnetic resonance (NMR) (Butler 2004; Li and Vederas 2009; Kingston 2011) 
with the structure finally being confirmed by synthesis and spectroscopic comparison 
with the isolated material. Then, the mode of action of the active compound can be 
studied comprehensively (Fig. 1.2). 
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In 1997, Lipinski et al. , formulated Lipinski's Rule of Five, also known as Pfizer's 
Rule of Five or the Rule of Five (ROS), which represented an evaluation of drug-
likeness based on properties that would make the compound a likely orally active drug 
in humans. The rules encompass a set of physico-chemical properties that influence the 
compound' s absorption, distribution, metabolism, and excretion which are important for 
a drug's pharmacokinetics in the human body. The ROS represents a strategy for 
identifying compounds that will have a greater probability of successfully passing 
clinical trials and getting to market (Lipinski 2004; Leeson and Springthorpe 2007). 
The rules require that a compound should meet at least three of the four following 
specifications: 
1) number of hydrogen bond donors (HBDs; nitrogen or oxygen atoms with one or 
more hydrogen atoms) ::; 5. 
2) number of hydrogen bond acceptors (HBAs; nitrogen or oxygen atoms)::, 10. 
3) molecular weight (M,) ::; 500 daltons. 
4) octanol-water partition coefficient log P ::; 5. 
Since the formulation of these rules a number of refinements have been proposed, 
including a reduction of molecular weight (::, 300 Da), increasea hydrophobicity (log P 
::; 3), limits on the number of rotatable bonds (::, 3) and a molecular polar surface area 
(PSA) of::; 140 A2. More recently, Bickerton et al. , (2012) proposed an empirical 
measure of drug-likeness called the quantitative estimate of drug-likeness or QED 
which weights the chosen molecular descriptors (M,, octanol-water partition coefficient, 
number of HBDs, number of HBAs, PSA, number of rotatable bonds, number of 
aromatic rings and absence of unwanted functionalities - see (Brenk, Schipani et al. 
2008) to derive a continuum of QED values ranging from zero, where all properties are 
unfavour~ble, to one, where all the chosen properties are favourable (Bickerton, Paolini 
et al. 2012). Despite the increased sophistication of these measures of drug-likeness, it 
nevertheless remains the case that biological activity must be ultimately determined by 
some sort of biological assay. 
Once bioactive chemical entities have been identified, it is then open to drug 
designers to modify the structure to improve drug targeting, tissue distribution and 
solubility to enhance the therapeutic efficacy as drug candidates for clinical trials. An 
example of this process is Taxol that although being an effective therapeutic in its own 
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right has given rise to a number of synthetic derivatives including taxotere, ortataxel 
and docetaxel (Itokawa, Morris-Natschke et al. 2008). 
1.4. Flavonoids: Bioactive secondary metabolites from plants 
Flavonoids are a large group of plant-specific secondary metabolites. More than 
8000 flavonoids have been described (Harbome and Williams 2000; Ververidis, Trantas 
et al. 2007) and categorised into flavonols , flavones, flavanones, isoflavones, catechins 
and anthocyanidins (Ross and Kasum 2002). These compounds occur widely in fruits , 
vegetables, grains, derived beverages (tea, coffee, wine, and beer) and processed foods 
(syrups, jams, etc.) mainly as flavonoid glycosides (Passamonti, Terdoslavich et al. 
2009). 
Flavonoids are polyphenolic compounds characterised by a common Cl5 
phenylchromane core, composed of a benzo-y-pyrone (C6-C3-C6) backbone (Fig. 1.3). 
Various combinations of multiple hydroxyl, methoxyl and O-glycos ide substituents on 
the basic benzo-y-pyrone can be recruited to form the large number of identified 
flavonoids (Table 1.1 ). In the case of the isoflavones, the B ring is connected to the C 
ring at C3 instead ofC2 (Fig. 1.3; Table 1.1). 
In plants, flavonoids have roles in signalling, fertility , defence, as antioxidants, 
pigments and in nodule formation. They are also known to influence plant development 
by interactions with the cytokinin and auxin families of plant growth substances 
(Winkel-Shirley 2002; Wasson, Ramsay et al. 2009; Buer, Imin et al. 2010). 
The consumption of flavonoids has been associated with a number of health benefits 
in humans including a decreased risk of heart and cardiovascular disease, improvements 
of menopausal symptoms and bone resorption (Formica and Regelson 1995; Somekawa, 
Chiguchi et al. 200 I ; Hooper, Kroon et al. 2008). Flavonoids are also known to inhibit 
the proliferation of cancer cells, induce apoptosis, decrease tumour invasiveness, 
activate the immune response against cancer, modulate the inflammatory cascade and 
inhibit angiogenesis as part of the treatment strategies for breast, prostate, and colon 
cancers (Table 1.2) (Neuhauser 2004; Kale, Gawande et al. 2008). 
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Figure 1.3. Chemical structure of benzo-y-pyrone backbone. 
Flavonoids can be subdivided according to the presence of an oxy group at position 4, a double bond 
between carbons 2 and 3, or a hydroxyl group in position 3 of the C ring. The on ly exception to this 
skeleton is the iso flavones where the B ring is connected via the carbon 3 of the C ring instead of carbon 
2 as shown. The hydroxyl groups may a lso be substituted by a methyl group to yield methoxyls, or a 
variety of mono- or disaccharides to yield the corresponding glycosides. 
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Table 1.1. Flavonoids subclasses with some representative compounds and typical 
food sources. 
Subclass 
Flavanols 
i' °" ( ~·/ 
,o,cxo---- ...... •· .___;;::.J, 
, '::::: 2 · R, 
II I 
'-._h ........... l ....... 
• . °" J.. 
' (1~.,..,0" 
,o.___,~o'-, ... •·-..__y!,,, 
l.A.) .°" 
J.. 
Anthocranidins 
(t._,,o, 
,o.___ CXo' ) ____;l.___ 
1 '::::: l Rz 
l_,.,, ), L . °" 
Flavanones 
!' (::::::-.4·/'½ 
•(Xo'-1. •'-..__y! 
. /' 
Typical rich food 
Name R1 R2 sources (Beecher 
2003) 
( + )-Catechin OH H 
( + )-Gallocatechin OH OH 
Teas, red grapes and red 
wines (-)-Epicatechin OH H 
(-)-Epiga llocatechin OH OH 
Pelargonidin H H 
Cyanidin OH H 
Delehinidin OH OH Red, purple and blue 
Peonidin OCH3 H be1Ties 
Petunidin OH OCH3 
Malvidin OCH3 OCH3 
Naringenin* H OH 
Eriodictyol* OH OH Citrus fru it and peels 
Hesperetin* OH OCH3 
LI These compounds are 5,7-dihydroxy-flavanones 
Flavones 
,. ' c"~,/ 
II l 
"°'·(X°)("-/ ,,, 
Ari.gen in 
Luteolin 
Tan.s.eretin • 
Acacetin 
Chrysin 
OH H 
OH OH 
OCH3 H Green leafy sp ices, e.g. , 
OCH1 H 
Parsley 
L LI 
• Tangeretin has OCH3 at 5, 6, 7 and 8 positions 
lsoflavones 
Genestein OH OH ,o.___/~r"o'r1 
lA_.,,,,'Y') 
Ly ~ •. 
' '""" ~ ' " 'm LI Soybeans, soy derived r H 
________ tOods and legumes 
Biochanin A OCH3 H 
- -Flavonols 
H H 
OH H 
--
'· Kaempferol 
r.··J:.::::-.4,........0H _Q~u_e_r_ce_t_i.n _______ _
H 
' '.::::: '-../-........::?'"'½ 
OH OH 
"° cxo \,I .,; l Isorhamnetin OCH., (,.,, J _M~yr._ic_e_ti_n ____________ _ 
1 , ' 00 _:G:.:a:..:l=an'"g'"1"'n'-------------------------
°" Y NB: Galangin has no substituents on tbe Bring 
Flavonoids can be substituted with one or more sugars at a number of different sites in addition to C7. 
Adapted from (Passamonti, Terdoslavich et al. 2009). 
11 
Chapter 1 
1.5. Legumes as source of bioactive compounds 
1.5.1. Phytoestrogens 
Legumes are important dietary components, serving as a source of starch, fibre, 
protein, lipid and minerals. In addition to their nutritive value, legumes contain 
significant quantities of phenolic and polyphenolic compounds such as phenolic acids, 
flavonoids and li gnans (Sosulski and Dabrowski 1984; Lin and Lai 2006). The legume 
attracting much attention recently is the soybean which is a ri ch source of 
phytoestrogens including isoflavones and lignans (Setchell 1998; Tham, Gardner et al. 
1998). These two classes of phenolic compounds are of relevance to thi s thesis and 
their bioactivity in humans will be further discussed in chapters 4 and 5. 
Twelve isoflavones have been isolated from soybean including aglycones (genistein, 
daidzein and glycitine) (Table 1.1), glucosides (genistin, daidzin, glycitin), malonyl 
glucosides (malonyl daidzin, manolyl genistein, malonyl glycitin), and acetyl glucosides 
(acetyl daidzin, acetyl genistein, acetyl glycitin) (Wang and Murphy I 994; Wang and 
Murphy 1994). Six lignans, namely secoisolari ciresinol, matairesinol, syringaresinol, 
lariciresinol, isolariciresinol, and pinoresinol (Fig. 4.17), have- also been identified in 
soybean (Penalvo, Heinonen et al. 2004). 
Phytoestrogens have similar chemical structures (2-phenylnaphthalene-type) to 
oestrogens and have been found to bind to oestrogen receptors (ERP) (Kuiper, Lemmen 
et al. 1998). Phytoestrogens are associated with a number of health benefits in humans 
including reducing levels of chronic diseases such as coronary heart disease and 
atherosclerosis through the lowering of serum cholesterol and through their anti-
oxidative _effects. They are also known to have anti-viral , anti-angiogenic, anti-cancer 
(breast, bowel and prostate) and anti-osteoporosis effects as well as serving to reduce 
menopausal symptoms (Mazur, Duke et al. 1998; Tham, Gardner et al. 1998; Boue, 
Wiese et al. 2003; Cornwell, Cohick et al. 2004). 
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Table 1.2. Clinical effects of flavonoids on animal cells. 
Clinical effects 
Anti-atherosclerotic 
Anti-inflammatory 
Anti-tumour 
Anti-thrombogenic 
Anti-osteoporotic 
Mechanism of action 
Flavonoids have anti-oxidative properties and protect low-density 
lipoprote in (LDL) from oxygen radicals, which injure the endothelial wall 
and lower atherosclerotic changes and protect against coronary heart di sease 
(Dewhalley, Rankin et al. 1990; Hertog, Feskens et al. 1993). 
Inhibit the lipoxygenase, cyclooxygenase and 5-lipoxygenase pathways 
(Moroney, Alcaraz et al. 1988; Ferrandiz, Nair et al. 1990). 
Inhibiting eicosanoid biosynthesis (Laughton, Evans et al. 199 1; Formica 
and Regelson 1995). 
Inhibit neutrophi l degranulation (Hou lt, Moroney et al. 1994; Tordera, 
Ferrandiz et al. 1994). 
Inhibition of cell prol iferation and angiogenesis (Fotsis, Pepper et al. 1997) 
by inhibition of protein kinases (O ikawa, Shimamura et al. 1992). 
Inhibition of platelet aggregation (Osman, Maalej et al. 1998). 
Inhibition of the activity ofcyclooxygenase and lipoxygenase pathways 
(Alcaraz and Ferrandiz 1987). 
Prevention of osteoporosis (Hegarty, May et al. 2000). 
Adapted from (Nijve ldt, van Nood et al. 200 I). 
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1.5.2. Nodulation factors 
Part of the agricultural importance of legumes derives from their ability to recruit the 
Rhizobium family of bacteria into symbiotic nodules for the purpose of fixing 
atmospheric nitrogen. The signalling cascade that controls this process includes the 
rhizobial secretion of a group of short lipo-chitooligosaccharides (LCOs, also known as 
nodulation or Nod factors) in response to the legume secreting flavonoids into the 
rhizosphere. The LCOs enable the rhizobia to fac ilitate many of the plant's early 
responses in nodule organogenesis, allowing them to penetrate the root hair at the start 
of their migration into the root where they form the nitrogen fixing nodules (Fig. 1 .4A) 
(Lerouge, Roche et al. 1990; Cullimore, Ranjeva et al. 2001 ). 
These Nod factors have been found to be active in modulating angiogenesis in in 
vitro and in vivo mammalian systems (Patent AU2006/000432) (Djordjevic, Bezos et al. 
2013) (Fig. 1 .4B and 1 .4C). This then led to the idea that further angiogenic modulating 
compounds may be present in soybean. 
1.5.3. Other angiogenesis modulating molecules from soybeans 
Preliminary studies by the Parish and Djordjevic laboratories in the Australian 
Research Council Centre for Integrative Legume Research (CILR) showed, through the 
use of an in vitro angiogenesis bioassay, that soybean xylem sap contained a number of 
small molecules with either pro- or anti-angiogenic activity in animal cells (Du Fall 
2009). These pro- and anti-angiogenic activities were found in the low molecular 
weight (<1000 Da) fractions from size exclusion chromatography of the soybean sap, 
however, insufficient material was isolated for any structural elucidation to be 
attempted: My thesis builds upon these initial findings. 
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Figure 1.4. Chemical structures of angiogenesis modulating Nod factors. 
Generic structure of Nod factors (chitin parameter backbone), n= l-3, R, =H, Me, R2= Cl 6:2, C16:3, 
CI 8-C26(w-l)OH, C l 8: I, C 18:3, C 18:4, C20:3, C20:4, R3_4_5= Ac(O-6), Cb, Cb(O-3), Cb(O-4), Cb(O-6), 
H, R,;= S, H, Ac, AcFuc, MeFuc, AcMeFuc, R7= H, glycerol (A), Anti-angiogenic compound (m-
Benzamide, Cl8:l, Fucosyl) (B), Pro-angiogenic compound (Phenyl acetyl, Fucosyl) (C). Me, methyl; 
Ac, acetyl, Fuc, fucosyl; Cb, carbamoyl; S; sulphate ester. Reproduced from (Denarie, Debelle et al. 
1996). 
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1.6. Biology of angiogenesis 
Blood vessels transport blood into growing and mature tissues, providing nutrients, 
oxygen, hormone delivery and the removal of waste materials (Folkman, Bach et al. 
1971; Clapp, Thebault et al. 2009). This vascular network is essential for the growth of 
both healthy and neoplastic tissues (Papetti and Herman 2002) and the process by 
which mature blood vessels are remodelled to form new capillary networks is known as 
angiogenesis. In simple terms, angiogenesis involves the proliferation, migration and 
maturation of endothelial cell s (Fig. 1.5) (Griffioen and Molema 2000). 
In adult tissues, angiogenesis is normally under very tight regulation (Ejaz and Lim 
2005) and is inhibited, except for processes including the female reproductive cycle, 
wound healing, placentation and in fracture healing (Folkman 2007; Samaranayake, 
Maatta et al. 2010; Chung and Ferrara 2011). Angiogenesis is also associated with 
various disease and pathological conditions including inflammation, infection, 
retinopathies, atherosclerosis, peptic ulcers, rheumatoid arthritis and tumourogenesis 
(Carmeliet 2003; Folkman 2007). However, insufficient angiogenesis leads to various 
ischemic conditions such as ischemic heart disease and peripheral artery disease 
(Tammela, Enholm et al. 2005) as well as hypertension (Sane, Anton et al. 2004). 
As illustrated in Figure 1.5, in a healthy adult body (non-angiogenic state), 
endothelial cells have long half-lives and are protected by low level stimulation from 
angiogenic factors including vascular endothelial growth factor (VEGF), angiopoietin-1 
(Ang-1) and fibroblast growth factors (FGFs), to help maintain blood vessel integrity 
(Carmeliet and Jain 2011). Angiogenesis is initiated when vessels receive an 
angiogenic signal from growth factors such as VEGF, Ang-2, basic fibroblast growth 
factor (bF_GF/FGF-2) or platelet-derived growth factor (PDGF) induced by angiogenic 
stimuli (hypoxia, inflammation or tumour cells) (Collinson and Donnelly 2004; Pandya, 
Dhalla et al. 2006). In the case of Ang-2, it wi ll compete with Ang-1 in binding to 
endothelial Tie-2 receptors on the endothelial cells, a process which results in the 
release of matrix metalloproteinases (MMPs) into the extracellular matrix (ECM). In 
tumourogenesis, MMPs are also secreted from tumour cells along with VEGF, 
activating endothelial cells and facilitating the formation of endothelial cell sprouts 
which can then develop into new capi llaries (Carmeliet and Jain 20 1 1 ). 
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MMPs also mobilise pro-angiogenic proteins from the stroma by proteolytic 
degradation of the basement membrane, as well as removing local angiogenesis 
inhibitors by, for example, cleaving endostatin from collagen XVIII in the vessel wall 
and angiostatin from circulating plasminogen (Folkman 2007). Integrins and cadherins 
are cell adhesion molecules which facilitate cell-ECM and cell-cell binding, 
respectively, and are required to maintain the viability of the endothelial cells and their 
responsiveness towards regulatory signals. In angiogenesis, certain pro-angiogenic 
proteins can up-regulate endothelial integrins and in response to induced integrin 
signalling, endothelial cells migrate into the ECM (Liekens, De Clercq et al. 2001; 
Otrock, Mahfouz et al. 2007). In the meantime, the proteolytic action of MMPs on the 
ECM liberates more angiogenic molecules, such as FGF, Ang-2 and VEGF, which bind 
to the glycosaminoglycan heparan sulphate in the ECM. To form a tube from the 
proliferating endothelial cells, one cell , known as the tip cell, is selected via signalling 
pathways induced by receptors such as VEGF receptors and neuropilins (NRPs) (Cross 
and Claesson-Welsh 2001; Carmeliet and Jain 2011). Not all new endothelial cells are 
derived from proliferating endothelial cells at the site of angiogenesis as some will be 
provided by bone marrow endothelial cells. In the later stages of angiogenesis, smooth 
muscle cell pericyte and fibroblast recruitment leads to the formation of mature thick 
walled vessels (Fig. 1.5) (Folkman 2007). 
As mentioned above, some growth factors are delivered directly by tumour cells to 
the local endothelium. However, it has also been found that some of the angiogenesis 
regulators including both pro- and anti-angiogenic proteins, are scavenged by platelets 
and stored in different sets of alpha granules (Fig. 1.5) (Folkman 2007). 
1. 7. Regulation of angiogenesis 
Angiogenesis is a complex and highly controlled process of interaction of various 
endogenous angiogenic stimulators and inhibitors (Table 1.3). Growth factors and 
cytokine-related peptide signalling molecules are the key regulators of angiogenesis and 
are synthesised by both normal and malignant cells. VEGFs (Ferrara 2002) and FGFs 
are the best characterised of the pro-angiogenic regulators (Turner and Grose 20 IO; 
Tenhagen, van Diest et al. 2012). 
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Figure 1.5. Overview of the molecular mechanisms and key cellular steps involved 
in angiogenesis. 
The process of fonnation of new capillaries from pre-existing vessels involves the major cellular steps 
of proliferation, migration and maturation of endothelial cells (EC). In response to angiogenic stimuli, 
induced angiogenic factors interact with receptors on endothelial ce lls and trigger the fonnation of new 
blood vesse ls. Adapted from (Folkman 2007). 
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1.7.1. Vascular endothelial growth factor (VEGF) 
The VEGF family consist of seven members, VEGF-A, VEGF-B, VEGF-C, VEGF-
D, VEGF-E, VEGF-F and placenta growth factor (PIGF) 1 and 2, which selectively 
bind to 3 types of tyrosine kinase receptors, VEGFR-1 (Flt-I), VEGFR-2 (Flk-1 or 
KDR) and VEGFR-3 (Flt-4) (Hoeben, Landuyt et al. 2004; Roy, Bhardwaj et al. 2006). 
Neuropilins (semaphoring receptors) , such as NRP-1 and NRP-2 are VEGF co-receptors 
and enhance the activity of VEGFR-2 but also are involved in axonal guidance during 
neural development (Chen, Chedotal et al. 1997; Tammela, Enholm et al. 2005; Roy, 
Bhardwaj et al. 2006). VEGF-A (also known as VEGF) has been identified as the main 
component that stimulates angiogenesis in health and disease (embryogenesis, wound 
healing and during tumour growth) by binding to VEGFR-1 and VEGFR-2 on 
endothelial cells (Roy, Bhardwaj et al. 2006; Carmeliet and Jain 2011) whereas VEGF-
C and VEGF-D can also induce lymphangiogenesis by binding to VEGFR-3 on 
lymphatic endothelium (Fig. 1.6) (Ferrara 2001; Tammela, Enholm et al. 2005; Alitalo 
2011). 
In humans, VEGF is a secreted 34-42 kDa glycoprotein with seven isoforms, VEGF-
A,21, VEGF-A145, VEGF-A14s, VEGF-A16s (most effective stimulator of angiogenesis), 
VEGF-A 183, VEGF-A1s9 and VEGF-A206 as a result of alternate splicing of mRNA from 
a single, 8-exon, VEGF gene (Ferrara 2001; Ferrara 2004; Hoeben, Landuyt et al. 2004; 
Nowak, Woolard et al. 2008). 
In angiogenesis, the binding of VEGF to its receptors increases the permeability of 
the endothelium including the formation of intercellular gaps (Bates, Hillman et al. 
2002). VEGF also induces proliferation, sprouting, migration and tube formation of 
endothelial cells (Ferrara, Gerber et al. 2003; Otrock, Mahfouz et al. 2007). The main 
signalling pathways involved in VEGF-mediated angiogenesis are phosphoinositide 3-
kinase/anti-apoptotic kinase (PI3K/Akt), mitogen activated protein kinase (MAPK) and 
protein kinase C (PKC) (Cross and Claesson-Welsh 2001; Roy, Bhardwaj et al. 2006; 
Otrock, Mahfouz et al. 2007). Several VEGF blockers have been approved for anti-
angiogenic therapy in cancer and eye disease (Jain, Duda et al. 2006; Ferrara 2009). 
The US Food and Drug Administration (FDA) has approved the use of the VEGF-
antibody bevacizumab (Avastin) for metastatic colorectal cancer, metastatic non-small 
cell lung cancer, metastatic breast cancer and metastatic renal cell carcinoma (RCC). 
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YEGFR-,1 (Flt-I), VEGFR-2 (KOR Flk-1), and YEGFR-3 (Flt-4) are signalling tyrosine kinase 
receptors with seven immunoglobuLin-like structures in the extracellular domain, a single trans-membrane 
region, and a consensus tyrosine kinase domain interrupted by a kinase insert domain. Tbe neuropilin-1 
and neuropilin-2 receptors (NRP-1 ,2) do not have kinase activity but enhanceVEGFR-2 signalling. The 
heparan sulphate proteoglycan (HSPG) not on ly enhances VEG FR binding but also serves as a reserve of 
VEGF. YEGF-A, VEGF-8 and PIGF-1 ,2 bind VEGFR-1 and VEGFR-2 on the blood vascular 
endothelium and YEGF-C and VEGF-D primarily bind VEGFR-3 on lymphatic endothelium inducing 
angiogenesis and lymphangiogenesis, respectively. Adapted from (Hoeben, Landuyt et al. 2004; 
Tammela, Enholm et al. 2005). 
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Also, sorafenib (Nexavar), sunitinib (Sutent) and pazopanib (Votrient), which block 
the VEGF signalling pathway, have been approved for metastatic RCC (Carmeliet and 
Jain 2011). Moreover, angiogenic therapeutic strategies using VEGF might be 
beneficial and may lead to increased neovascularization in some cardiovascular 
disorders (Khurana, Simons et al. 2005). 
However, the clinical use ofVEGF inhibitors in cancer patients has been shown to be 
challenging. For example, the use of bevacizumab is approved only when combined 
with cytotoxic or cytokine therapy (Carmeliet and Jain 2011). Also, many patients with 
metastatic disease may show rejection or resistance to VEGF inhibitors (Bergers and 
Hanahan 2008). Therefoi;e, more comprehensive studies need to be conducted in order 
to achieve promising results in this therapeutic area. 
1.7.2. Fibroblast growth factors (FGFs) 
The fibroblast growth factors (FGFs) are a family of 23 secreted and cell surface 
proteins with a size range of 17 to 34 kDa (Ornitz and Itoh 200 I; Javerzat, Auguste et 
al. 2002). FGFs have a high affinity for the glycosaminoglycan, heparan sulphate, 
carried by glycoproteins called heparan sulphate proteoglycan {HSPG) located on the 
surface of certain cell types, especially endothelial cell s, as well as in the ECM. This 
association assists the binding of FGFs to four highly conserved transmembrane bound 
tyrosine kinase FGF receptors (FGFR). This results in a phosphorylation cascade of 
target proteins and activation of several parallel signalling pathways, including PLCy, 
ST A Ts, AKT and MAPK, which alters the pattern of gene expression with resultant 
stimulation of angiogenesis (Fig. 1.7) (Powers, McLeskey et al. 2000; Cross and 
Claesson-Welsh 2001; Turner and Grose 2010; Tenhagen, van Diest et al. 2012). 
FGFs are involved, firstly, in the early invasive phase of angiogenesis during 
embryonic development, tissue repair, wound healing and tumour angiogenesis, which 
involve degradation of basal lamina, migration and cell proliferation. They are also 
involved in the later phase of vessel maturation, regulating endothelial cell 
morphogenesis and vessel maturation (Eswarakumar, Lax et al. 2005; Presta, Dell'Era et 
al. 2005). 
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Table. 1.3. Endogenous angiogenesis stimulators and inhibitors. Adapted from 
(Li, Li et al. 2012). 
Stimulators Inhibitors 
13-Estradiol 2-Methoxyestrad iol 
Adenosine Angiopoietin-2 (in the absence of VEGF) 
Adrenomedullin Angiostatin (Plasmin fragment) 
Aminopeptidase N/CD 13 Anti-angiogenic anti-thrombin Ill 
Angiogenin Arresten (fragment of collagen IV al chain) 
Angiopoietin- 1 (Ang- I) Canstatin (fra.gment of the a2 chain oftvoe IV collagen) 
Endogenous opioids (Endomorphin-1, endomorphin-2 and Chondromodulin I deltorphin I) 
Endothelial cell stimulating angiogenesis factor (ESAF) Connective tissue growth factor (CTGF) 
Erythropoietin (EPO) Decorin 
Fibroblast growth factors (FGFs) ; 23 members Endorepellin (Endorepellin , a C-terminal fragment of the 
vascular basement membrane proteoglycan perlecan) 
Follistatin Endostatin ( collagen XVIII fragment) 
Granulocyte-colony-stimulating factor (G-CSF) Fibronectin fragment 
Heme oxygenase (HO- I) Histidine-rich gJvcoorotein (HRR domain) 
Heparanase lnterferon-a,13 ,v (JFN-a,13 ,v) 
Hepatocyte growth factor (HGF) Interferon-inducible orotein- 10 (JP-I 0) 
Hepatocyte growth factor/scatter factor (HGF/SF) lnterleukin-4,- 10, - 12,-18 (IL-4, IL-10, IL-1 2, IL-18) 
Histidine-rich glycoprotein (HRG) Kringle 5 
Hyaluronan oligosaccharides Maspin 
Hypoxia-induced factor-I (HIF-1) Metastatin 
lnterleukin-3, -8 (IL-3 , IL-8) METH-I 
Jntermedin METH-2 
Leptin Osteopontin cleavage product 
Macrophage chemoattractant protein- I (MCP-1) PEX 
Matrix metalloproteases (MMPs) Pigment eoithelium derived factor (PEDF) 
Midkine , Plasminogen activator inhibitor- I (P Al- I) 
Neuregulin Platelet factor-4 
Nitric oxide synthase (NOS) Prolactin ( 16 kDa fragment) 
Osteogenic protein- I Proliferin-related protein 
Oxytocin (OT) Prothrombin krine.le 2 
Placental growth factor (P IGF) Restin 
Platelet-derived endothelial-cell growth factor (PD-ECGF) Soluble fros- like tvrosine kinase-I (S-Flt-1 ) 
Platelet-derived growth factor (PDGF) SP ARC cleavage product 
Pleiotrophin Tetrahydrocorti sol-S 
Progranulin Thrombospondin-1,2 (TSP- I, TSP-2) 
Proliferin Tissue inhibitors of matrix metallooroteinases (TIMPs) 
Stromal-derived factor- I a (SDF-1 a) Transforming growth factor-I:\ (TGF-13) (activated form) 
Thyroid hormone Troponin-1 
Transforming growth factor-a (TGF-a) Tumstatin (fragment of the a3 chain oftvoe IV collagen) 
Transforming growth factor-13 (TGF-13) Vascular endothelial growth inhibitor (VEG !) 
Tumour necrosis factor-a (TNF-a) Vasostatin 
Urotensin-11 (U-11) 
Vascular endothelial growth factors (VEGFs); 7 members 
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Basic FGF (bFGF, FGF-2) is the most potent angiogenesis inducer in the FGF family 
(Ferrara, Chen et al. 1998; Bouis, Kusumanto et al. 2006). It is ubiquitously expressed 
in cells of mesodermal and neuroectodermal origin at low and high concentrations, 
respectively, as well as in a variety of tumour cells (Seghezzi, Patel et al. 1998). FGF-2 
is a potent mitogen for different cell types, including vascular endothelial cells, 
fibroblasts , smooth muscle cells and glial cells (Nugent and Iozzo 2000; Liekens, De 
Clercq et al. 2001) and has been reported to induce proliferation, migration, proteinase 
production, and expression of specific integrins (e.g. , aV~3) on cultured endothelial 
cells (Moscatelli , Presta et al. 1986; Klein, Bikfalvi et al. 1996; Presta, Dell'Era et al. 
2005). 
It has been shown that increased levels of bFGF expression as measured in the serum 
(approximately 10%) (Folkman 1993) is associated with progression or tumour 
recurrence of lung, prostate, breast, bladder and esophageal cancers (Faridi, Rudlowski 
et al. 2002; Polnaszek, Kwabi-Addo et al. 2003; Barclay, Li et al. 2005; Shariat, 
Youssef et al. 2010). Also, bFGF has been tested in human trials for neovascularisation 
fo r conditions such as myocardial ischemia and skeletal muscle ischemia in order to 
induce cardiac repair (Zhao, Zhao et al. 2011). However, it failed in a phase II clinical 
trial to show significant efficacy in treating coronary artery disease but in another trial it 
showed a significant therapeutic effect in treating peripheral artery disease, although the 
benefit was not regarded as satisfactory at the dose tested (Aviles, Annex et al. 2003; 
Zhao, Zhao et al. 20 11 ). 
Based on the current knowledge of the bFGF and FGF-FGFR signalling pathways, 
FGF-2 may prove to be a valuable marker for cancer progression and a target for anti-
angiogenic therapies (Turner and Grose 2010) as well as therapeutic angiogenesis (pro-
angiogene~is) (Aviles, Annex et al. 2003). 
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Figure 1.7. FGF-FGFR structure and downstream signalling. 
The extracellular domain of FGFR consists of three ligand binding (lg) sites. Binding of FGF is 
stabilised by the heparan sulphate proteoglycan (HSPG) chain. Once, FGF-FGFR binding occurs, the 
receptor dimerises and the kinase domains transphospborylate each other. This leads to the docking of 
adaptor proteins and activation of four key downstream pathways: PLCy, ST A Ts, AKT and MAPK. 
FGF, fibroblast growth factor; HSPG, heparan sulphate proteoglycans; TK, tyrosine kinase domain; 
STAT, signal transducer and activator of transcription; FRS2a, fibroblast growth factor receptor substrate 
2a; GRB2, growth factor receptor-bound protein 2; GAB I, GRB2-associated binding protein I ; Pl3K, 
phosphoinositide-3 kinase; AKT, v-akt murine thymoma viral oncogene; SOS, son of sevenless; RAS, rat 
sarcoma; MAPK, mitogen-activated protein kinase; PLCy, phospholipase Cy; PIP2, phosphatidylinositol 
4,5-biphosphate; lP3, inositol 1,4,5 -tripbosphate; DAG, diacylglycerol; PKC, protein kinase C. Adapted 
from (Turner and Grose 20 I 0). 
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1.8. Significance of angiogenesis as a therapeutic target 
The disruption of the regulatory mechanisms controlling angiogenesis can have a 
significant impact on health as it underlies the pathology of diseases characterised by 
uncontrolled blood vessel formation, including cancer, psoriasis, arthritis, retinopathies, 
obesity, asthma, and atherosclerosis (Table 1.4) (Carmeliet 2003; Carmeliet 2005). In 
1971 , Folkman first introduced the concept of "anti-angiogenesis" as a potential 
anticancer strategy. He suggested that angiogenesis can be a target for the treatment of 
solid tumours since malignant tumours cannot grow beyond 2-3 mm3 without recruiting 
new capillary blood vessels to supply the nutrients required for further cell proliferation 
(Folkman, Bach et al. 1971). Therefore anti-angiogenic agents can effectively be used 
for inhibiting the progression or recurrence of tumour growth. To date, approximately 
50 anti-angiogenic agents have been discovered, some of which have already been 
approved by the US FDA for clinical use and scores of others that are undergoing 
clinical trials (Table 1.5) (Li, Li et al. 2012). 
In addition, insufficient angiogenesis and abnormal vessel regression can lead to 
heart and brain ischemia, neurodegeneration, hypertension, osteoporosis, respiratory 
distress, preeclampsia, endometriosis, postpartum cardiomyopathy, and ovarian 
hyperstimulation syndrome (Table 1 .4) (Carmeliet 2003; Carmeliet 2005). So far, 
clinical studies of pro-angiogenic therapeutic strategies have involved the 
administration of growth factors such as VEGF and FGF to stimulate angiogenesis. As 
mentioned in sections 1.7.1 and 1.7.2, despite pre-clinical in vivo trials showing 
promise, clinical trials testing VEGF and FGF-2 have failed at the phase II or Ill stages 
(Stewart, Kutryk et al. 2009; Zhao, Zhao et al. 2011). Therefore more studies need to 
be conducted to discover more effective pro-angiogenic agents. 
1.9. Natural small molecules as exogenous angiogenesis modulators 
Angiogenic modulators are agents that can interact with the regulatory pathways 
controlling angiogenesis to either enhance or inhibit angiogenesis (Cristofanilli, 
Chamsangavej et al. 2002). Due to the critical role of angiogenesis in health and 
disease, the identification of strategic drugs that regulate angiogenesis has been a 
challenge for clinical investigators. Although, the maj ority of angiogenic regulators are 
typically endogenous proteins such as VEGF and FGF, as described previously, the 
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research for small exogenous molecules that are capable of either promoting or 
inhibiting angiogenesis may offer rational targets for drug development. 
There are several examples of traditional medicines affecting the process of 
angiogenesis and these have then been studied to identify the active constituent. For 
example, si libinin (also known as silybin), a flavonolignan, is the active constituent of 
Silymarin, a standardised extract derived from the milk thistle plant (Silybum 
marianum) (Fig. 1.8A). Silymarin has been used for more than 2000 years as a natural 
remedy for treating hepatitis and cirrhosis and to protect the liver from toxic substances 
(Ramasamy and Agarwal 2008). Silymarin has also been extensively studied in both in 
vivo and in vitro experiments for its anti-angiogenic effect against various cancers 
including colon, breast and prostate cancers (Yang, Lin et al. 2003; Davis-Searles, 
Nakanishi et al. 2005). 
It has been shown that some of its anti-angiogenic effect has been associated with 
inhibition of VEGF secretion, down regulation of VEGFR-3, up-regulation of 
angiopoietin-2 (Zi, Feyes et al. 1998; Jiang, Agarwal et al. 2000; Agarwal, Agarwal et 
al. 2006; Singh, Deep et al. 2006) and down-regulation of MMP-2 (Lah, Cui et al. 
2007). 
Another traditional oriental medicinal plant Cinnamomum cassia has been used to 
improve blood circulation (Choi, Baek et al. 2009). It has also been shown to affect 
bone formation in osteoblastic cells and consequently contributes to the prevention of 
osteoporosis and inflammatory bone diseases (Lee and Choi 2006). The active 
constituent was identified as cinnamic acid and this has now been used as a novel pro-
angiogenic compound which, in in vitro and in vivo studies was found to up-regulate 
VEGF and_ the VEGF receptors (VEGFR-2/Flk-l/KDR) (Fig. 1.8B) (Choi, Baek et al. 
2009). 
Tables 1.6 and 1.7 show more examples of angiogenesis modulating small molecules 
derived from natural sources. However, the majority of the low molecular weight 
exogenous molecules are inhibitors of angiogenesis. Therefore, this thesis is focused on 
the identification of novel pro-angiogenic molecules from the soybean plant which 
already has a well-established reputation for providing human health benefits. 
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Table 1.4. Examples of diseases where targeting angiogenesis has therapeutic 
application. 
Disease 
Cancer 
Infectious disease 
Obesity 
Psoriasis 
Diabetic retinopathy 
Asthma 
Arthritis 
Stroke 
Hypertension 
Diabetes 
Osteoporosis 
Treatment strategy 
lnhibi tion of blood vessel growth to sol id tumours 
Inhibiting ang iogenesis stimulated by angiogen ic 
promoting genes of pathogens 
Inhibiting angiogenesis induced by a fatty diet 
Preventing dermal microvascul ar expansion that 
supports excess ive skin production 
Inhibiting abnormal blood vesse l growth that contributes 
to diabetes related vision loss 
lnhibiting angiogenesis that cou ld contribute to 
abnormal tissue growth 
Inhibiting angiogenesis to prevent tissue lining the joints 
from invading and destroying cartilage and bone leading 
to arthritis 
Stimulation of ang iogenesis in the brain , restoring 
oxygen supply, could increase survival chance and 
preventing stroke if administered following early 
warning signs 
Treat by reversing the effects ofmicrovessel rarefaction 
due to impaired angiogenes is 
Restoring peripheral bloody supply to ischem ic limbs 
Preventing the age dependent decline of VEG F 
stimulated angiogenesis 
Adapted from (Carmeliet 2003). 
Therapeutic effect 
Anti-a□g iogenesis 
Anti-angiogenesis 
Anti-angiogenesis 
Anti -angiogenes is 
Anti -angiogenesis 
Anti-angiogenesis 
Anti-angiogenesis 
Pro-angiogenes is 
Pro-angioge nes is 
Pro-angiogenes is 
Pro-angiogenesis 
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Table 1.5. Examples of FDA approved anti-angiogenic agents. 
Agent 
Bevacizumab (Avastin) 
Cetuximab (Erbitux) 
Endostatin * 
Erlotinib (Tarceva) 
Everolimus 
Gefitinib (lressa) 
lmiquimod 
Interferon a (IFN-a) 
Lena I idomide 
Pazopanib (Votrient) 
Pegaptanib (Macugen) 
Sorafenib 
Sunitinib 
Temsirolimus (Torise l) 
Thalidomide 
Vandetanib 
Cancer type 
Colon, Lung, Breast, Brain, Kidney 
Colon, Head and Neck 
Lung 
Lung, Pancreatic 
Kidney, Pancreatic, Brain 
Lung, breast 
Actinic keratos is, Basal cell carcinoma 
Melanoma, Kaposi's sarcoma 
Myleodysplastic syndrome, Multiple 
myeloma 
Kidney 
Age-related macular degeneration 
Kidney, Liver 
Kidney, GIST, Pancreatic 
Kidney, Lymphoma 
Multiple mye loma 
Thyroid 
Target 
VEGF 
EGFR 
bFGFNEGF 
EGFR 
mTOR 
EGFR 
Activate the immune system mostly 
via TLR7 
Direct anti-tumour effect 
Inhibition of the microenvironment 
support for tumour cells 
lmmunomodulator_t role 
VEGFRI , 2, 3 
VEGF 
VEGFR, PDGFR, Rafkinases 
RTK 
mTOR, VEGF 
bFGF 
VEGFR 
bFGF, basic fibroblast growth factor ; EGFR, epidennal growth factor receptor; mTOR, mammalian target 
of rapamycin; PDGFR, platelet-derived growth factor receptor; RTKs, receptor tyros ine kinases; VEGF, 
vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; TLR7, toll-like 
receptor 7. Adapted from (Li, Li et al. 20 12). 
*Endostatin is approved by the State FDA in China. 
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OH 
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Silibinin 
0 
B 
::::::--- OH 
Cinnamic acid 
Figure 1.~. Chemical structures of silibinin (Silybum marianum), the anti-
angiogenic constituent of Silymarin (A) and cinnamic acid, the pro-angiogenic 
compound derived from Cinnamomum cassia (B). 
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Table 1.6. Examples of exogenous anti-angiogenic small molecules from natural 
products. 
Compounds 
Anthocyanins 
Curcumin 
Ell agitannins 
Epigallocatechin-3-gallate 
(EGCG) 
Genistein 
Lycopene 
Menaquinone 
(vitamin K2, fat so luble) 
Omega-3, Polyunsaturated 
fatty acids (PUF As) 
Quercetin 
Natural source 
Berries, grapes, red wine 
Curcuma longa, turmeric spice 
Pomegranate, strawberries, 
blackberries, raspberries, 
muscadine grapes, walnuts and 
ecans 
Green tea 
Soybean 
Fruits with bright red colour such as 
tomato, watermelon and papaya 
Bacteria in fermented dairy 
products, including cheese and 
yogurt, soy and also dark meat 
Co ld water oily fish such as sa lmon, 
herring, mackerel, anchovies, 
sardines and trout 
Mechanism of action 
Suppression ofVEGF and HIF-la 
express ion (Lu, Li et al. 2006; Wang, 
Dombkowski et al. 20 11). 
MMP-10 expression (Stoner, Chen et al. 
20062 
Down-regulation of gene transcripts 
for VEGF, bFGF, and MMP-2; COX-2 
inhibition; up-regu lation ofTfMP; 
disruption of vascular tube formation; and 
inh ibi tion of endothelial cell motility by 
interfering with the Ras-mediated JNK 
pathway (Thaloor, Singh et al. 1998; Mohan, 
Sivak et al. 2000; Shin, Kim et al. 2001 ; 
Gururaj, Belakavadi et al. 2002; Shao, Shen 
et a l. 20022-
Suppression of secretion ofVEGF and HIF-
1 a (Sartippour, Seeram et al. 2008). 
Inhi bition of endothelial cell proliferation 
stimulated by bFG F (Cao and Cao I 999). 
Inhibition ofVEGF express ion (Liao, Yang 
et al. 2004). 
Inhi bition of MMP-2 and MMP-9 (Garbisa, 
B iggin et al. r999; Garbisa, Sartor et al. 
2001 
Inhibition ofbFGF- and VEGF-driven 
endothelial cell proliferation, migration, and 
tube format ion; inhibition of extracellular 
matrix degradation by suppression ofbFGF-
induced endothelial production of PA and 
PA I; and suppression ofRTK activity for 
VEGF, EGF and PDGF (Akiyama, Ishida et 
al. 1987; Fotsis, Pepper et al. 1993). 
Suppresses signalling by PDGF and Platelet 
Activation Factor (Wu, Chiang et al. 2007). 
Induci ng apoptosis (Shibayama- lmazu, 
Aiuchi et al. 2008). 
Down-regulating Ang-2 (Szymczak, Murray 
et al. 2008). 
Suppression of Akt/m-TOR signalling 
pathway (Friedrichs, Ruparel et al. 20 1 I). 
Numerous types of fruits and Inhibition of MMP-2 and MMP-9 secretion 
vegetables (Davis, Emenaker et al. 20 I 0). 
bFGF, basic fibroblast growth factor; HIF-la, Hypoxia-inducible factor l-a; mTOR, mammalian target of 
rapamycin ; PDGF, platelet-derived growth factor; RTK, receptor tyrosine kinase; VEGF, vascular 
endothelial growth factor; JNK, c-Jun N-terminal kinase; PAI , plasminogen acti vator inhibitor; PA, 
plasminogen act ivator receptor; Ang-2, angiopoietin-2; COX-2, cyc looxygenase-11 ; MMP-2 ,-9, matrix 
metalloproteinase-2,-9,-1 O; TIMPs, tissue inhibitors of matrix metalloproteinase; EGF, endothelial growth 
factor. Adapted from (Li, Li et al. 20 I 2). 
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Table 1.7. Examples of exogenous pro-angiogenic small molecules from natural 
products. 
Compounds 
Cinnamic acid 
Dibenzoylmetbane (DBM) 
Nicotine 
Resveratrol 
Sokotrasterol Sulphate 
Natural source 
Cinnamomun cassia 
Licorice plants 
Plants oftbe Solanaceae famil y, 
such as tobacco (Nicotiana 
tabacwn) and the coca plant 
(E,ythroxylum coca) 
Red grapes 
Marine sponges 
Mechanism of action 
Up-regulation ofYEGF and Flk- 1/KDR 
(VEGF receptor-2) (Choi, Baek et al. 
2009). 
Increasing HI F -1 a protein and VEG F 
secretion (Mabjeesh, Willard et al. 2003). 
Stimulation ofnicotinic acetylcholinergic 
receptors (particularly); inducing the 
expression of bFGF, PDGF and VEGF; 
up-regulation ofFlk-1/KDR; increasing 
the recruitment of endothelial progenitor 
cell s (EPC) into blood vessel s (Mousa and 
Mousa 2006; Costa and Soares 2009; 
Egleton, Brown et al. 2009). 
Stimulation ofTrx-1 , HO- I and VEGF 
synthesis (Kaga, Zhan et al. 2005). 
Increasing expression ofNFkB and Sp-I 
(Fukuda, Kaga et a l. 2006). 
Increasing VEGF and Flk-1 express ion 
(Wallerath , Deckert et al. 2002). 
Up-regulation ofbFGF (Murphy, Larrivee 
et al. 2006). 
bFGF, bas ic fibroblast growth factor; PDGF, platelet-derived growth factor ; YEGF, vascular endothelial 
growth factor; VEG FR, vascular endothelial growth factor receptor; Trx- 1, Thioredox.in-1 ; HlF- 1 a, 
Hypoxia-inducible factor I-a; HO-I , heme oxygenase-1; NFkB, nuclear factor kappa B; Spl, specificity 
protein I. 
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1.10. Angiogenesis bioassays 
The key to successful natural product drug discovery is the availability of an 
appropriate assay for the desired bioactivity (New, Miller-Martini et al. 2003; Koehn 
and Carter 2005). Angiogenesis bioassays are an essential tool not only fo r screening 
for angiogenic activity but also for studying the mechanism of action of active 
compounds (Donovan, Brown et al. 2001). Angiogenesis assays can be performed 
either in in vivo or in vitro settings. As reviewed by Jain et al. , 1997 and Auerbach et al. , 
2003, numerous in vivo assays have been developed in recent years including the chick 
chorioallantoic membrane (CAM) assay, the Matrigel plug assay, and a group of assays 
using implants of sponges containing test cells or compounds in animal bodies (Jain, 
Schlenger et al. 1997; Auerbach, Lewis et al. 2003). 
Although in vivo assays give a direct and more comprehensive insight into how the 
test compounds might affect the angiogenic process, there are a number of 
disadvantages associated with their use including being expensive, time consuming and 
sometimes a source of ethical problems (Donovan, Brown et al. 2001 ). 
In vitro assays provide critical information as a first step -of angiogenic compound 
validation as they tend to be less expensive, less time consuming, more reproducible, 
easier to monitor and have fewer ethical problems. As the aim of this PhD thesis 
project is to screen a large number of compounds and chromatographic fractions for 
angiogenic activity, an in vitro angiogenesis assay was employed (Jain, Schlenger et al. 
1997; Donovan, Brown et al. 2001; Auerbach, Lewis et al. 2003). in vivo assays are 
required in the later steps of drug development but they have not been used in the 
research described in this thesis and, therefore, will not be discussed further. 
The in vitro angiogenesis assays involve using either a single cell type (cellular) or 
organ culture (organotypic) assays (Goodwin 2007). In vitro cellular assays are often 
used to study one particular step in angiogenesis such as proliferat ion, migration and 
differentiation of endothelial cells. These assays can portray a specific part of the 
angiogenic cascade being affected by the test compounds (Bootle-Wilbrahan1, 
Tazzyman et al. 2000; Donovan, Brown et al. 2001). Therefore, these assays can be 
employed to study the cellular mode of action of angiogenically active compounds. 
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The organotypic assays allow the effect of a test agent on multiple cell types in the 
angiogenesis environment to be analysed and include mouse metatarsal, rat and mouse 
aortic ring and chick aortic arch assays. Both mouse metatarsal (using embryonic 
mouse bones) and chick aorta arch (using embryonic aorta arches) assays have the 
disadvantage of the cells themselves undergoing rapid cell proliferation and 
angiogenesis which make them less ideal bioassays for screening for pro-angiogenic 
compounds (Auerbach, Lewis et al. 2003; Goodwin 2007). 
1.10.1. In vitro rat aorta ring assay 
The in vitro rat aorta ring assay is a 7-14 day assay in which the thoracic aorta is cut 
into approximately 1 mm lengths and embedded into a matrix-containing environment 
such as Matrigel, fibrin or collagen gels. Among the available in vitro angiogenesis 
assays, the rat aorta bioassay (Nicosia and Ottinetti 1990) represents a more ideal in 
vitro model in that it bridges the gap between the in vivo and in vitro models. Firstly, 
the wounding that occurs during the cutting of the aorta is sufficient to induce 
angiogenesis and hence exogenous factors do not need to be added. Secondly, it 
reproduces more accurately the environment in which angiogenesis takes place in vivo 
than alternative procedures using preselected endothelial cells and their su.bsequent in 
vitro passaging. Thirdly, it not only includes endothelial cells but also the surrounding 
cells which are also involved in angiogenesis. Fourthly, the pro-angiogenic factors are 
best tested in the assays where baseline angiogenesis is relatively low, as with the rat 
aortic ring assay, rather than in in vitro assays using embryonic organs (Auerbach, 
Lewis et al. 2003; Goodwin 2007). 
On the other hand, since the in vivo angiogenesis mainly occurs at the microvascular 
level, th!'! use of aorta may be a disadvantage (Auerbach, Lewis et al. 2003 ; Goodwin 
2007). However, since the in vitro rat aorta assay was instrumental in the identification 
of PI-88 (also known as Muparfostat) (Parish, Freeman et al. 1999) (Fig. 1.9), an anti-
angiogenesis compound that has progressed to advanced (phase III) clinical trials with 
hepatocellular carcinoma patients, this assay was used in this thesis to monitor 
compounds modulating angiogenic activity. 
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A B 
Figure 1.9. The rat aorta angiogenesis bioassay. 
Untreated control (A), angiogenesis i.riliibited by Pl-88 at 14 days post-treatment (B). From (Parish, 
Freeman ei al. I 999). 
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1.11. Research objectives 
The Djordjevic and Parish laboratories have previously identified a number of 
fractions from soybean (Glycine max) xylem sap that modulate angiogenesis using the 
in vitro rat aorta bioassay (Lauren Du Fall, ANU Honours thesis, characterisation of low 
molecular weight bioactive plant metabolites, unpublished data) (Du Fall 2009). 
The aim of this PhD project was to screen for pro-angiogenic natural products from 
soybean xylem sap using an activity-guided bioassay to purify and isolate sufficient 
material to enable their identification. The active constituents of these fractions may 
have therapeutic value in situations where the formation of new blood vessels is 
described, such as in cardiovascular disease and wound healing. 
To this end I planned to: 
1) Fractionate and screen the soybean xylem sap for compounds that promote 
angiogenesis, 
2) Purify and elucidate the structure of the bioactive compounds, 
3) Determine their cellular mode of action using human cell lines, and 
4) Investigate the pro-angiogenic activity and structure-activity relationship, at 
physiological concentrations, of a selection of flavonoids, including naringenin 
and genistein. 
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Chapter 2 
Materials and Methods 
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2.1. Materials 
The reagents used for chemical analyses were analytical grade mostly obtained from 
Sigma-Aldrich, St. Louis, MO and Ajax Chemicals, Auburn, NSW, Australia. Plant 
media were adjusted to the correct pH with IM NaOH, 3M KOH and IM HCL. Details 
of reagents, cells, media and buffers used throughout this thesis are listed in Table 2.1 , 
2.2 and 2.3. 
2.2. Methods 
2.2.1. Cultivation of soybean plants and treatments 
The soybean (Glycine max) seeds (cv. Bragg) (CILR, Brisbane, Australia) were 
planted two per pot (30 cm x IO cm x 10 cm) in vermiculite (Ausperl , Australia) under 
glasshouse conditions of 14 hours light (28 °C) and 10 hours dark photoperiod (25 °C). 
Plants were watered every day with ~ 200 mL of urban water for each pot and it was 
replaced with modified Herridge ' s nutrient solution (Herridge 1997) (IM KH2PO4 (pH 
to 6.0) 2 mM, K2HPO4 lmM, MgSO4.7H2O 2 mM, KC! I .5 rnM, CaC]z.2H2O 2.5 mM, 
ferric monosodium salt of EDTA (FeIII-EDTA) I mM, H3BO3 2.86 g/L, MnC]z.4H2O 
1.812 g/L, ZnC]z 0.112 g/L, CuC]z.2H2O 0.051 g/L, Na2MoO4.2H2O 0.024 g/L) from 
the second week of planting with application on every second day. The solutions were 
made up individually and mixed and diluted into IO litres of water. Half of the plants 
were inoculated with the commercial soybean inoculum Nodulaid 100 (Bradyrhizobium 
japonicum strain CB 1809, Bio-Care Technology P/L Somersby NSW, 10 10/gram) at 
one week post-germination. 
Uninoculated plants were treated with a range (1-l0mM) ofKNO3 fertiliser and IO 
mM KNO3 which when added to other solutions mentioned above was determined to be 
sufficient to support growth until harvesting time at 4-6 weeks. 
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Table 2.1. General reagents used in this thesis. 
General reagents 
Acetonitrile 
£-aminocal'_roic acid 
Amphotericin B (fungizone) 
Aprotinin 
bFGF 
BSA 
DMSO 
Endothel ial cell growth factor 
Endothelial cell growth supplement 
Ethanol absolute 
Fibrinogen 
Fibronectin (bovine plasma) 
Formic acid 
Gelatine (porcine skin) 
Gentamycin 
G lycerol 
Heparin (bovine lung) 
HEPES 
HlFCS 
Hydrocortisone 
L-glutamine 
Matri_gel 
Milli-Q water(> 18.2 MO.cm resistivity) 
PD173074 
Plasmin (human) 
PSN (x 1000) 
Rose Bengal pure A.R (dye) 
Thrombin 
Thymidine ('H) 
Trypan B lue 
Vitronectin (human) 
Supplier 
Labscan Analytical Sciences, HPLC grade, 99.9% 
Sigma-Aldrich, St. Loui s, MO 
Sigma-Aldrich, St. Louis, MO 
Boehringer, Mannheim, Germany 
R&D Systems, Minneapolis, MN 
Sigma-Aldrich~. Louis, MO 
Cambridge Isotope Laboratories, Andover, MA 
Gibco BRL, Grand Island, NY 
Sigma-Aldrich, St. Louis, MO 
Chem Supply, Gilma, SA 
Calbiochem, La Jolla, CA 
lnvitrogen, Carl sbad, CA 
Fluka, puriss. P , HPLC grade for mass spectrometry,~ 98% 
Si_gma-Aldric~t. Loui_s, MO 
Sigma-Aldrich , St. Louis, MO 
Ajax Chemica ls, Auburn, NSW, Australia 
Sigma-Aldrich , St. Louis, MO 
Sigma-Aldrich, St. Louis, MO 
SAFC, Street Lenexa, KS 
Sigma-Aldrich, St. Louis, MO 
Sigma-Aldrich, St. Loui s, MO 
BD Biosciences,J3_edfo_r_cl_,_ MA 
Milli!'_ore, Billerica, MA, USA 
Stemgent, San D_iego, CA 
Sigma-Aldrich, St. Louis, MO 
Penicillin G 30.072 g/L, streptomycin sulphate 50 g/L, 
neomycin sulphate 50 g/L 
Koch-Light Laboratories Ltd. , Colnbrook, Berkshire, England 
Sigma-Aldrich, St. Loui s, MO 
MP Biomedicals, Solon, OH 
BDH Poo le Chemicals, London, England 
Gibco BRL, Grand Island, NY 
bFGF, basic-fibroblast growth factor; BSA, bovine serum albumin; DMSO, dimethyl sulphoxide; 
HEPES, (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid); HIFCS, heat inactivated foetal calf serum. 
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Table 2.2. Media and buffers used in this thesis. 
Media and buffers Composition 
DMEM Hl6 med ium Hl6 powder 9.99 g/L (G ibco BRL, Grand Island, NY), NaHCO3 3.7 g/L 
HBSS( x 10) 
M199 medium 
MCDB 13 1 
PBS 
Trypsin/EDT A 
NaCl 100 g/L, KC! 5 g/L, MgSO4.7H2O 1.25 g/L, MgCl2 6H2O 1.25 g/L, 
CaCl2 1.4 g/L, glucose 12.5 g/L, Phenol Red I g/L, Na2HPO4.2 H2O 3.9 
g/L KH,PO4 3 g/L 
Ml 99 powder 9.5 g/L (Gibco BRL, Grand Island, NY), NaHCO3 2.2 g/L 
MCDB 13 1 Medium liquid (G ibco BRL, Grand Island, NY) 
NaCL 8 g/L, Na2HPO4 .2H2O 1.25 g/L, Na2HPO4 .H2O 0.35 g/L 
4.25% trypsin (Na2HPO4.2H2O 0.075 g/L, KH2PO4 0.06 g/L), 5.3% 
versene (1% EDTA) in PBS 
DMEM, Dulbecco 's modified Eagle's med ium; HBSS, Hank' s balanced salt solution; PBS, phosphate 
buffered sa line ; EDTA, ethylenediaminetetraacetic ac id. 
Table 2.3. Cell lines, media and supplements used in this thesis. 
Cell lines 
HlNEC 
HMEC 
NIH-3T3 
Origin and details 
Human umbilical vein 
endothelial cells, primary cell 
I ine, adherent 
Human micro vascular 
endothelial cell line, 
immortalised cell line, 
adherent 
Mouse fibroblast cell line, 
adherent 
Media and supplements 
M199, 20% HJFCS, 0.24 mg/mL gentamyc in, 2 mM 
L-glutamine, 0.04-0.08 mg/mL ECGS, 0.1 35 
mg/mL heparin 
MCDB 13 1, 10% HIFCS, 2 mM L-glutam ine, 0.1% 
PSN (0.03 g/L penicillin G, 0.05 g/L streptomycin 
sulphate, 0.05 g/L neomyc in sulphate), 0.0 I µg/mL 
endothelial cell growth factor, I µg/mL 
hydrocortisone 
DMEM, 10% HI FCS, I mM L-glutamine, 2.5 
mg/mL fungizone, 0.24 mg/mL gentamyc in, 20 mM 
HEPES 
HlFCS, heat inactivated foetal calf serum; ECGS, endothelial cell growth supplement; DMEM, 
Dulbecco' s modified Eagle 's medium; HEPES, 4-(2-hydroxyetbyl)-l-piperazineetbanesulfo□ ic acid. 
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2.2.2. Collection of soybean xylem sap 
Soybean xylem sap was collected four-six weeks post-germination (Fig. 2. IA). Sap 
extraction was optimised by watering the plants one hour prior to extraction. The plants 
were decapitated with a scalpel blade at 5-8 cm above the vermiculite at the lowest 
section that can provide a secure fit for the plastic collection tubing (Fig. 2.IB). The 
collection procedure was as described by (Djordjevic, Oakes et al. 2007). The sap was 
collected over 0-7 and 7-24 hours. Negative pressure was provided by repositioning the 
5 mL syringes during extraction hours and the plants left to bleed sap overnight. Sap 
exudation for each plant was estimated at 0.34 mL/hour over 24 hours. The extracted 
sap from 50 plants was pooled and lyophilized overnight (200-300 mT vacuum; Flexi-
dry MP Microprocessor controlled bench top lyophiliser). 
2.2.3. Compound purification from xylem sap 
Molecular weight spin filters with different pore sizes (10 kilo Daltons (kDa), 3kDa 
and lkDa) (Merck Millipore, Billerica, MA) were utilised to isolate the small molecules 
from the crude concentrated extract (Scheme 1). The I kDa filtrate was freeze dried, 
redissolved in I mL water ( ~ 400 fold concentration) and distributed into IO x 100 µL 
aliquots for freeze drying and stored at -20 °C. Next, reverse phase high performance 
liquid chromatography (HPLC) with a C 18 column was used to fractionate the filtered 
extract. The freeze dried samples were redissolved in I 00 µL water and run on HPLC 
(2 x 50 µL injections representing 20 mL of xylem sap). 
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Figure 2.1. Extraction of xylem sap from soybean ( Glycine max) plants. 
Xylem sap was extracted from 4-6 week old soybean plants (A) by decapitating at ~ 5-Scm above the 
venniculite and attaching a syringe by placing a piece of plastic tube over the stem. A 200µL pipetteman 
tip (-->) was used to create the negative back pressure by holding the extended syringe in place (B). 
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10 tubes x 40 ml of 
xylem sap extract 
lyophilise 
Add 1 ml MQ H2O to each tube and 
collect all in one tube 
10 kDa filtration 
3 kDa filtration 
1 kDa filtration 
lyophilise 
Add 1 ml water and distributed into 
1 0 x 100 µl aliquots 
lyophilise 
Store powder in -20° C 
Scheme 1. Preparation of xylem sap prior to HPLC purification. 
Chapter 2 
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2.2.4. High Performance Liquid Chromatography (HPLC) 
Samples were subjected to chromatographic separation on a Shimadzu LC I 0-VP 
series HPLC using an Alltech Platinum Cl8 column (5µm, 250 x 4.6 mm) and guard 
cartridge run at 35 °C and eluted over 30 min with a linear gradient of 5% to 85% 
acetonitrile (Labscan Analytical Sciences, HPLC grade, 99.9%) (hold 5 min). Sample 
components were detected with a photodiode array (PDA) detector (190 ~ 800 run) . 
Water for HPLC analysis (>18.2 MD.cm) was supplied from a linked reverse osmosis 
and Milli-Q Gradient water purification system (Millpore, Billerica, MA, USA). 
Peaks were collected by monitoring UV absorbance in real time at 254 run at a flow 
rate of I mL/min. Fifty six fractions were collected from 2-30 min at 30 seconds 
intervals. Fractions were dried under nitrogen to remove acetonitrile, diluted to 200 µL 
with Milli-Q water and either screened for activity in the pro-angiogenic bioassay or 
stored at -70 °C. 
The final purification of pro-angiogenic compounds was carried out on the Alltima 
C 18 column as per the above method (injected 50 µl , 20 mL sap equivalent); however 
elution was over I 5 min (5-20 min) with a linear gradient of 20% to 31 % acetonitrile 
with final wash from 20 to 25 min with acetonitrile gradient of 31 % to 85% (hold 5 
min). 
2.2.5. Rat aorta model angiogenesis bioassays 
The in vitro rat aorta angiogenesis bioassay was used to screen for activity in the 
HPLC xylem sap fractions. Inoculated and nitrate treated plants were tested using a 
pro-angio_genic variant of an aorta test used to identify compounds that modulate 
angiogenesis (Parish, Freeman et al. 1999). The original method describes an anti-
angiogenesis assay but to test for pro-angiogenic activity, the heat inactivated foetal calf 
serum (HIFCS) concentration in the culture medium is reduced from 20% to 5% (A 
Bezos, C Parish; unpublished method). 
Thoracic aorta were excised from 5-9 month old female Fischer rats, rinsed in 2.5 
µg/mL Hanks solution containing I% amphotericin B (fungizone 250 µg/mL, Sigma) 
and cut into - Imm wide sections. All the periadventitial fibroadipose tissue and blood 
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clots were removed. Dissecting and sectioning of the vessels were performed using a 
dissecting microscope. The assay was carri ed out in a 48 well culture plate (Costar, 
Coming, Lowell, MA) with 6 repeats for each sample. The vessel segment was 
embedded in a mix of 500 µL fibrinogen (3 mg/mL, bovine plasma, Calbiochem, La 
Jolla, California) in serum free medium Ml 99 (GibcoBRL) and 2.5 µL aprotinin (5 
µg/mL, Sigma) in PBS (phosphate buffer solution). The aprotinin prevents fibrinolysis 
of the vessel fragments. Then 15 µL of thrombin (50 NIH U/mL in 0.15 M NaCl: EC 
3.4.21.5 bovine plasma: Sigma St Louis, MO) was added to each well and mixed 
rapidly to set the fibrin gel. 
After clot formation , 500 µL of M199 medium (Life Technologies), with or without 
test compounds, supplemented with 20% or 5% HIFCS (SAFC, Street Lenexa, KS), 
0.24 mg/mL gentamycin (Sigma-Aldrich, St. Louis, MO), 2.5 mg/mL fungizone 
(Sigma-Aldrich, St. Louis, MO), I mM L-glutamine (Sigma-Aldrich, St. Louis, MO) 
and 0.1 % i;-aminocaproic acid (Sigma-Aldrich, St. Louis, MO) was added to each well. 
The plates were incubated at 37 °C in 5% CO2 and the medium was changed on day 4 of 
culture. The vessel outgrowth was quantified manually as percent growth under a 
Nikon TMS inverted phase contrast microscope (Nikon Instrument Inc. , Tokyo, Japan) 
at 40 x magnification on days 5-7 of culture. Two controls -cultures were used: one 
received medium with the diluent and to the second the known anti-angiogenic agent, 
PI-88 (Parish, Freeman et al. 1999) was also added at 100 µg/ml. Percent growth is 
subject of estimation and was determined by the density and number of new vessels that 
had sprouted from the aorta ring in the fi eld of view. 
2.2.6. Liquid Chromatography Mass Spectrometry (LC-MS) 
Mass spectrometry was performed using an Agilent 6530 Accurate Mass LC-MS Q-
TOF (Santa Clara, CA, USA). Samples were subjected to ESI in the Jetstream interface 
in the positive and negative modes under the following conditions : gas temperature 300 
°C, drying gas 4 L/min, nebulizer 35 pi ig, sheath gas temperature 350 °C and flow rate 
of 11 L/min, capillary voltage 3500 V, fragmentor 175 V, and nozzle voltage I 000 V. 
Samples (3 µL) were inj ected onto an Agilent Eclipse XDB-C18 column (2.1 x 50 mm; 
1.8 µm) and xylem sap crude extract or HPLC purified pro-angiogenic compounds were 
eluted with a linear gradient from 10 to 50% mobile phase Bin 8 min, then to 70% in 4 
min (hold for 8 min) at a flow rate of 200 µL/min . Mobile phase A consisted of water 
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containing 0.1 % formic acid while mobile phase B consisted of acetonitrile/water (9: 1 
v/v) containing 0.1 % formic acid. The instrument was run in extended dynamic range 
mode from mlz l 00-3000 and data acquired by targeted collision induced dissociation 
(CID; N2 collision gas supplied at 18 psi) MS/MS (2 spectra/s). Data were acquired and 
analysed with Agilent's MassHunter software. 
2.2.7. Nuclear Magnetic Resonance Spectroscopy (NMR, performed by Tom 
Carruthers in the ANU Research School of Chemistry) 
NMR spectroscopy experiments were recorded on either a Bruker AVANCE 800 or 
600 spectrometer with TCI cryoprobe using 0 20 as the solvent at 298 K. 1H NMR 
chemical shifts in parts per million (ppm) are reported using the residual water solvent 
peak as an internal chemical shift reference (4.80 ppm). 
1H. lD proton spectra were performed using solvent suppression via pre-saturation. 
128 scans were taken of the 8.43 ppm spectral width. 
1H-DQF-COSY. A phase-sensitive 2D double quantum filtered COSY with pre-
saturation was measured with 2K and 512 points were taken- in the t2 and 11 proton 
dimensions respectively, sweep widths of 8.43 ppm each and 4 scans for each 11 
increment. 
1H-TOCSY. The phase sensitive 2D TOCSY with pre-saturation was measured with 
4K and 212 points in the t2 and t 1 proton dimensions respectively, a spectral width of 
8.43 ppm in both dimensions, a MLEV mixing time of 60 ms and 4 scans for each 11 
increment. 
1H_IH NOESY. A 2D homonuclear phase-sensitive NOESY with pre-saturation was 
run with 16384 and 512 points in the t2 and t1 proton dimensions, sweep widths of 8.43 
and 11.11 respectively and 32 scans were measured for each t1 increment. 
13C-HSQC. The phase-sensitive 2D 13C-HSQC with adiabatic inversion pulses on 
13C was measured with 2K points in the proton dimension (t2) and lK points in the 13C 
dimension (11), spectral widths of 8.43 ppm and 166 ppm respectively, and 8 scans for 
each 11 increment. 13C-HMBC. The phase-sensi tive 2D 13C-HMBC included a two-fold 
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low-pass J-filter to suppress one-bond correlations. 4K points in the proton dimension 
(12) and 857 points in the 13C dimension (11) were measured with spectral widths of 8.43 
ppm and 222 ppm respectively with 32 scans for each t1 increment. 
2.2.8. Cell Culturing 
2.2.8.1. Subculturing mammalian cell lines 
Three mammalian cell lines were used in this thesis. The human umbilical vein 
endothelial cells (HUVEC), a human microvascular endothelial cell line (HMEC) and a 
NIH-3T3 mouse fibroblast line were each cultured in specific media described in Table 
2.3 and incubated in a Hepa-filtered IR incubator (Forma Scientific, Marietta, OH) at 37 
~C in a humidified atmosphere containing 5% CO2. The cells were not re-assessed after 
thawing; however, cells were routinely tested for contamination by Mycoplasma. 
The cells were routinely passaged every two to three days according to their cell 
proliferation rate and subcultured when they achieved 80% confluence. The number of 
passaging for HUVECs was not more than 8 and it was less than 16 for HMEC and 3T3 
mouse fibroblasts. The HMEC and 3T3 mouse fibroblasts were cultured in 75 and 175 
cm
2 flasks (Nurre, Roskilde, Denmark) and HUVEC cultured in 0.1 % gelatine-coated 75 
cm
2 flasks (Coming, Lowell, MA). Since all these cell lines are adherent, cell 
monolayers were released for sub-culturing with trypsin/EDT A mixture (PBS/0.05% 
EDT A/0.00025% Trypsin). Culture supematants were removed from culture flasks and 
the adherent cells washed once with PBS to remove dead cell s and residual medium. 
Into a 75 mL flask, 7.5 mL of pre-warmed trypsin/EDT A mixture at 37 °C was added 
and incubated for 3-5 min at 37 °C in 5% CO2 Then, the flask was gently tapped to lift 
adherent ~ells. Once adherent cells were dislodged, 7.5 mL of culture medium was 
added to stop the action of the trypsin (proteolytic cleavage of cell surface receptors). 
The cells were then transferred to a 50 mL centrifuge tube and an extra 5 mL of culture 
medium was added to the flask as a final wash, which was also transferred to the 
centrifuge tube. The cells were centrifuged at 290 g for 5 min, the supernatant 
discarded and the cell pellet re-suspended in a recorded volume of culture medium. 
Finally, cells were sub-cultured at an appropriate cell density. For 175 mL flasks, all 
the media volumes were doubled. 
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2.2.8.2. Cell counting and viability 
A IO µL cell suspension of known volume was diluted I: I with 0.1 % Trypan Blue 
(BDH Poole Chemicals, London, England) and loaded into a haemocytometer chamber 
and viewed at 20 x magnification under a standard Olympus B light microscope 
(Olympus Optical, Tokyo, Japan) to assess the cell number and viabi lity. 
2.2.9. Cryopreservation of mammalian cell lines 
The cells were collected as described in section 2.2.8.1 and re-suspended in culture 
medium containing 6% dimethyl sulphoxide (DMSO) (Cambridge Isotope Laboratories, 
Andover, MA) and stored in liquid nitrogen until use. 
2.2.10. Cell proliferation assay (mitogenic assay) 
The HUVEC and 3T3 fibrobl ast proliferation assays were based on a determination 
of 3H-thymidine incorporation. The 3T3 fibroblast cells were cultured into 96-well 
culture plates (Linbro, Aurora, OH) at 3 x 103 cells/well in 100 µL/well DMEM, 
supplemented with 10% HlFCS, I mM L-glutamine, 2.5 mg/mL fungizone, 0.24 
mg/mL gentamycin, 20 mM HEPES (Sigma-Aldrich, St. Louis, MO) and incubated at 
37 °C in 5% CO2 for 2-5 days until confluent. The confluent monolayers were then 
serum starved for 48 hours by changing the medium to serum free DMEM (100 
µL/well). Subsequently, 100 µL/well oftest compound in serum free DMEM medium 
with or without bFGF (R&D Systems, Minneapolis, MN, USA) was added to each well. 
Then 0.5 µC i/well of 3H-thymidine (MP Biomedicals, Solon, OH) was added and the 
cells incubated for the final 24 hours. · lncubation was stopped by freezing and thawing 
the cultures three times. Finally, thawed cultures were harvested using a 96-well cell 
Filtermate 196 harvester (Packard Bioscience, Meriden, CT), with EasyTab™-c self-
Aligning Filters (Packard Bioscience, Meriden, CT) and the radioactivity incorporated 
by the cells counted with a Topcount®NXT™ Microplate Scintillation & Luminescence 
Counter (Packard Bioscience, Meriden, CT). 
HUVEC were cultured in Ml 99 medium supplemented with 20% HIFCS, 0.24 
mg/mL gentamycin, 2 mM L-glutamine, 0.04 mg/mL endothelial cell growth 
supplement (ECGS) (Sigma-Aldrich, St. Louis, MO) and 0.135 mg/mL heparin (Sigma-
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Aldrich, St. Louis, MO) in gelatine-coated 96-well plates and incubated for 4 days at 37 
~C in 5% CO2 to reach confluence. The cells were then serum starved for 24 hours. 
Serum starved cells were incubated in serum free medium with or without the test 
compounds for another 24 hours before adding 3H-thymidine. Incubation was stopped 
with adding 100 ~tL/well of trypsin/EDT A to lift the cells from the gelatine layer with 
100 µL/well of Ml99 medium supplemented with 20% HIFCS to neutralise trypsin 
enzymatic activity. Finally, plates were frozen and thawed 3 times and cells were 
harvested as described above and 3H-thymidine incorporation determined. 
2.2.11. Cell migration assay (wound healing assay) 
The IncuCyte™ live-cell imaging system (Essen BioSciencen, Ann Arbor, MI) was 
employed for this assay which provides a 96-well wound making tool, automated image 
acquisition software (IncuCyte) and image processi ng metrics (IncuCyte) to provide a 
reproducible, label-free, kinetic assay for cell migration. 
HMEC cultures were added to 96-well ImageLock Essen plates (Essen BioSciences, 
Ann Arbor, MI) at 2.5 x 104 cells/well in 100 µL/well of MCDB 131 medium 
supplemented with I 0% HIFCS, 0.1 % PSN (0.03 g/L penicillin G, 0.05 g/L 
streptomycin sulphate, 0.05 g/L neomycin sulphate), 2 mM L-glutamine, 0.01 ~tg/mL 
endothelial cell growth factor (ECGF), (Gibco BRL, Grand Island, NY) and I µg/mL 
hydrocortisone (Sigma-Aldrich, St. Louis, MO) and incubated for 2 days at 37 °C in 5% 
CO2 to reach confluence. 
After removing the media from each well, a wound was then made in the HMEC 
monolayer using the 96-pin WoundMaker device to produce precise and reproducible 
wounds b¥ gently removing the cells. The use of Essen lmageLock plates ensured that 
the wounds were automatically located and registered by the IncuCyte software for 
imaging and data recording. 
Each well was then rinsed twice with 100 µL/well of culture medium to prevent 
dislodged cells from settling and re-attaching. Then, 100 µL/well of medium, with or 
without test compound, was added to each well and the plate was placed inside the 
IncuCyte. Wound images were then captured and saved at 2 hours interval s until 
control wounds recovered completely. The data were analysed either by the IncuCyte 
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software package or extracted by three integrated metrics (wound with, wound 
confluence, relative wound density) and analysed by other statistical softwares. 
2.2.12. Endothelial cell tube formation assay 
HMEC and HUVEC cultures were used in in vitro endothelial tube formation assays. 
Matrigel (BD Biosciences, Bedford, MA) was thawed overnight at 4 °C and then plated 
into ice-cold 96-well ImageLock Essen plates at 50 µL/well using pre-cooled pipettes, 
tips and tubes. The plates were incubated at 37 °C in 5% CO2 for I hour to allow the 
Matrigel to form a stable gel. HUVEC at 4 x 104 cells/well in 100 µL of MI 99 medium 
supplemented with 20% HIFCS, 0.24 mg/mL gentamycin, 2 mM L-glutamine, 0.04 
mg/mL ECGS, and 0.135 mg/mL heparin with or without test compounds were added 
and Matrigel cultures placed inside the IncuCyte and incubated at 37 °C for 24 hours. 
A hundred microlitre of HMEC at 5 x 104 cells/well in MCDB 131 medium 
supplemented with 10% HIFCS, 0.1% PSN, 2 mM L-glutamine, 0.01 µg/mL ECGF, 
and I µg/mL hydrocortisone ± test compounds was added onto Matrigel. Tube 
formation images were obtained at 2 hours intervals using the IncuCyte™ live-cell 
imaging system with phase-contrast ImageLock scan type. The images were analysed 
by measuring percentage of denuded area and number of sprouting cells at early stages 
of tube fomiation (4 hours) and number of tubes and total length of tubes formed at later 
stages of tube formation (6 hours) in each well using IncuCyte and NIH ImageJ 
softwares. 
2.2.13. Rose Bengal cell adhesion assay 
The cell adhesion assay performed in this thesis is based on a method developed by 
(O' Neill and Parish 1983) to measure the interaction of antibodies with cell surface 
antigens using an automated colorimetric assay. 
A 96 round bottom (U-well) culture plate (Costar, Coming, Lowell , MA) was first 
coated either with bovine plasma fibronectin (Invitrogen, Carlsbad, CA) or purified 
human vitronectin (Gibco BRL, Grand Island, NY) at 50 µL/well at selected 
concentrations ranging from 0.3 13 to 10 µg/mL and incubated overnight at 4 °C. The 
next day, the solution in the wells was flicked off and the wells then washed by 
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submerging the plate twice in a PBS bath (flicking off PBS in between washes). The 
non-specific binding sites were then blocked by incubation with 200 µL/well of 1 % 
BSA in Hank's balanced solution (HBSS) for 1 hour at 37 °C before flicking off the 
supernatant. HMEC (5 x 104 cells/well) were added in 100 µL/well of serum free 
culture medium supplemented with 0.1 % BSA with or without test compounds. The 
plates were then incubated either for a time course study (2.5-30 min) or for 60 min at 
37 °C. The plates were then flicked to remove unbound cells and 100 µL/well of0.25% 
(w/v) Rose Bengal dye (Koch-Light Laboratories Ltd., Colnbrook, Berkshire, England) 
in PBS was added and allowed to stain the bound cells, for 3 min at room temperature. 
The un-absorbed dye was then removed by flicking the plate and the plate washed twice 
by submerging it in separate PBS baths, with the PBS being changed between washes. 
The plate was then allowed to drain and 200 µL/well of 50% ethanol in PBS added 
and mixed to liberate dye from the cells. Non-specific binding of the dye to 
fibronectin/vitronectin-coated and uncoated wells in the presence and absence of cells 
was also determined and optical density values subtracted from test values. The relative 
number of bound-cells in each well was quantified by determining each well's optical 
density (OD) at A.1=540 nm and A.2=650 nm, on a Thermomax microplate reader. The 
data were then analysed by GraphPad prism 5.04 software. 
2.2.14. Statistical significance 
Data and results are reported as means ± SEM (standard error of the mean) unless 
noted otherwise. Statistical significance was measured using a two-tailed unpaired /-
test and Student-Newman-Keuls test after one-way ANOV A comparing the sample 
treated group and the untreated control group using the GraphPad prism 5.04 software 
(GraphPac;l Software, San Diego, CA). Also, two-way ANOVA data analysis followed 
by Bonferroni post-test was applied to some graphs to compare each column to all the 
other colunms. P values less than 0.05 were considered statistically significant. 
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Chapter 3 
Purification and Structural Elucidation of Two 
Low Molecular Weight Pro-angiogenic Molecules 
from Glycine max 
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3.1. Introduction 
Natural products derived from plants have intrinsic broad scientific interest but most 
particularly have been used as therapeutics. For example, the bark of the willow tree 
(Salix sp.) contains salicylic acid. The willow tree bark was used by the ancient Greeks 
and native Americans to treat a wide range of ailments (Rishton 2008). The salicylic 
acid present in the willow tree bark is not only a plant defence hormone but also the 
precursor of aspirin, a common over-the-counter analgesic that can also be used to treat 
inflammation and to inhibit platelet aggregation (Mahdi, Mahdi et al. 2006). More 
recently, the Pacific yew tree (Taxus brevifolia) (Wani, Taylor et al. 1971) and the 
French lilac (Galega officianalis) were the source of the active compounds in the drugs 
taxol and the biguanide class of antidiabetic, respectively, used in the treatment of 
breast cancer (Witters, Santala et al. 2003). Other plant derived anticancer drugs 
include; vincristine, vinblastine and camptothecin (Pezzuto 1997; Gordaliza 2007). 
Many natural products have pharmacological effects in humans and therefore may have 
potential therapeutic applications and commercial value. 
Pharmacologically active compounds in plants often exist at very low concentrations 
and may include different classes of chemicals with a range of different polarities and 
solubilities (Tu, Jeffries et al. 2010). The challenge that this presents in developing an 
extraction and purification protocol is complicated since plant tissues represent a very 
complex matrix from which these materials must be retrieved. 
One strategy that enhances the potential for success in identifying biologically active 
components in fractionated plant material is to couple a purification strategy with an 
activity guided assay (Li and Vederas 2009). If the assay is sensitive and robust enough 
to detect biologically active components in crude plant fractions, it can also be used 
subsequently to follow the active components through further purification steps (Butler 
2004). These purification steps often involve various fo rms of chromatography that 
separate molecules according to size, charge or hydrophobicity such as size exclusion 
chromatography (SEC), molecular weight spin filters , ion exchange or reverse phase 
chromatography (Cannell 1998; Wu, Yang et al. 2008). Once the active fractions have 
been fully purified in sufficient quantities then the classical techniques of nuclear 
magnetic resonance (NMR) and mass spectrometry (MS) can be applied to the problem 
of elucidating the structure of the active components (Kingston 2011 ). 
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The laboratory I worked in has a background in identifying biologically active plant 
components in xylem sap that are involved in long distance signalling (Djordjevic, 
Oakes et al. 2007). Since quantities of xylem sap were available for screening this 
material was utilised in my research to screen for biologically active components that 
have activity with mammalian cells. The choice of xylem sap also had other advantages 
since it is known to be a rich source of metabolites (Krishnan, Nataraj an et al. 2011), 
can be isolated relatively easily and it is free from pigments and cell wall material that 
are major components of plant tissue extracts. In addition, preliminary work identifying 
biologically active components in this material had been undertaken by Lauren Du Fall 
in 2009 (Du Fall 2009). In this work, the xylem sap was initiall y fractionated by size 
exclusion chromatography and a bioactive fraction was found in the low molecular 
weight eluate (<1 kDa). This low molecular weight fraction was then subject to reverse 
phase HPLC chromatography on a CI 8 column and further testing showed this fraction 
to contain compounds that could promote or inhibit angiogenesis. 
A well understood, frequently utilised in vitro bioassay (Auerbach, Lewis et al. 2003) 
was used to monitor the activity of the various fractions derived from soybean. This 
assay has been used by researchers in the Parish laboratory to screen for anti-angiogenic 
compounds, with the new anti-angiogenic, sulphated _oligosaccharide, drug PI-88 
(US6271215, also called Muparfostat) being identified (Parish, Freeman et al. 1999). 
PI-88 is currently undergoing a phase III clinical trial in hepatocellular carcinoma 
patients (Liu, Lee et al. 2009). However, since a large number of anti-angiogenic 
compounds were already in different stages of commercial development (Li, Li et al. 
2012), this angiogenesis assay was then modified to enable detennination of pro-
angiogenic activity of Nod factors (Djordjevic, Bezos et al. 2013) as well as screening 
of plant natural products by DuFall (Du Fall 2009) and in this thesis. 
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3.2. Research aims 
This chapter describes the further investigation of the xylem sap of Glycine max 
using activity-guided fractionation based on the in vitro rat aorta angiogenesis bioassay. 
One of the problems with the initial investigation was the failure to isolate enough 
material for examination by nuclear magnetic resonance (NMR). In order to increase 
the throughput of the purification process it was decided to replace the size exclusion 
chromatography with molecular weight cut-off spin columns as these were potentially 
capable of readily processing larger volumes of the xylem sap, in parallel, and at a faster 
rate. Studies were also initiated to maximise the yield of the active compounds in the 
xylem sap and different planting regimes and conditions for growth for the glasshouse 
grown soybeans were examined. It was expected that a combination of both enrichment 
and higher throughput would allow sufficient material to be accumulated to successfully 
complete the structural elucidation, using liquid chromatography mass spectrometry 
(LC/MS) and nuclear magnetic resonance spectrometry (NMR), of the pro-angiogenic 
molecules. 
3.3. Research objectives 
1) Identify and isolate the pro-angiogenic compounds less than 1 kDa from xylem 
sap using in vitro pro-angiogenesis rat aorta bioassay. 
2) Purify the compounds with pro-angiogenic activity. 
3) Determine the structure of pro-angiogenic molecules using LC/MS and NMR. 
4) Confirm the determined structure of natural compounds with synthetic versions. 
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3.4. Results 
3.4.1. Soybean cultivation optimisation 
As soybeans (Glycine max) are subtropical plants, they were cultivated in a 
glasshouse between spring and autumn using artificial lighting to extend day length was 
necessary. However, planting in mid- to late-summer seemed to result in the most 
robust growth and this was reflected in the enhanced yield of the bioactive compounds 
(Table 3.1) (Fig 3.1 , 3.2, 3.3A and 3.3B). 
Plants were either inoculated with Bradyrhizobium or uninoculated and 
supplemented with nitrate fertili ser (lmM or 10 mM KNO3). In order to establish the 
optimal amount of nitrate required for growth, uninoculated soybean plants were treated 
with varying concentrations of nitrate (1 or 10 mM KNO3). It was determined that 200 
mL of IO mM of KNO3 solution every two days was sufficient to support growth for 4-6 
weeks. Plants were decapitated at 6 weeks and the xylem sap extracted over 0-7 and 7-
24 hours. 
3.4.2. Purification of small molecules of xylem sap 
In the initial experiments, size exclusion chromatography (SEC) using the 
Superdex™ Peptide HR 10/30 size exclusion column was used to fractionate the xylem 
sap material (Oakes, Bezos, Parish & Djordjevic, unpublished data; DuFall 2009) to 
purify thirty one fractions (lmL) collected from reverse phase HPLC (C18). Two pro-
angiogenic and three anti-angiogenic fractions were identified. The late elution of these 
active fractions suggested that firstly, the active compounds were <1000 Da and 
secondly, a mixed mode of separation was occurring (i.e. size exclusion and adsorption 
to the dextran/cross-linked agarose matrix ; see for example (Schluter and Zidek 1993). 
Later, LC/MS analysis of one of the pro-angiogenic molecules, showed the molecular 
mass of375 Da. Therefore, the aim of this research described in this thesis was focused 
on purifying molecules less than 1 kDa on a large enough scale to complete the 
structural analysis of the isolated angiogenic compounds. 
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Table 3.1. Volume of extracted xylem sap from soybeans planted at different times 
and grown under different conditions. 
Number of Season of Season of Rhizobium Volume of 
soybean planting harvesting inoculated or KN03 extracted plants supplemented xylem sap 
100 Mid-October End-November Rhizobium inoculated ~ 700 mL 
100 Mid-October End-November I mMKNO3 ~ 600 mL 
100 Mid-October End-November !0mMKNO3 ~ 700 mL 
100 Mid-January End-February !0mMKNO3 ~ 750 mL 
100 Mid-March End-May !0mMKNOi ~ 400 mL 
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In order to max1m1se the amount of material , new purification methods were 
developed to isolate small molecules from the soybean crude extract. A succession of 
10, 3 and 1 kDa of molecular weight spin filters was used to isolate the low molecular 
weight fractions. However, it was found that the 1 kDa filter retained a proportion of 
biologically active molecules, so the isolation steps were limited to using only the 10 
and 3 kDa filters (Fig. 3.3B and 3.3C). This had the advantages of decreasing the 
spinning time at a reduced cost purification method. Thus, the 3 kDa spin filtration 
following a 10 kDa spin filtration appeared to offer the best purification of the bioactive 
compounds. The small molecule fraction was lyophilised by freeze-drying for storage at 
-80 °C. 
3.4.3. Reverse phase HPLC purification of xylem sap small molecules 
Different combinations of water, polar and non-polar organic solvents (Diethyl 
Ether, Ethyl acetate and Acetonitrile) were tested to determine the optimal liquid 
composition for resuspending the lyophilised filtrate for chromatographic separation by 
HPLC. The use of all except water showed incomplete re-suspension of the dried 3 kDa 
xylem sap filtrate. Therefore, deionised water (> 18.2 MO.cm) was used to resuspend 
the lyophilised material prior to HPLC fractionation. 
The concentrated reconstituted xylem sap was fractionated by C18 reverse phase 
chromatography into 30s fractions over a 5%-85% acetonitrile gradient and all the 
fractions were screened for pro-angiogenic activity (Fig. 3.1, 3.2 and 3.3). Three 
fractions (FKI , FK2 and P6) from the 1 0mM KN03 treated soybean extracts were 
selected for further analysis. The UV absorbance of both FKI and FK2 were essentially 
identical with UV absorbance maxima (Amax) at 265 nm and a shoulder at 298 nm, 
suggesting some structural similarity. The UV absorbance of P6 had a Amax at 283 and 
343 nm, as previously described by (Du Fall 2009) (Fig. 3.4). These UV absorbances 
are characteristic of phenols and conjugated double bond systems. 
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Figure 3.1. Pro-angiogenesis rat aorta assay on Bradyrhizobium inoculated xylem 
sap HPLC fractions. 
HPLC eluate (2-20 minutes) was collected at 30 seconds intervals, then dried down to I 00 µL and 
analysed. Data are expressed as a percentage of aorta vessel outgroW1hs observed on days 5 (A), 6 (B) 
and 7 (C). Pl-88 has clinically proven anti-angiogenic activity and was used as a negative control. Data 
analysis was performed by unpaired I-test, comparing each group to the control. Error bars represent SEM 
(n~6). *, P '.o 0.05 , **,:, 0.01 , *** :, 0.00 I. Pro-angiogenic active fractions (D). 
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Figure 3.2. Pro-angiogenesis rat aorta assay on 10 mM KNO3 xylem sap HPLC 
fractions. 
HPLC el uate (2-20 minutes) was collected at 30 seconds intervals, then dried down to I 00 µL and 
analysed. Data are expressed as a percentage of aorta vessel outgrowths observed on days 5 (A), 6 (B) 
and 7 (C). PI-88 has clinically proven anti-angiogenic activity and was used as a negative control. Data 
analysis was performed by unpaired I-test, comparing each group to the control. Error bars represent 
SEM (n=6). *, P <: 0.05, **, <: 0.0 I, *** <: 0.001. Pro-angiogenic active fractions(□). 
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Figure 3.3. HPLC chromatograms of xylem sap from Bradyrhizobium inoculated 
and nitrate supplemented soybean plants. 
HPLC separation of 3 kDa filtrate xylem sap from the Rhizobium inoculated (A) and un-inoculated, 
10 rnM nitrate supplemented (B) soybeans. HPLC separation of 1 kDa filtrate xylem sap from 10 rnM 
nitrate supplemented soybeans (C). An equivalent amount of material (50 µ! inj ection equivalent to 20 
mL sap) was loaded in all inj ections. Absorbance was monitored at 254 nm. Fractions were collected at 
30 s intervals from A and B and tested by the rat ~orta pro-angiogenesis bioassay. Prn-angiogenic active 
fractions (D). 
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Figure 3.4. UV absorbance of pro-angiogenic HPLC fractions FKl, FK2 and P6. 
FKJ (A) and FK2 (B) UV absorbance spectra were essentially identical with Arna,= 265 nm and 
shoulder at 298 nm. The UV spectra of P6 was characterised by a A,n" at 283 and 343 nm. Absorbance 
was monitored at 254 nm. 
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3.4.4. Hydrolysis experiments 
To investigate the possibility that FKJ , FK2 or P6 may be glycosylated, the purified 
material was subject to acid hydrolysis with lM HCl in a plastic tube immersed in 
boiling water for an hour. HPLC analysis of the reaction mixtures showed the 
disappearance of each of FKJ, FK2 or P6 from the HPLC trace and their replacement 
by a single, later eluting peak (Fig. 3.5A) with a UV absorption spectra characterised by 
Amax at 204 and 260 nm and a shoulder at 298 nm (Fig. 3.5C). In a blank hydrolysis 
without a sap fraction, it became clear that this peak was an artefact derived from a 
particular batch of plastic tubes (Fig. 3.5B). However, it was interesting to note that this 
compound had pro-angiogenic activity. Attempts to NMR analysis were unsuccessful 
as sufficient material could not be isolated. 
3.4.5. Yield of pro-angiogenic compounds is seasonally and nitrate dose 
dependent 
The yield of the pro-angiogenic compounds FKJ , FK2 and P6 were found to be 
dependent on a number of factors including time of planting, and the concentration of 
applied KNO3 (Fig. 3.6). 
The optimal yield of FKJ , FK2 and P6 was found to be from plants grown in 
January/February and supplemented with 10 mM KNO3 (Fig. 3.6C). However, for 
some reasons, not fully understood, the yield of P6 was subject to a large degree of 
variation. For this reason, it was decided to concentrate on only isolating FKJ and FK2 
in sufficient amounts for NMR and MS analysis. 
3.4.6. Final purification of bioactive fractions for structural analysis 
The HPLC separation of FKJ and FK2 was optimised to enable the isolation of pure 
FKJ and FK2 prior to NMR and MS analysis (Fig. 3.7). A total of 458 µg of FKJ and 
387 µg of FK2 were purified. This represented 2 L of sap from 300 6 week old 
soybeans. The pro-angiogenic activity of the purified FKJ and FK2 were then 
confirmed by bioassay before NMR and MS analysis (Fig. 3.8). 
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Figure 3.5. HPLC chromatogram and UV absorbance spectra of the IM HCI 
hydrolysis product from the plastic tubes. 
HPLC separation of hydrolysed a plastic tube (A) and hydrolysed FKJ (B) and UV absorbance 
spectra (C) of the artefact derived from the IM HCl hydrolysis. This proved to der.ive from the plastic 
container in which the hydrolysis was performed. 
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Figure 3.6. Growth conditions affect yield of pro-angiogenic compounds. 
HPLC chromatograms of xylem sap extracted from 6 weeks old soybeans grown under different 
conditions (A), seeds were planted in October and supplemented with IO mM nitrate (B), seeds were 
planted in October and supplemented with I rnM nitrate (C), seeds were planted in January and 
supplemented with 10 mM nitrate. An equivalent amount of material (50 µL inj ection equivalent to 20 
mL sap) was loaded in all injections . Absorbance _was monitored at 254 nm. 
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Figure 3.7. Semi-preparative purifica_tion of FKJ and FK2 by HPLC. 
High resolution separation of FKJ and FK2 from xylem sap was optimised by modifying the 
analytical HPLC method (A) and FKJ and FK2 peaks were individually collected (B). An equivalent 
amount of material (50 µL injection equivalent to 20 mL sap) was loaded. Absorbance was monitored at 
254 run. 
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Figure 3.8. Pro-angiogenesis rat aorta assay on purified FKJ, FK2 and P6 from 
xylem sap. 
FKJ , FK2 and P6 fractions from xy lem sap were coUected from HPLC, then dried down to I 00 µL 
and analysed. Data are expressed as a percentage of aorta vessel outgrowths observed on days 5, 6 and 7. 
Pl-88 has clinically proven anti-angiogen ic activity and was used as a negative control. Data analysis was 
performed by Student- Newman-Keuls test after one-way ANOVA comparing each group to control in 
each treatment. Error bars represent SEM (n=6). ~, P :c 0.05, **, :c 0.0 I, *** :c 0.00 I. 
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3.4.7. NMR analysis of purified FKJ and FK2 
FKJ chemical shifts 
o( 1H, D20, 800 MHz) 6.88 (d, J4=2.0 Hz, lH, H-2), 6.74 (d, J3=8. l Hz, lH, H-5), 
6.86 (dd, J3= 8.1 Hz, J3=1.9 Hz, lH, H-6), 4.7 (overlapped m, 2H, H-7), 4.66 (m, lH, 
H-8), 4.07 (dd, J2= 12.3 Hz, J3= 2.8 Hz, lH, H-9a), 3.94 (dd, J2= 12.3 Hz, J3= 6.7 Hz, 
lH, H-9b), 3.68 (s, 3H, H3-10), 6.98 (bs, lH, H-2'), 6.97 (overlapped s, lH, H-5') , 6.97 
(overlapped s, lH, H-6') , 6.56 (dt, J3=16.0 Hz, J4=l Hz, lH, H-7'), 6.31 (dt, J3=15.9 
Hz, J3=6.0 Hz, lH, H-8') , 4.25 (dd, J3=6.0 Hz, J4=!.0 Hz, 2H, H2-9'), 3.70 (s, 3H, H3-
l0'). 
o(13C, 0 20 , 201 MHz) 130.60 (C-1) , 111.38 (C-2), 147.72 (C-3), 147.2 (C-4), 
115.42 (C-5), 121.13 (C-6), 72.54 (C-7), 83.56 (C-8), 61.52 (C-9), 55.69 (C-10), 
131.13 (C-1'), 109.78 (C-2'), 149.22 (C-3'), 146.94 (C-4'), 116.56 (C-5'), 119.45 (C-
6'), 130.61 (C-7'), 126.76 (C-8'), 62.29 (C-9'), 55.46 (C-10'). 
FK2 chemical shifts 
o(1H, D20, 800 MHz) 6.94 (d, J4=1.9 Hz, IH, H-2), 6.77 (d, ./J=8.1 Hz, lH, H-5), 
6.85 (overlapped dd, J3= 8.1 Hz, J3=1.7 Hz, lH, H-6), 4.89 (d, ,J3=5.5 Hz, 2H, H-7), 
4.61 (m, 1 H, H-8), 3.59 (dd, J2= 12.2 Hz, J3= 6.0 Hz, 1 H, H-9a), 3.77 (dd, J2= 12.9 Hz, 
J3= 3.7 Hz, lH, H-9b), 3.69 (s, 3H, H3-10 or 10'), 7.08 (d, J3=1.8 Hz, IH, H-2'), 6.87 
(d, J3=8.64 Hz lH, H-5'), 6.92 (dd, J3=8.46 Hz, J 3= l.8 Hz IH, H-6'), 6.52 (dt, J3=15.9 
Hz, J4= l .0 Hz, lH, H-7'), 6.27 (dt, J3=15.8 Hz, J3=6.0 Hz, lH, H-8'), 4.18 (dd, J3=6.l 
Hz, J4=1.2 Hz, 2H, Hi-9'), 3.71 (s, 3H, H3-10' or 10). 
o( 13C, D2O, 201 MHz) 110.75 (C-2), 115.48 (C-5), 119.59 (C-6), 72.43 (C-7), 83.21 
(C-8), 60.49 (C-9) , 55.43 (C-10 or 10'), 109.81 (C-2') , 115.42 (C-5') , 119.48 (C-6'), 
130.09 (C-7'), 126.70 (C-8'), 61.95 (C-9'), 55.43 (C-10' or 10). 
Initial QTOF MS data implied a chemical formula of C20H22O6, however, through 
the NMR structure elucidation process an extra proton shift was found correlated to the 
molecule of interest. It was proposed that the mass initially observed in the QTOF MS 
was in fact the [M-H2Or peak, implying a formula of C20H24O7• Further MS studies did 
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find the corresponding molecular ion by both +ve ESI (M+, m/z 376; and [M+Na]+, mlz 
399) and -ve ESI ([M-HL m/z 375) with the application of a reduced nebulizer spray 
temperature (see section 3.4.8 below). 
Initial ID proton NMR spectra were recorded for both FKJ (458 µg) and FK2 (387 
µg). FKJ was determined to be more pure and of higher concentration, so initial 
structure determination was performed on this product. 1H, 13C-HSQC, 13C-HMBC, 1H-
1H DQF-COSY, 1H- 1H TOCSY and 1H-1H NOESY NMR spectra were then measured 
for FKJ and structural fragments were constructed as follows. Two methoxy 
resonances were identified in the 1H NMR spectrum at 8 3.68 (3H, s, H-10) and 3.70 
(3H, s, H-10'). Two protons at 8 6.56 (IH, dt, J = 16.0, 1.0 Hz, H-8') and 8 6.30 (IH, 
dt, J = 15.9, 6.0 Hz, H-7') were identified in a trans double bond arrangement due to 
their J3 coupling of 16.0 Hz, and were linked to a degenerate methylene group, 8 4.25 
(2H, dd, J = 6.0, 0.9 Hz, H2-9'), via their J3 and J4 couplings respectively. Proton 
signals at 8 4.07 (dd, J2= 12.3 Hz, J3= 2.8 Hz, IH, H-9a) and 8 3.94 (dd, J2= 12.3 Hz, 
J3= 6.7 Hz, IH, H-9b) were linked through their J2 coupling and their shared carbon 
shift in the 13C-HSQC, and were linked to a multiplet at 8 4.66 (m, lH, H-8) via the 
DQF-COSY. An ABX aromatic coupling system was identified, and positioned the 
aromatic proton at 8 6.86 (dd, J3= 8.1 Hz, J3=1.9 Hz, IH~ H-6) meta from 8 6.88 (d, 
J4=2.0 Hz, IH, H-2) and ortho to 8 6.74 (d, J3=8.1 Hz, IH, H-5). Three further 
aromatic protons were identified and linked via the TOCSY, but needed correlations 
from the HSQC and HMBC to resolve H8 6.97, (overlapped s, IH, H-6') as ortho to H8 
6.97, (overlapped s, lH, H-5'), and para to 8 6.98 (bs, IH, H-2'). The HSQC and 
HMBC were also used to resolve a solvent overlapped peak, H8 4.7 C8 72.54 
(overlapped m, 2H, H-7, C-7) and link this resonance to C8 61.52 (C-9). The methoxy 
gro4p H3-10 was linked to H-2 via the NOESY spectrum and to C8 147.72 (C-3) via 
the HMBC, which was also linked to H-6 and H-5. Methoxy H3-10' was linked to H-2' 
via the NOESY spectrum and to C8 149.22 (C-3') via the HMBC, which was further 
linked to H-5' and H-6'. NOEs were observed between H-2', H6' and H-7', linking 
these fragments, and was positioned on the aromatic ring by the HMBC correlation 
between H-7' to C8 119.45 (C-6') and C8 109.78 (C-2') as was H-8' to C8 131.13 (C-
l'). Finally, HMBC correlations between H-6, H-2 and C-7 and further correlations 
between H-8 and C8 146.94 (C-4') constructed the final compound. NOEs between H-
2', H-5' and H-8 confirmed this ether linkage. 
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Assigmnents could easily be correlated to FK2 due to the similarity of the 13C-HSQC 
resonances to those of FKJ. It was then proposed that FKJ and FK2 were stereoisomers 
of the same compound. Four possible stereoisomers of the above product are possible, 
with chiral centers at C-7 and C-8, however, two of the possible isomers have already 
been isolated from nature and described in the literature (Lourith, Katayama et al. 
2005). The assigned shifts of both FKJ and FK2 agree with previously published 
measurements for both erythro- and lhreo-guaiacylglycerol-,8-O-4'-coniferyl ether, 
respectively. However, it is not possible to determine whether one or both of the 
respective two enantiomers is present (erythro- 7S, 8S/7R, 8R; threo- 7R, 8S/7S, 8R) 
(Fig. 3.9). 
3.4.8. LC-MS/MS analysis of purified FKJ and FK2 
The purified neolignans, erythro-guaiacylglycerol-8-O-4 '-coniferyl alcohol (FKJ) 
and threo-guaiacylglycerol-8-O-4'-coniferyl alcohol (FK2) were subject to high 
resolution accurate mass analysis fo llowing electrospray ionisation (ESI) in both the 
negative and positive modes. 
In the negative mode, the MS/MS spectra (Fig. -3.10), generated from the 
deprotonated FKJ and FK2 molecules (mlz 375, [M-Hr) were essentially identical to 
those reported by Marreel et al. (20 10), comprising a series of losses of H2O (mlz 357, 
[M-H-H2OD, formaldehyde (m/z 327, [M-H-H2O-CH2OD and a methyl moiety (m/z 
312, [M-H-H2O-CH2O-CH3]") (Marreel, Kim et al. 2010). A comparison of the 
observed and calculated masses for the deprotonated molecules and their associated 
fragments showed them to be in good agreement (~ppm between -3.19 and 4.85) (Table 
3.2). 
In the positive mode, the MS spectra was dominated by the sodium adduct (m/z 399 
([M+Nat) and successive losses of OH (m/z 359, [M-OHD, H2O (m/z 341 , [M-OH-
H2Or) and formaldehyde (m/z 311, [M-OH- H2O-CH2Or (Fig 3.11). A comparison of 
the observed and calculated masses for these ions showed them to also be in good 
agreement (~ppm between -1.32 and 0.58) (Table 3.3). The NMR and MS data are all 
consistent with FKJ and FK2 being identified as erylhro-guaiacylglycerol-8-O-4' -
(coniferyl alcohol) ether and threo- guaiacylglycerol-8-O-4'-(coniferyl alcohol) ether, 
respectively. 
69 
A 
Chapter 3 
OH 
H3C/ Oxr7~ 8/0n 4• ~ 
I I I 8' OH ~ ,,,,, 9 ,// 1/" / HO HO ,,, 0 7' ~ 
I CH3 
Erythro-guaiacylglycerol-S-0-4 '-coniferyl alcohol (FKJ) 
(7S, SS/7R, SR) 
B OH 
0 ' 0 HC/xr7~ / u~·  3 I 8 
I I · 
~ g ,// ,,,- 8' OH HO HO / 0 7'1/ ~ 
I CH3 
T/ireo-guaiacylglycerol-S-0-4'-coniferyl alcohol (FK2) 
(7R, SS/7S, SR) 
Figure 3.9. Chemical structures of FKJ and FK2 as determined by NMR. 
FKJ and FK2 are 20 carbon molecules with two chiral carbons (C20H240 6). Later, commercial FKI 
(A) was purchased from BOC Sciences, NY, USA and naturally derived FK2 (8) was provided by the 
Second Military Medical University, Shanghai, China to confirm the structural identification and study 
the cellular mode of action. 
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A commercially purchased sample of FKJ and an independently derived natural 
product isolate of FK2 (isolated from Bretschneidera sinensis) were found to have 
essentially the same spectroscopic and chromatographic properties as the isolated FKJ 
and FK2 and were also found to promote angiogenesis in the in vitro rat aorta bioassay. 
Xylem sap was directly analysed by LC/MS and peaks corresponding to FKJ , FK2 
and P6 were found at the expected retention times, indicating that the structural integrity 
of these compounds had been maintained throughout the purification process. 
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Figure 3.10. Negative ion mode ESI-MS/MS spectra. 
ESI-MS/MS of FKI , e,ythro-guaiacylglycerol-8-O-4"-(coni fery l alcohol) ether (A) and FK2, lhreo-
guaiacylglycerol-8-O-4 "-(coniferyl alcohol) ether (B), selecting mlz 375 ([M-Hr) for CID at I0eV. 
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Table 3.2. Comparison of elemental formulas derived from the observed negative 
ion mode ESI MS/MS spectra with the calculated elemental formulas for FKl and 
FK2. 
Product ion Structure Empirical Cale m/z Appm Loss formula m/z 
-✓~d.=(~ C20 H 2301 FKI 375. 1444 1.4 [M-Hr 375. 1449 H ~ to0 D /2 _,,:::, OH 
)., FKl 375. 1447 0.6 
~/:xx:r~ C20H 2106 FKI 357. 1355 -3. 19 [M-H,or /2 /2 A OH 357. 1344 H20 )., FK2 357. 1351 -2.07 
,✓X(Y))~ C19H210r; FKI 345 .1333 3.08 [M-CH,O]" 345. I 344 CH20 
• ~ MO 0 /2 _.,;:::CH, 
I FK2 345. 1347 -0.98 
" 
✓~~ C1siH190s FKI 327. 1236 0.6 [M-H,0 -CH,o r ~ /2 /2 OH 327. 1238 CH.i02 )., FKl 327. 1237 OJ 
'~~ FKI 312.0989 4.56 [M-H20 -CH,0 -CH3)" 
0 
~ I I : 4 OI< Ci~H,60 5 312.1003 C2H10 1 
k FKl 312. 1005 -0. 57 
CIOl-li10 ~ FKJ 195.0663 0.09 
':C:r:( A. ",C/0 1/",,,,;::. .y 195.0663 C10H1 20 3 
FK2 195.0662 0.42 
C9H90 3 
FK/ 165.0559 -I. I ✓~~ [A-CH,o r 
. " I 165.0557 C 11H 14Q_. 
FKl 165.0560 -1.7 1 
~~ FKI 179.0705 4.85 C10HnO3 s- 179.07 14 C10H 120~ )., FK2 179.07 13 038 
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Figure 3_11. Positive mode ESI MS spectra. 
Positive mode ESI-MS of FKI , e,ythro-guaiacylglycerol-8-0 -4'-(coniferyl alcohol) ether (A) and 
FK2., lhreo-guaiacylglycerol-8-0-4 · -(coniferyl alcohol) ether (B). 
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Table 3.3. Comparison of elemental formulas derived from the observed positive 
ESI MS/MS spectra with the calculated elemental formulas for FKJ and FK2. 
Product ion Empirical Cale mlz mlz Appm Gain/Loss formula 
[M+Naj' FKJ 399. 1419 -1.19 C,oH240 7Na 399.1414 Na adduct 
FK2 399. 1417 -0.69 
FKJ 394. 1861 -0. 18 
[M+Nl--Li)' C20H280 7N 394. 1860 NH4 adduct 
FK2 394. 1858 0.58 
[Mt FKJ 376. 1520 -0 .92 C,oH,.o, 376.1517 
FK2 376. 151 7 -0. 12 
FKJ 359. 1492 -0.79 
[M-OHt C2oH220 6 359. 1489 -OH 
FK2 359.1492 -0.79 
FKJ 341.1388 -1 .32 
[M-OH-H20]' C20H200 , 34 1.1 384 
-H30 2 
FK2 34 1.1 385 -0.44 
[M-OH-H20-CH,Ot FKJ 311.1279 -0.3 7 C19H1904 311.1278 
-CH503 
FK2 311.1279 -0.37 
75 
Chapter 3 
3.5. Discussion 
Historically, plants have been a source of therapeutics. Over one hundred discovered 
chemical substances being considered as important drugs have been derived from 
different plants as a result of chemical studies focused on the isolation of active 
compounds from plants used in traditional medicine (Cragg and Newman 2001; Cragg 
and Newman 2001). In plants, soybean has long been identified as a source of 
isoflavones, genistein and daidzein. These molecules have been associated with health 
benefits such as relief of menopausal symptoms (Nestel, Pomeroy et al. 1999; Murkies, 
Lombard et al. 2008), reduction of osteoporosis (Civitelli 1997; Gennari, Agnusdei et 
al. 1998), lowering blood cholesterol levels (Kirk, Sutherland et al. 1998; Merz-
Demlow, Duncan et al. 2000), and reduction in risk of certain hormone related cancers 
i.e. breast (Peterson and Barnes 1991 ; Banerjee, Li et al. 2008) and coronary heart 
disease (Middleton, Kandaswami et al. 2000). Therefore, soybean derived fl avonoids 
became a matter of additional interest in this project for their potential therapeutic 
applications. 
Soybean growth studies showed that the yield ofpro-angiogenic compounds could be 
maximised when uninoculated plants, planted in early to mid-summer, were grown in 
the presence of IO mM KNO3. The enriched xylem sap from these plants could then be 
quickly passed through the spin columns to yield an act ivity-containing, low molecular 
weight fraction, as determined by the in vitro rat aorta bioassay. Bioactivity guided 
fractionation showed three consistent areas of pro-angiogenic activity in both 
Bradyrhizobium inoculated and 10 mM KNO3 treated soybean extracts (Fig. 3.3). 
Initially, FKl, FK2 and P6 were purified for structural determination. However, P6 
appeared to be very low in quantities in different plant cultures, seasonal dependent and 
also unstable. Therefore, FKl and FK2 were chosen for structural elucidation and 
further experiments. 
FKl and FK2 were then purified by semi-preparative HPLC to yield sufficient 
material (- 400 µg) fo r structural elucidation using NMR and high resolution accurate 
mass spectra, enabling their identification as erythro-guai acylglycerol-8-O-4 ' -coniferyl 
alcohol (FKl), and lhreo-guaiacylglycerol-8-O-4' -conifery l alcohol (FK2). In plants, 
these molecules are derived from the dimerisation of monolignols which are the 
precursors of the lignin, a key structural element laid down in the secondary plant cell 
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walls. There are three monolignols, p-coumaryl, coniferyl and synapyl alcohols which 
can be dimerised and polymerised into lignans and the lignin complex, respectively 
(Fig. 3.12) (Whetten and Sederoff 1995; Boerjan, Ralph et al. 2003). 
Lignin, the second most abundant polymer after cellulose, is an aromatic 
heteropolymer found mainly in secondary-thickened plant cell walls and xylem cells 
(Whetten and Sederoff 1995). It provides strength for the plant to grow upwardly and 
also allows the transport of water, solutes and nutrients through the vascular system 
along with protecting plants fr6m pathogen infection and other environmental stresses 
(Whetten and Sederoff 1995; Boerjan, Ralph et al. 2003). However, in angiosperms 
(flowering plants), lignin polymer is made predominantly from the monolignols 
coniferyl and sinapyl alcohol (Fig. 3.12) (Baucher, Monties et al. 1998), while the lignin 
of gymnosperms (seed-bearing plants) does not have sinapyl alcohol precursor 
(Marreel, Ralph et al. 2004). 
Lignans and neolignans are phenylpropanoid dimers with a wide range of structural 
diversity (Mander and Liu 20 I 0) which have previously been shown to have a number 
of medically important biological activities such as anti-tumour (Qu, Madi et al. 2005; 
Zhou, Liu et al. 2009), anti-oxidant (Kancheva, Saso et al. 2012) and anti-inflammation 
activities (Hallund, Tetens et al. 2008; Baumgartner, Sosa et al. 2011 ). 
In angiosperms (soybean) the monolignols coniferyl and sinapyl alcohol are 
transported to the cell wall where they are dehydrogenised by oxidative enzymes, such 
as peroxidases or laccases to form radicals with unpaired electron density at positions 
including O-C4-, CS-, and CS- (Boerjan, Ralph et al. 2003; Damiani, Marreel et al. 
2005; Marreel, Dima et al. 2010). The radicals then bind by a combinational radical-
radical coupling mechanism to form CS-CS', CS-CS ', CS-CS ', C4-O-C5' and C8-O-C4' 
dimers (Fig. 3.13) (Bunzel, Ralph et al. 2001; Peterson, Dwyer et al. 2010). However, 
by definition, only CS-CS' are known as lignans and the other dimers (CS-CS', CS-CS', 
C4-O-C5' and C8-O-C4') are classified as neolignans (Macrae and Towers 1984). 
Clearly, some of these dimers either leak out into the xylem sap, albeit in low 
concentrations, or are transported in xylem sap prior to being polymerised into high 
molecular weight lignins. Back calculations from the HPLC profile showed the 
concentrations of FKJ and FK2 to be approximately 5 x 10·7 M in concentrated 
soybean xylem sap. 
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Figure 3.12. An overview of monolignol biosynthetic pathway as precursors for 
lignans, neolignans and lignin. 
L-Pbenylalanine which is produced by the shikimic acid pathway is de-aminated by phenylalanine 
ammonia- lyse (PAL) to yield cinnamate. Cinnamate is hydroxylated by cinnamate 4-hydroxylase (C4H) 
to form p-coumarate. The hydroxyl groups can be methylated by an O-methyltransferase (OMT). Ferulic 
acid is hydroxylated by ferulate 5-hydroxy lase (F5H). The p-coumaroyl-CoA, feruloyl-CoA and sinapol-
CoA intermediates give rise to p-coumaryl alcohol, coniferyl alcohol and sinapyl alcohol, respectively 
following the action of cinnamyl alcohol dehydrogenase (CAD) on aldehyde forms. These monolignols 
can then be dimerised to form lignans and neolig_nans such as FKJ and FK2 or polymerised to yield 
lignin. Adapted from (Whetten and Sederoff 1995; Boerjan, Ralph et al. 2003). 
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Figure 3.13. Radical-radical coupling of monolignols (Coniferyl alcohol). 
Monolignol radicals can covalently bind to form C8-C8' (lignan), C5-C5', C8-C5', C4-O-C5' and C8-
O-C4 ' (neo lignan) dimers. However, C8-O-C4', C8-C5' and C8-C8' dimers are main types ofmonolignol 
dimerisatio□s. Adapted from (Boerjan, Ralph et al. 2003 ; Marreel, Ralph et al. 2004 ; Marreel, Dima et 
al. 2010). 
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Both of these 8-0-4' neolignans (FKJ and FK2), were found to be obtained 
commercially (in the case of FKJ) or available in collections of natural products. FK2 
was obtained from a collection of 6000 purified natural products from the Laboratory of 
Natural Products in the School of Pharmacy of the Second Military Medical University 
in Shanghai, China. These samples were confirmed as having identical spectroscopic 
(Morreel, Dima et al. 2010; Morreel, Kim et al. 2010) and biological properties as the 
biologically derived material, opening the way for extensive study of the mode of action 
on human model cell lines (Chapter 4). 
For reasons that were not clear, the yield of P6 from the plants proved to be variable 
and P6 was also found to be unstable to long term storage at -20 °C. By contrast, FKJ 
and FK2 proved to be stable to repeated freeze/thaw cycles and could be satisfactorily 
stored at -20 °C for periods in excess of a year. 
Overall, we were able to successfully identify and purify two pro-angiogenic small 
molecules from Glycine max xylem sap by bioactivity directed fractionation using the in 
vitro rat aorta bioassay. These two molecules were then found to be from the lignan 
family and were identified as erythro-guaiacylglycerol-8-O-4'-(coniferyl alcohol) ether 
(FKJ) and threo-guaiacylglycerol-8-O-4 ' -( coniferyl alcohol) ether (FK2) using NMR 
and MS data. Independently-derived samples of these two neolignans were found to 
have essentially the same spectroscopic and chromatographic properties as the isolated 
FKJ and FK2 and were also found to promote angiogenesis in the in vitro rat aorta 
bioassay. To our knowledge, this is the first report on angiogenic activity of these 
molecules. The cellular mode of action studies on their mechanism of promoting 
angiogenesis will be further studied in chapter 4 using the independently-derived 
counterparts of FKJ and FK2. 
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Chapter 4 
The Cellular Mode of Action Studies of 
E,ythro-guaiacylglycerol-8-0-4 '-coniferyl alcohol 
(FKJ) and 
Threo-guaiacylglycerol-8-0-4 '-coniferyl alcohol 
(FK2) 
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4.1. Introduction 
Angiogenesis is the formation of new capillaries from a pre-existing vascular 
network. Angiogenesis is a tightly controlled process in adult mammals (Fig. 1.5) and 
many pathological states associated with major classes of chronic diseases are 
associated with either excessive or insufficient angiogenesis. For example, excessive 
angiogenesis is associated with diseases such as cancer, psoriasis, blindness induced by 
age-related macular degeneration (AMD) and arthritis (Folkman 2000; Carmeliet 2003 ; 
Folkman 2007). Therefore, there has been much interest in the discovery of anti-
angiogenic agents and a diverse and extensive range of anti-angiogenic molecules have 
been isolated and identified and tested in clinical trials (Pezzuto 1997; Newman 2011). 
More recently, the possibility of using pro-angiogenic molecules as therapeutic 
agents has emerged. Pro-angiogenic drugs are less researched than anti-angiogenic 
drugs nonetheless they also have potential to aid in the treatment of a range of clinical 
situations (Carmeliet 2003) where the formation of new blood vessels is needed, such as 
in wound healing (Tonnesen, Feng et al. 2000; Bao, Kodra et al. 2009), cardiovascular 
disease (Pandya, Dhalla et al. 2006) and ischemic conditions such as stroke (Beck and 
Plate 2009; Font, Arbo ix et al. 2010). 
Moreover, only a limited number of pro-angiogenic molecules have been studied in 
clinical settings. These have included erythropoietin (EPO) (Ribatti , Presta et al. 1999), 
P-carotene (Dembinska-Kiec, Polus et al. 2004), nicotine (Mousa and Mousa 2006; 
Morimoto, Takemoto et al. 2008; Costa and Soares 2009), ferulic acid (Lin, Chiu et al. 
2010) and stromal cell-derived factor 1 (SDF-1) (Deshane, Chen et al. 2007). 
Therefore, it is of great interest to identify and explore more compounds with pro-
angiogenic activity. 
Plants have been used for centuries as a source of therapeutics to treat disease and 
continue to be the source of many new potential therapeutic agents. In more recent 
times, plant extracts have been screened using bioassays to discover the active 
ingredients of plants used in traditional medicine (Balunas and Kinghorn 2005). ln 
chapter 3, two small molecules (FKJ and FK2) were isolated from soluble fractions of 
soybean and shown to enhance angiogenesis using in vitro mammalian angiogenesis 
assays. The structures of FKJ and FK2 were then determined using NMR and high 
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resolution accurate mass spectroscopy, to be erythro-guaiacylglycerol-8-O-4 '-coniferyl 
alcohol (FKJ) and lhreo-guaiacylglycerol-8-O-4' -coniferyl alcohol (FK2) (Fig. 3.9). 
In plants, FKJ and FK2 are precursors for lignin formation (Boerjan, Ralph et al. 
2003; Morreel, Dima et al. 2010). Next to cellulose, lignin is the most abundant 
macromolecule on earth and it provides the structural support to enable woody higher 
plants to support their own weight, grow to great heights and resist wind damage. 
Molecules such as FKJ and FK2 are examples of structurally-diverse plant secondary 
metabolites derived from phenylpropanoid metabolism which are cross linked randomly 
in free radical-dependent reactions to form lignins. FKJ and FK2 are formed primarily 
from monolignols, coniferyl alcohol, by dehydrogenative dimerisation and 
distinguished by the intermonomer C8-O-C4' linkage (Fig. 3.13). From this family, 
dimers from monolignols (p-coumaryl, coniferyl and synapyl alcohols) with C8-C5' and 
C8-C8' bonds have been previously reported as having bioactivity in humans (Milder, 
Feskens et al. 2005; Van Miert, Van Dyck et al. 2005; Peterson, Dwyer et al. 2010). 
Therefore, molecules derived from the same plant pathway may have multiple activities 
and may represent a rich treasure trove of potential therapeutics. 
This chapter describes detailed studies of the angiogenesis modulating activity of 
synthetic FKJ and an independently derived natural source of FK2 (isolated from 
Bretschneidera sinensis). Commercial FKJ was purchased from BOC Sciences, NY, 
USA and the naturally derived FK2 was provided as a gift from Prof. Dr. Wei-Dong 
Zhang and Dr. Shan Lei from the Second Military Medical University, Shanghai, China. 
These molecules were shown to exhibit pro-angiogenic activity based on angiogenesis 
bioassay studies on their naturally occurring counterparts isolated from soybean (in 
chapter 3). Since molecules such as FKJ and FK2 occur throughout the plant kingdom, 
they are likely to be a common component of the human diet. Therefore, FKJ and FK2 
might be expected to have low toxicity. Given this, this increases the likelihood that 
they could potentially be developed as new drugs for manipulating angiogenesis. In this 
chapter, FKJ and FK2 were tested in several in vitro angiogenesis assays, which 
represent some of the key steps involved in angiogenesis. By testing each of these steps 
individually this offered the possibility of dissecting angiogenesis and perhaps 
pinpointing which step in this complex and highly regulated process could be targeted 
by FKJ and FK2. By exploring these research avenues, important information about 
the cellular mode of action of these molecules could be determined. The bioassays were 
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aimed at detem1ining if FKJ and FK2 affected endothelial cell proliferation, migration, 
tube formation or their adhesion to endothelial cell ECM components. 
4.1.1. Endothelial cell proliferation assay 
Endothelial cell proliferation is one of the important steps in angiogenesis and occurs 
in response to a number of angiogenic factors to provide sufficient cells to form new 
vessels. Pro-angiogenic or anti-angiogenic effects of test compounds on cell 
proliferation can be measured by direct cell counts, quantification of DNA synthesis, or 
assessment of metabolic activity (Goodwin 2007). 
Among the well-established cell proliferation assays, thymidine incorporation is the 
most frequently used assay. The 3H-thymidine incorporation assay has been carried out 
widely in order to identify if test substances can either enhance or inhibit angiogenesis 
by influencing DNA synthesis (Auerbach, Lewis et al. 2003). Proliferation assays can 
be carried out with low- or serum-free conditions to measure the pro-angiogenic activity 
of test compounds. Growth factors can be also applied to the serum-free culture 
medium. Anti-angiogenic activity of the compounds of interest is measured using 
normal levels of serum and/or growth factors (Goodwin 2009). 
In this thesis, the proliferation of human umbilical vein endothelial cells (HUVEC) 
was followed in the presence of FKJ and FK2 in serum free medium. Basic fibroblast 
growth factor (bFGF) was added in some experiments to evaluate if the compounds 
influence the mitogenic effects ofbFGF. 
4.1.2. Endothelial cell tube formation assay 
Angiogenesis requires the assembly of endothelial cells into vessel tubes. One of the 
most specific tests for angiogenesis modulators is to screen for their ability to affect 
endothelial cells forming three-dimensional tubular structures on an appropriate 
basement membrane matrix (Auerbach, Lewis et al. 2003; Goodwin 2007; Amaoutova 
and Kleinman 2010). In vitro bioassays measuring tube formation involve several steps 
of new blood vessel formation, including endothelial cell migration, adhesion to 
extracellular matrix components, and differentiation (Grant, Lelkes et al. 1991 ; 
Arnaoutova and Kleinman 20 I 0). Therefore, the endothelial tube formation assay 
84 
Chapter 4 
usually will be followed with endothelial migration and adhesion assays as they are 
mostly focused on a single specific step in angiogenesis (Conn 2012). Matrigel is the 
most widely used basement membrane model along with fibrin and collagen clots. It is 
an artificial ECM derived from Engelbreth-Holm-Swarm (EHS) tumour cells and highly 
enriched in laminin (a predominant extra cellular matrix component), collagen N , 
HSPG and various growth factors that initiate the formation of tubules (Auerbach, 
Lewis et al. 2003; Arnaoutova and Kleinman 2010; Conn 2012). Endothelial cell tube 
formation on Matrigel is a very quick assay and can be assessed within 24 hours. Initial 
vascular networks become evident after 2 hours of seeding endothelial cells onto the 
basement membrane and tubular bodies form after 5 hours. The capillary like structures 
become complete in 20 hours with the contraction of cell aggregates and then the fusing 
and elongation of cell branches (Conn 2012). In the current work, the effect of FKJ on 
endothelial cell tube formation on Matrigel was measured using HUVEC and HMEC 
cultures. 
4.1.3. Endothelial cell migration assay 
During angiogenesis, endothelial cells migrate into surrounding tissue following 
extra cellular ECM degradation. Endothelial cell migrati-on occurs in response to a 
gradient of angiogenic stimulatory factors, inducing VEGF and FGFs (Turner and 
Grose 2010; Weis and Cheresh 2011). Therefore, endothelial cell migration is an 
essential component of angiogenesis that requires a tight regulation of signalling and 
physiological mechanisms (Lamalice, LeBoeuf et al. 2007). 
In vitro cell migration assays can be used to determine the cell motility response to a 
particular angiogenic modulating agent. These assays include trans-well (based on 
modified Boyden chambers), under-agarose and scrape-wound assays (Auerbach, Lewis 
et al. 2003; Goodwin 2007; Staton, Reed et al. 2009). 
In the scrape-wound assay, a wound is introduced to the monolayer of confluent 
endothelial cells using a pipette tip, needle or cell scraper. The speed of cell migration 
towards the cleared area can be assessed over time by measuring the distance moved by 
endothelial cells as the wound closes. Closing the wound in this assay is initially based 
on cell migration, although cells in the cleared area will eventually proliferate as well. 
Therefore, for pro-angiogenic compounds enhancing migration, rather than cell 
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proliferation, can be addressed in the scrape wound assay by adding anti-proliferative 
agents to the culture medium (Goodwin 2007). In this project, endothelial cell 
migration was evaluated using HMEC monolayer and the IncuCyte wound scraper and 
imaging system. 
4.1.4. Endothelial cell adhesion to ECM components 
Endothelial cell adhesion to the ECM plays an essential role in angiogenesis and it is 
mediated by adhesion molecules such as integrins. Integrins are cell-matrix adhesion 
molecules that bind to ECM components and integrate signals between the ECM and 
intracellular pathways (Weis and Cheresh 201 1). During angiogenesis, the expression 
of angiogenic specific integrins that bind to fibronectin and vitronectin ECM ligands 
increases and this induces migration and tube formation events (Liekens, De Clercq et 
al. 2001; Weis and Cheresh 2011) . 
Over time, various methods have been used for in vitro adhesion assays to quantify 
the binding of cells to the target molecules. These techniques include counting cells 
under a microscope (Lackie and Bono 1977) using a particle counter (Mcfaul and 
Bowman 1990) and radiolabeling the cells using either 3H-thymidine (Roszkowski, 
Beuth et al. 1989) or 51Cr (Haskard, Strobel et al. 1989) and measuring the incorporated 
radioactivity of adherent cells. Recently cell adhesion has been estimated by staining 
adherent cells with dyes such as Rose Bengal and measuring the optical density (OD) of 
the absorbed dye within the bound cells (Chong and Parish 1985; Pan, Ren et al. 2012). 
Thus, in the present work, the adhesion of HMEC to immobilised fibronectin and 
vitronectin, as good representatives of angiogenic ECM components, was determined 
using the Rose Bengal adhesion assay. 
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4.2. Research aims 
Over the past 20 years, searches for effective anti-angiogenic therapeutics have been 
central to pharmacological research relating to angiogenesis. Anti-angiogenic 
molecules may be effective treatments for diseases such as solid tumour formation 
where the provision of a blood supply is thought to be important for tumour progression 
(Kerbel 1997). The aim of this research was to develop potential pro-angiogenic drugs 
that may find utility in treating several cardiovascular disorders or to aid wound healing. 
As a result of research conducted in chapter 3, two pro-angiogenic molecules derived 
from soybean were isolated. In this chapter, the validity of the biological activity of 
these molecules was first determined using synthetically-derived or independently 
sourced molecules of identical structure and the cellular mode of action of these 
molecules was studied using biological assays that incorporated the major steps of 
angiogenesis. 
4.3. Research objectives 
1) Confinn the pro-angiogenic activity of the synthetic versions of FKI and FK2 
using the rat aorta pro-angiogenesis bioassay. 
2) Investigate the pro-angiogenic activity of the synthetic molecules at 
physiologically relevant concentrations. 
3) Investigate the cellular mechanism of action of FKI and FK2 in enhancing 
angiogenesis using human endothelial cells in specific angiogenesis bioassays. 
4) Determine their possible interactions with angiogenic growth factors such as 
bFGF and its receptor. 
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4.4. Results 
4.4.1. In vitro activity of synthetic FKI and independent naturally-derived FK2 in 
the rat aorta ring bioassay 
Initially, standard rat aorta ring model (RARM) angiogenesis assays were performed 
using growth medium containing 20% Heat Inactivated FCS (HIFCS). The level of 
growth factors in HIFCS at this concentration allows vessels to grow at near maximum 
capacity. This results in newly forming vessels occupying approximately 80-90% of the 
observable field of view after 7 days of culture as they encroach on the walls of the 
containment vessel (48-well plate). The standard assay was configured to measure the 
inhibition of angiogenesis at a day 5 endpoint by manually quantifying the relative 
density and number of new vessels sprouted from the aorta ring in the field of view at 
this time. 
In this chapter, the standard RARM assay was modified to maximise the probability 
of identifying compounds with pro-angiogenic activity. This involved performing the 
pro-angiogenesis bioassay using 5% HIFCS instead of 20% HIFCS. This resulted in 
slower vessel outgrowth (approximately 60% vessel occupancy occurred after 7 days of 
culture). It also enabled the stimulatory and inhibitory effects of test compounds to be 
measured manually based on field of view observation on three days (days 5-7) instead 
of one day (Fig. 4.1 ). Successful utilisation of this modified human angiogenesis assays 
was first used to determine the pro- or anti-angiogenic activity of Nod factors (Susanti 
2011 ; Djordjevic, Bezos et al. 2013) as well as screening for compounds from soybean 
that could either enhance or inhibit vessel outgrowths (Du Fall 2009). This modified 
assay was also used in this thesis. 
Independently derived versions of FKJ and FK2 were either purchased (i.e. 
synthetically derived; FKJ) or obtained as a purified chemical from a plant extract 
(FK2). The biological activity of these FKJ and FK2 preparations was investigated over 
a range of concentrations (5 x I o·6 M to 5 x 10·9 M) to independently confirm that they 
had the same activity as those derived from soybean, and to satisfy Koch' s molecular 
postulates (Falkow 1988). The results, expressed as percent growth, showed significant 
enhancement of vessel outgrowth compared to the control after 5, 6 and 7 days of 
culture at all concentrations examined (Fig. 4.2). Since the independent samples of 
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synthetic FKJ and naturally derived FK2 reflected the activity of soybean derived FKJ 
and FK2, they were then used for the cellular mode of action studies outlined in this 
chapter. 
4.4.2. Effects of synthetic FKJ and independent naturally-derived FK2 on 
endothelial cell proliferation 
Synthetic FKJ and naturally derived FK2 were tested from 5 x 1 o·6 M to 5 x 10·12 M 
for their effect on the proliferation of serum-starved confluent HUVEC with or without 
bFGF at 12.5 ng/mL (Fig. 4.3). Previously, bFGF had been used at 25 ng/mL (Susanti 
2011) to test for the activity of Nod factor derivatives. However, the pro-angiogenic 
activity of FKJ and FK2 was considerably higher than the Nod factor derivatives 
(Susanti 2011). Thus, bFGF was used at 12.5 ng/mL instead to assess the mitogenic 
effects of FKJ and FK2 in the presence and absence ofbFGF. 
Synthetic FKJ and naturally derived FK2 significantly induced H1NEC 
proliferation at 5 x 10·6 M to 5 x 10·8 Mand 5 x 10·6 M to 5 x 10·12 M concentrations, 
respectively, when cultures contained 12.5 ng/mL of bFGF. The peak of activity 
occurred at 5 x 1 o·8 M in both cases and tapered off at lower and higher concentrations. 
In addition, the results showed that in the absence of bFGF, FK2 (but not FKJ) 
significantly enhanced -HUVEC proliferation between 5 x 10·8 M to 5 x 10·10 M 
compared to the control. 
These results suggest that both FKJ and FK2 require bFGF to significantly enhance 
cell proliferation but FK2 may also induce proliferation in the absence ofbFGF. 
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A 
B 
Figure 4.1. Measuring the activity of the test compounds in in vitro rat aorta 
angiogenesis assay. 
ln this thesis, the pro-angiogenic activity of the test compounds is expressed as a percentage of aorta 
vessel outgrowths observed on day 5, 6 and 7 based on the field view. 0% outgrowth (A), 60% outgrowth 
(B). 
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Figure 4.2. Pro-angiogenic activity of synthetic FKJ and independent naturally-
derived FK2 in the in vitro rat aorta assay. 
Synthetic FKJ and independent naturally-derived FK2 were tested at concentrations from 5 x 10·6 M 
to 5 x 10-9 M. Control cultures contained the same diluent dilution as the test compounds. Data are 
expressed as a percentage of aorta vessel outgrowths observed on days 5, 6 and 7. Data analysis was 
performed by Student- Newman-Keuls test after one-way ANOV A comparing each group to control in 
each treatment. Error bars represent SEM (n=6). * ,.P <: 0.05, • • , <: 0.0 I. 
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Figure 4.3. HUVEC proliferation assay of synthetic FKl and independent 
naturally-derived FK2. 
Effect of synthetic FK1 and independent naturally-derived FK2, at concentrations from 5 x 10·' M to 
5 x 10·12 M on confluent serum-starved HUVEC proliferation in serum free media (SFM) with and 
without the mitogen bFGF (12.5 ng/mL). Control cultures contained the same diluent dilution as the test 
compounds. Cell proliferation was measured as 3H thymidine incorporation after 24 hours incubation. 
Data analysis was performed by Student- Newman- Keuls test after one-way ANOV A comparing each 
group to control in each treatment. Error bars represent SEM (n=6). *, PS 0.05 , ••, S 0.01 , ••• , S 0.001. 
A two-way ANOVA data analysis showed significant difference for all tested concentrations comparing 
their effect in SFM to SFM+bFGF (12.5 ng/mL) treatments, P S0.000 I. 
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4.4.3. Effect of synthetic FKI on endothelial cell differentiation (tube formation 
assay) 
To determine the effect of synthetic FKJ on endothelial cell tube formation, in vitro 
HUVEC and HMEC tube formation assays on a Matrigel plug were employed. 
HUVEC (4 x 104 cells/well) were cultured on Matrigel in 96 well plates and incubated 
at 37 °C in an IncuCyte incubator and observations were recorded every 2 hours. The 
tube formation process includes the following steps: migration and initial tube 
formation (0-2 hour), reorganization of tubular bodies into larger polygonal shapes (2-6 
hour), and completion of tube formation into more angular polygonal structures (6-18 
hour) (Fig. 4.4). Tube formation was evident after 2 hour culture, and became complete 
in 12-18 hour (Fig. 4.4). It was found that after 18 hour culture, cells lost their 
connections and started to die. Different steps in tube formation in control cultures with 
cultures treated with synthetic FKJ at concentrations from 5 x 10·6 M to 5 x 10·12 M 
were compared. 
Semi-quantitative analyses have been established to measure the capacity of test 
compounds to induce or inhibit tube formation in this assay. Until recently, most 
approaches involved measuring the number of tubes, the number of branch points, the 
length of tubules, and the percentage of area covered by tubules versus total area 
(Aranda and Owen 2009). In this thesis, tube formation was quantified using the NIH 
ImageJ and IncuCyte software at earlier time points (4 hour incubation) by measuring 
percentage denuded areas and number of sprouting cells, and at later time points (6 hour 
incubation) by measuring the number of tubes and the total tube length (Fig. 4.5) . The 
results showed that synthetic FKJ significantly enhanced tube formation above control 
levels with all four measured parameters and activity tapered down with increasing 
dilution. The total number of sprouting cells and the number of tubes were significantly 
higher with synthetic FKJ addition at the high concentrations tested (5 x 10·6 M and 5 x 
10·7 M) whereas denuded areas and total tube length did not reach to statistical 
significant levels (Fig. 4.6). 
Further experiments were performed with HMEC (4 x 104 cells/well), to investigate 
the tube formation response on a Matrigel plug. Tube formation was evident after 2 
hour incubation and a very strong response was observed at higher concentrations (5 x 
1 o·6 M and 5 x 10·7 M) of synthetic FKJ (Fig. 4. 7; shows results for 5 x I o·6 M only). 
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HMEC are smaller than HUVEC in size and consequently the sprouting cells and tubes 
are shorter. Therefore, tube formation can be analysed by number of completed circles. 
The HMEC tube formation experiment confirmed the stimulatory effect of synthetic 
FKJ on HUVEC tube formation on Matrigel plugs (Fig. 4.8). Also, similar HUVEC 
and HMEC tube formation enhancement results suggested that HMEC is a good 
endothelial cell candidate for pursuing the further cellular mode of action studies. 
In conclusion, FKJ significantly enhanced tube formation of both HUVEC and 
HMEC on Matrigel and the effect was titrated out from higher to lower test 
concentrations (5 x 10·6 M to 5 x 10·12 M). 
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Figure 4.4. Time course and quantification of HUVEC tube formation assay on 
Matrigel in an untreated control. 
Different stages observed when 4 x I 04 HUY EC/well were seeded onto Matrigel and the same field 
of focus was followed for the entire 24 hour incubation period. HUVEC at O hours (A). Migration and 
initiation of formation of tubular bodies, 2 hours (8). Reorganisation of tubular bodies into larger 
polygonal shapes, 6 hours (C, D, E). Completion of tube formation into more angular polygonal 
structures, 12 hours (F). Death of cells and loss of cell connections begins to become evident, 18 and 24 
hours (G, H). Denuded area(*), sprouting cell(➔), tube (➔), losing connections (--->). 
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Control FKJ , 5 X 10"6 M 
6 hours 6 hours 
12 hours 12 hours 
18 hours 18 hours 
24 hours 24 hours 
Figure 4.5. Effect of synthetic FKJ on HUVEC tube formation assay on Matrigel. 
Effect of synthetic FKJ at a concentration of 5 x 10·• M on HUVEC tube fonnation was observed 
from Oto 24 hours. Control cultures contained the same diluent dilution as the test compounds. 
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Figure 4.6. Effect of synthetic FKl on various parameters of a HUVEC tube 
formation assay on Matrigel. 
Effect of synthetic FKJ , at concentrations from 5 x 10-• M to 5 x 10-12 M, on HUVEC tube fonnation 
was measured, as percentage denuded area (A), number of sprouting cells (B), number of tubes (C) and 
total tube length (D). Parameters shown in (A) and (B) were measured after 4 hours culture and in (C) 
and (D) after 6 hours culture. Control cultures contained the same diluent dilution as the test compounds. 
Data analysis was performed by Student- Newman- Keuls test after one-way ANOVA comparing each 
group to control in each treatment. Error bars represent SEM (n~6)_ •• , :S 0.01 , ***, :S O_OOL 
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Control FKJ , 5 X 10·6 M 
6 hours 6 hours 
12 hours 12 hours 
18 hours 18 hours 
24 hours 24 hours 
Figure 4.7. Effect of synthetic FKJ on HMEC tube formation assay on Matrigel. 
Effect of synthetic FKI , at a concentration of 5 x 10·6 M, on HMEC tube formation was observed from 
0 to 24 hours. Control cultures contained the same diluent dilution as the test compounds. Completed 
circle (*). 
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Figure 4.8. Effect of synthetic FKJ on HMEC tube formation assay on Matrigel. 
Effect of syntbetic FKI , at concentrations from 5 x 10·• M to 5 x 10·12 M, on HMEC tube formation 
was measured as number of completed circles after 6 hours culture. Control cultures contained the same 
diluent dilution as the test compounds. Data analysis was performed by Studeot- Newman- Keuls test 
after one-way ANOV A comparing each group to control in each treatment. Error bars represent SEM 
(n=4). *, P '.S 0.05. 
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4.4.4. Effect of synthetic FKJ on endothelial cell migration (wound healing assay) 
An endothelial cell migration assay based on cell migration into a denuded area was 
employed to determine the effect of synthetic FKJ on endothelial cell migration. Cell 
migration is a critical event in angiogenesis and wound healing processes and these tests 
were designed to measure the effects of FKJ on in vitro cell migration. 
Tn this assay, a wound was created in a confluent monolayer of human microvascular 
endothelial cells (HMEC) (section 2.2.11). Subsequently, the extent and speed of 
wound closure was monitored microscopically every 2 hours. HMEC migration into the 
cleared space was evident after 4 hours of culture and the wound fully recovered within 
18-20 hours of incubation (Fig. 4.9). Images were taken every 2 hours using the 
IncuCyte machine and these were analysed by the IncuCyte and Prism software, using 
an unpaired t-test, to quantify the effect of synthetic FKJ on the width of wounds from 
0 to 26 hours of culture for control and treated wells. The results were then expressed 
as percentage wound confluence relative to the initial scratched wound mark. 
Synthetic FKJ appeared to have no measurable effect on the speed and extent of 
wound closure (Fig. 4.10). This experiment was repeated six times with six replicates 
each time and synthetic FKJ was found to consistently have no significant effect on the 
wound healing response. 
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0 hours 4 hours 
8 hours 1"2 hours 
16 hours 20 hours 
Figure 4.9. Time course ofHMEC wound healing assay. 
Wounds were made in HMEC monolayer in each well of a 96-well plate using the lncuCyte wound 
maker. Cell migration towards the denuded area was recorded every 2 hours and wound recovery was 
complete within 18-20 hours. 
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Figure 4.10. Effect of synthetic FKJ on _HMEC wound healing assay. 
Effect of synthetic FKI , at concentrat ions from 5 x 10·' M to 5 x 10·12 M, on wound recovery was 
measured as% wound confluence from 0 to 26 hours relative to the initial wound mark. Control cultures 
contained the same diluent dilution as the test compounds. Data analys is was performed by one-way and 
two-way ANOV A, comparing each group to control and other groups. Error bars represent SEM (n=6). 
No significant di ffe rence in ce ll adhes ion was observed. 
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4.4.5. Effect of synthetic FKl on endothelial cell adhesion (Rose Bengal assay) 
As discussed earlier in section 4.4.4, synthetic FKl had no significant effect on cell 
migration as measured by the wound healing assay, but it was able to significantly 
enhance HUVEC and HMEC tube formation on the artificial basement membrane, 
Matrigel. Therefore, it was pertinent to examine the effect of these compounds on cell 
adhesion to chosen ECM components. 
Cell adhesion of the endothelial human cell line, HMEC to the ECM components, 
fibronectin and vitronectin, was determined using a Rose Bengal adhesion assay 
(section 2.2.13). First, fibronectin and vitronectin concentrations required for cell 
adhesion were optimised by coating the plastic wells of the microplates with a 
concentration range. The coating concentration of fibronectin and vitronectin was 
varied from O to IO ~tg/mL to establish the concentrations where sub-optimal cell 
binding was observed. At such conditions it was reasoned that both enhancement and 
inhibition of cell adhesion may be detected in the presence of synthetic FKl at different 
concentrations. The results showed the optimal concentrations of fibronectin and 
vitronectin for cell binding were 10 µg/mL and 5 µg/mL, respectively, and sub-optimal 
cell binding occurred at concentrations ranging from 0.313 to 2.5 µg/mL (Fig. 4.11 ). 
The effect of synthetic FKl at concentrations from 5 x 10-6 M to 5 x 10-12 M on 
HMEC endothelial adhesion to immobilised fibronectin and vitronectin was initially 
tested after 60 minutes incubation. The results showed that none of the tested 
concentrations had a significant effect on the binding of HMEC to either 10 µg/mL 
fibronectin (Fig. 4.12B) or to 5 and 10 µg/mL vitronectin (Fig. 4.13A and B). 
Moreover, similar results were obtained when the incubation time was decreased to 30 
minute incubation for fibronectin (Fig. 4.12A). 
In order to determine the cell adhesion rate, similar cell adhesion experiments were 
performed using a time course of incubations from 0-25 minutes. The results 
demonstrated a very fast cell binding response for fibronectin (Fig. 4.14) and gradual 
increase in adhesion to vitronectin, starting from 7 .5 minutes (Fig 4.15). Furthermore, 
no significant effect of FKl on the rate of HMEC cell adhesion to fibronectin or 
vitronectin was observed for the tested concentrations at the different time points. 
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Overall the results demonstrated that the pro-angiogenic synthetic FKJ had no effect 
on the adhesion of HMEC endothelial cell line to fibronectin or vitronectin at the time 
points tested, i.e., from 2.5 to 60 minutes incubation. 
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Figure 4.1 I. Optimisation of fibronec-tin and vitronectin concentrations used to 
coat wells for the Rose Bengal adhesion assay using HMEC. 
HMEC adhesion to fibronectin (A) and vitronectin (B) was measured as optical density of Rose 
Bengal staining of adherent cells. Error bars represent SEM (n=6). The background binding in the 
absence of fibronectin and vitronectin was < 0.04 optical density unit. 
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Figure 4.12. Effect of synthetic FKI on fibronectin-mediated HMEC cell adhesion. 
Effect of synthetic FKI , at concentrat ions from 5 x to·6 M to 5 x 10·12 M, on cell adhesion was 
measured after 30 minute (A) and 60 minute (B) incubation as optical density of Rose Bengal staining of 
adherent cell s. Data analys is was performed by Student-Newman- Keuls test after one-way ANOV A 
comparing each group to control in each treatment. Error bars represent SEM (n=4). No signi ficant 
difference in cell adhesion was observed. 
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Figure 4.13. Effect of synthetic FKJ on vitronectin-mediated HMEC cell adhesion. 
Effect of synthetic FKJ, at concentrations from 5 x 10-• M to 5 x 10-12 M, on cell adhesion was 
measured using wells coated with 5 µg/mL (A) and 10 µg/rnL (B) of vitronectin and after 60 minutes 
incubation as optical density of Rose Bengal staining of adherent cells. Data analysis was performed by 
Student-Newman-Keuls test after one-way ANOVA comparing each group to control in each treatment. 
Error bars represent SEM (n~4). No significant difference in cell adhesion was observed. 
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Figure 4.14. Time course of effect of synthetic FKJ on fibronectin-mediated 
HMEC cell adhesion. 
Effect of synthetic FKI , at concentrations from 5 x 10·6 M to 5 x 10·12 M, on cell adhesion was 
measured using wells coated with 10 µg/mL of fibronection and after 5-30 minutes incubation as optical 
density of Rose Bengal staining of adherent cell s. Data analys is was performed by one-way and two-way 
ANOVA, comparing each group to control and other groups. Error bars represent SEM (n=6). No 
significant difference in cell adhesion was observed. · 
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Figure 4.15. Time course of effect of synthetic FKJ on vitronectin-mediated 
HMEC cell adhesion. 
Effect of synthetic FKJ, at concentrations from 5 x 10·6 M to 5 x 10·12 M on cell adhesion, was 
measured using wel ls coated with 5 µg/mL vitronectin and after 2.5-25 minutes incubation as optical 
density of Rose Bengal staining of adherent cells. Data analysis was performed by one-way and two-way 
ANOY A, comparing each group to control and other groups. Error bars represent SEM (n~4). No 
significant difference in cell adhesion was observed 
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4.5. Discussion 
Plants have a long history of providing sources of medicinal therapeutics. To date 
some natural products have been reported as having angiogenesis modulating effects 
(Sagar, Yance et al. 2006). These include vincristine, vinorelbine and taxol (Pezzuto 
1997). Nevertheless, finding new classes of pro- and anti-angiogenic agents has been a 
major area of pharmacological interest (Newman 2011). These compounds may 
modulate angiogenesis by interacting with the multitude of pathways that underpin this 
process. Extensive literature searches indicate no prior reports of angiogenesis 
modulating activity for FKJ or FK2. Therefore, they constitute a new class of potential 
pro-angiogenic drugs. Following the identification and structural characterisation of 
FKJ and FK2 from soybean as pro-angiogenic molecules in chapter 3, the ability of 
these molecules to modulate angiogenesis was explored in this chapter. 
Angiogenesis, the process generating new capillary networks from mature blood 
vessels, is a complex process of overlapping events including activation of endothelial 
cells, degradation of the basement membrane surrounding the existing vessel , 
endothelial cell proliferation, migration and differentiation into a mature blood vessel 
(Pepper 1997). Therefore to pinpoint the cellular mode of action, several bioassays 
needed to be utilised and this was done in this chapter. Due to the low concentrations of 
FKJ and FK2 in soybean material s, the cellular mode of action was explored utilising 
synthetic FKJ and an independently derived source of natural FK2 isolated from 
Bretschneidera sinensis, a tree nati ve to the south and east of China, Taiwan, northern 
Thailand and Vietnam. 
Soybean derived FKJ and FK2 were shown to significantly enhance angiogenesis in 
the rat aorta pro-angiogenesis bioassay in Chapter 3 (Fig. 3.8). The activity of synthetic 
commercially-derived FKJ and the purified naturally-occurring compound, FK2, were 
shown to be essentially identical to the naturally occurring FKJ and FK2 purified from 
soybean using the RARM. The pro-angiogenic activity of synthetic FKJ and 
independently isolated FK2 were confirmed at concentrations ranging from 5 x 10·6 M 
to 5 x 10·9 M (Fig. 4.2). Interestingly, the activity of both compounds increased with 
increasing dilution with both peaking at 5 x 10·8 M and activity then tapering off with 
increasing dilution. The decrease in activity at concentrations higher than 5 x 1 o-8 M 
suggests that further increases in concentration may not have had significant effects on 
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angiogenesis. Indeed it is possible that at higher concentrations both that FKJ and FK2 
may have opposite effects, or possibly toxic effects on endothelial cells, so it is 
important to define the therapeutic range of these molecules. 
Although in vitro angiogenesis assays, such as the RARM, can be carried out rapidly 
and can provide initial valuable information about the overall biological activity, 
multiple biological assays need to be employed to obtain a comprehensive 
understanding of the activity of test compounds (Auerbach, Lewis et al. 2003). In order 
to investigate the cellular mode of action of synthetic FKJ and FK2, several in vitro 
assays portraying major steps in angiogenesis, including endothelial cell proliferation, 
migration, tube formation and adhesion to ECM components have been employed in 
sections 4.4.1 to 4.4.5. These steps can be studied in vitro while representing possible 
target interactions for these angiogenesis modulating molecules. In addition, in vitro 
studies on endothelial cells have been considered as good models for angiogenesis 
studies and for predicting possible in vivo effects of desirable vascular agents 
(Galbraith, Chaplin et al. 2001). 
Initially, endothelial cell proliferation assays were performed using serum-starved 
HUVEC in the presence and absence of bFGF (12.5 ng/mL-'). The idea behind using 
bFGF, a potent mitogenic and pro-angiogenic growth factor, was to explore whether 
FKJ and FK2 can modify the mitogenic activity of bFGF. Previously, in the Nod 
factors studies, bFGF was used at a concentration of 25 ng/mL (Susan ti 201 I; 
Djordjevic, Bezos et al. 2013). However, the pro-angiogenic activity of FKJ and FK2 
was considerably higher than the Nod factor derivati ves (Susanti 2011), and thus the 
concentration of bFGF was lowered to 12.5 ng/mL in the studies described in this 
chapter. Using sub-optimal concentrations of bFGF in the endothelial cell proliferation 
assays allowed either enhancing or inhibiting effects of the test compounds to be 
measured. Generally, FK2 was significantly more active than FKJ in the HUVEC 
proliferation assay. FK2 only significantly enhanced HUVEC proliferation in the 
absence ofbFGF and the apparent raised levels of proli feration recorded with FKJ were 
not significant. Also, in the presence of bFGF, synthetic FKJ showed significant 
enhancement of HUVEC proliferation at concentrations ranging from 5 x I o·6 M to 5 x 
I o·8 M, whereas FK2 significantly enhanced proliferation at all concentrations tested (5 
x 10·6 M to 5 x 10·12 M) (Fig. 4.3). This suggests that both FKJ and FK2 can 
significantly enhance bFGF-induced eel( proliferation, with FK2 also possibly 
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activating proliferation in a bFGF-independent manner. Moreover, FKJ significantly 
enhanced HUVEC and HMEC tube formation on an arti ficial ECM (Matrigel) (Fig. 4.6 
- 4.7). However synthetic FKJ showed no activity in the cell migration (wound healing) 
assay (Fig. 4.10) or also cell adhesion to the ECM components, fibronectin and 
vitronectin (Fig. 4.11 - 4.15). 
Activation of FGFRs by bFGF (FGF-2) induces endothelial cell proliferation, 
migration and tube formation and also changes the expression and/or activation of 
integrins (Fig. 4.16) (Boilly, Vercoutter-Edouart et al. 2000; Turner and Grose 2010). 
Therefore, as synthetic FKJ did enhance HUVEC proliferation and tube formation in 
the absence of bFGF, and as the HUVEC proliferation was even greater in the presence 
of bFGF, it can be hypothesised that these molecules have similar functionsto bFGF in 
enhancing angiogenesis directly rather than through activation of integrin-mediated 
attachment. 
Activation of the FGF receptors, FGFR-1 or FGFR-2, by angiogenic FGFs including 
bFGF (FGF-2) typically results in endothelial cell proliferation. The FGFR-bFGF 
interaction leads to activation of several parallel signalling pathways after 
phosphorylation of the receptor following recruitment of She, FRS2, and Crk adaptor 
molecules (Cross and Claesson-Welsh 2001). Moreover, in addition to activation of the 
MAPK signalling pathway, activation of protein kinase C (PKC) is also required for a 
full mitogenic response of bFGF in endothelial cell s (Presta, Tiberio et al. 1991) as 
down-regulation of PKC abrogates bFGF-induced endothelial cell proliferation. 
However, this does not affect urokinase-type plasminogen activator (uPA) up-regulation 
as it has been reported that phosphorylation of distinct tyrosine residues in FGFR-1 
mediates the mitogenic and uPA inducing activity of bFGF (Dell'Era, Mohammadi et al. 
I 999). This is expected as uPA is one of the key molecules involved in ECM 
I degradation during cell migration (Boilly, Vercoutter-Edouart et al. 2000). Therefore, 
the findings above suggest that the MAPK and PKC biological responses can be 
dissociated at the molecular level (Presta, Dell'Era et al. 2005; Turner and Grose 2010). 
It is possible that FKJ affects either MAPK or PKC pathways or their downstream 
signalling pathways but as it significantly enhanced HUVEC proliferation mostly in the 
presence ofbFGF, it can be hypothesised that it might also potentiate bFGF activity. 
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Integrins are key cell adhesion molecules involved in cell migration and 
differentiation in angiogenesis along with cadherins and ephrins. They are heterodimers 
with non-covalent dimerisation of a and p subunits that can fonn more than 24 
combinations to ligate one or several ECM proteins (Table 4.1) (Liekens, De Clercq et 
al. 2001 ; Otrock, Mahfouz et al. 2007; Barczyk, Carracedo et al. 2010). 
Once the specific matrix protein becomes available in the microenvironment of 
endothelial cells, and integrin ligation occurs, integrin-mediated signalling typically 
develops as a function of crosstalk between integrins and specifically activated cytokine 
or growth factor receptors. These signalling pathways result in cell survival, migration 
and differentiation (Weis and Cheresh 2011). For instance, aV and p3 are only 
expressed by angiogenic endothelial cells forming aVP3 , a receptor for both fibronectin 
and vitronectin and aVP5 which binds to vitronectin (Feldinghabermann, Mueller et al. 
1992; Filardo, Brooks et al. 1995; Liekens, De Clercq et al. 2001; Serini, Valdembri et 
al. 2006). Blocking aVP3 and aVP5 integrins has been found to block growth factor and 
tumour-induced angiogenesis (Eliceiri and Cheresh 2001 ; Liekens, De Clercq et al. 
200 1). Also, integrin a5Pl which is the main receptor for fibronectin, has also been 
reported to regulate vascular development and tumour angiogenesis (Serini, Valdembri 
et al. 2006). 
Interestingly bFGF has been found to regulate the expression of different integrins, 
including aVP3 and cadherins in cell-ECM and cell-cell adhesions (Presta, Dell'Era et 
al. 2005). Moreover, increasing the affinity of integrins for their ligands is another 
mechanism that cells can use to alter their adhesive response. For example, aVP3 
affinity has been reported to be modulated during angiogenesis and also selectively 
blocking high affinity aVP3 could interrupt EC migration (Hood and Cheresh 2002). 
Tntegrins are also involved in regulating the activities of proteolytic enzymes that 
hydrolyse or degrade the basement membrane by activating specific matrix 
metalloproteinases (MMP). For example, MMP-2 and MMP-9, which have the highest 
activity against type IV collagen (main constitute of basement membrane), are elevated 
in angiogenic endothelial cells (Weis and Cheresh 2011). Interestingly, integrin avp3 
has been shown to bind to MMP-2, thus localizing MMP-2 mediated matrix degradation 
to the EC surface (Liekens, De Clercq et al. 2001; Otrock, Mahfouz et al. 2007). 
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FGF 
Morphogenesis/Tube formation Vessel maturation 
Figure 4.16. Schematic representation of events triggered by FGFs in endothelial 
cells in angiogenesis. 
Adapted from (Presta, Dell'Era et al. 2005). 
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Table 4.1. Human integrins and their ECM ligands. 
Integrins ECM ligands 
al_l3_!J_CD49a, VLAI) Collagens (IV, I, IX) 
a2_[3_!J_CD49b, VLA2) Collagens (IV, I, IX) 
a3p! (CD49c, VLA3) Larninins 
a4~1 (CD49d, VLA4) Fibrinectin VCAM-1 
a5_[3_!J_CD49e, VLA5) Fibronectin 
a6pl (CD49f, VLA6) Laminins 
a7Ql Laminins 
a8Ql Fibronectin, vitronectin, nep_hronectin 
a9Ql Tenascin-C, VEGF-C, VEGF-D 
alOQl Collagens (IV, VI, II, IX) 
al lQl Collagens (I , IV, IX) 
aLp2 (CD! la) ICAM-1 , -2, -3 , -5 
aMP2 (CD! I b) iC3b, fibrino_gen+more 
axp2 (CDI le) iC3b, fibrino_gen+more 
aDp2 (CD I ld) ICAM-3 , VCAM-1 
aIIBP3 (CD4 1, GpIIb) Fibrino_gen, fibronectin 
a6Q4 Larninins 
aVPl (CD51) Fibronectin, vitronectin 
aVQ3 Fibronectin, vitronectin, fibrino_g_en 
aVQ5 Vitronectin 
aVQ6 Fibronectin, TGF-Q-LAP 
aVQ8 Vitronectin, TGF-Q-LAP 
aEP7 (CD103 , HML-1) E-cadherin 
a4Q7 Fibronectin, VCAM-1 , MadCAM-1 
Adapted from (Barczyk, Carracedo et al. 20 I 0). 
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Also, stimulation of endothelial cells by bFGF enhances fo1mation of cell surface 
membrane vesicles containing MMP-2 and MMP-9 together with the two MMP 
inhibitors TIMP-1 and TIMP-2. These vesicles stimulate capillary-like structure 
formation when added to endothelial cells on Matrigel (Taraboletti, D'Ascenzo et al. 
2002). Therefore, endothelial cell-ECM adhesion experiments using fibronectin and 
vitronectin were conducted to explore whether FKJ could affect the adhesion process 
via these two ligands. 
The results from HMEC-ECM adhesion in the presence of FKJ showed no 
significant enhancement of endothelial cell-fibronectin/vitronectin binding and 
suggested that the FKJ pro-angiogenic response is not an integrin-
fibronectin/vitronectin mediated process. These results can also explain the results 
obtained from the migration assay, where FKJ did not enhance the motility of 
endothelial cells. 
In contrast, the synthetic FKJ significantly enhanced endothelial tube formation on 
Matrigel. Matrigel is gelatinous mixture of ECM proteins, supplemented with laminin, 
collagen type IV, HSPG and various growth factors (Conn 2012). lntegrin a6~4 has 
been reported to be an angiogenesis-specific integrin which binds to laminin as well as 
a6~1 (Serini, Trusolino et al. 1996; Hood and Cheresh 2002). Also, it has been shown 
that high levels of the a6 subunit are essential for the bFGF-induced HUVEC tubular 
morphogenesis (Bauer, Margolis et al. 1992; Matou, Helley et al. 2002). Moreover, 
heparan sulphates protect bFGF from proteolysis and degradation, and active bFGF will 
be released once proteoglycan degradation occurs (Rusnati and Presta 1996; Turner and 
Grose 2010). HSPG also promotes bFGF binding to FGFR and its subsequent 
activation (Powers, McLeskey et al. 2000; Schlessinger, Plotnikov et al. 2000). 
Furthermore, it has been reported that integrin activation by their ligands can lead to 
stimulation of a wide range of intracellular signalling pathways including activation of 
Ras, MAPK, F AK, Src, Rac/Rho/cdc42 GTPase, PKC and PI3K. As mentioned earlier, 
many of these signalling events are also activated fo llowing growth factor stimulation 
(FGF-FGFR interaction). These overlapping signalling phenotypes indicate the 
coordination of endothelial cell adhesion with engagement of the growth factor 
receptors to regulate endothelial cell responses during angiogenesis (Eliceiri and 
Cheresh 2001). Thus, it has been suggested that angiogenic factors , either stimulators 
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or inhibitors, can modulate integrin function (Serini, Valdembri et al. 2006). Therefore, 
based on the above findings, it can be suggested that FKI might be modulating a6~1 
integrin expression or enhancing its interaction with bFGF and bFGF receptor and/or it 
might potentiate the activity of low concentrations of bFGF present in Matrigel or 
HJFCS. Also, during tube formation both cell-ECM and cell-cell interactions 
(cadherins) are involved, therefore, it may be a possibility that FKI enhances 
endothelial cell-endothelial cell adhesion as well. 
It should be mentioned that the adhesion and migration assays performed in this 
thesis used cell lines in which the integrins were already in an active, high affinity state 
so it is unlikely that pro-angiogenic FKI induces the integrin activation. This also may 
explain why FKI did not enhance cell adhesion to fibronectin and vitronectin as even if 
FKI could induce the high affinity integrin conformation, the adhesion assay would be 
unable to detect this as the integrins present on the cultured cells are already in the 
active, high affinity state. However, integrin-dependent cell adhesion might not be 
dependent on ligand-binding affinity. Bazzoni and Helmer (1998) showed that the 
regulation of a4~ I function by chemokines can be regulated by the actin cytoskeleton 
configuration (Bazzoni and Hemler 1998) suggesting that pro-angiogenic FKI might 
regulate integrin-mediated cell adhesion events in endothelial cell tube formation 
without altering the ligand-binding affinity. 
In this study, it was demonstrated that FKI and FK2 have pro-angiogenic activity. 
FKI and FK2 are precursors for lignin which is a polymer found in the wood and the 
secondary cell walls of vascular plants (Novaes, Kirst et al. 201 O; V anholme, Demedts 
et al. 2010). Lignin is comprised of the monolignol units (p-coumaryl, coniferyl and 
synapyl alcohols) (Fig. 3.12) binding as dimers at C8 (C8-C8') (lignans) and four other 
sites C5-C5', C8-C5', C4-O-C5' and C8-O-C4' (neolignans) (Bunzel, Ralph et al. 2001; 
Peterson, Dwyer et al. 2010) (Fig. 3.13). The erythro- and threo-guaiacylglycerol-8-O-
4'-coniferyl alcohols are neolignans (Mander and Liu 2010) and with the exception of 
maize, were identified in all investigated cereal fibres (barley, millet, oat, rice, rye, 
spelt, wheat and wild rice) (Begum, Nicolle et al. 2004; Bunzel, Ralph et al. 2004). 
Lignan (C8-C8') and neolignan (C8-C5') dimers have been reported to have a wide 
range ofbioactivity in humans (Table 4.2) (Milder, Feskens et al. 2005; Van Miert, Van 
Dyck et al. 2005; Peterson, Dwyer et al. 2010). Lignans with C8~C8' linkages occur 
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commonly in food (Fig. 4.17) (Umezawa 2007) and have also been shown to be 
precursors of mammalian lignans after fermentation by human large intestine 
microflora. For example, the plant lignans matairesinol, secoisolariciresinol , 
pioresinoland and syringaresinol can be converted to mammalian lignans enterolactone 
and enterodiol (Fig. 4.18) (Heinonen, Nurmi et al. 2001). 
In plants, lignin macromolecules have crucial structural roles including the 
thickening of xylem cells which, in tum, helps plants to stand upright and withstand 
wind damage. Lignin polymers also provide a hydrophobic surface that allows plants to 
transport water, nutrients and extractives. Lignin ' s physical and chemical properties 
also serve as a barrier against the invasion of pests and pathogens (Campbell and 
Sederoff 1996; Novaes, Kirst et al. 2010). 
As mentioned above, lignins are present in a large variety of foods and are 
particularly abundant in cereal grains (Begum, Nicolle et al. 2004; Bunzel, Ralph et al. 
2004) and nutritionally are components of insoluble dietary fibre (DeVries 2003). 
Dietary fibre is a macronutrient defined as the edible parts of plants or analogous 
carbohydrates that are resistant to digestion and absorption in the human small intestine 
with complete or partial fermentation in the large intestine bymicroflora (Prosky 2000). 
It has been hypothesised that plant lignins can be a potential precursor of the 
mammalian lignans as a result of bacterial fermentation in the large intestine (Birt, 
Markin et al. 1998). However, this was not supported by the results of Birt and 
colleagues in 1998. They showed that rats fed with 5% purified wood lignin were 
unable to produce the mammalian lignans. They also showed no influence of lignin 
feeding on mammary cancer induced by N-methyl-N-nitrosourea (Birt, Markin et al. 
1998). In contrast, Begum et al. (2004) showed that the feeding of synthetic lignin 
made from coniferyl alcohol (dehydropolymerase, DHP) to rats led to the detection of 
the mammalian lignan, enterolactone, in urine. They concluded that this resulted from 
the metabolism of lignin by the intestine microflora (Begum, Nicolle et al. 2004). 
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Table 4.2. Examples of biological activities of lignans in humans. 
Biological activity 
Anti-radical and anti-oxidant 
Postmenopausa l breast cancer prevention 
Anti-colon cancer 
Anti- prostate cancer 
Cardiovascul ar health 
Cytotoxicity and anti-tumour effect 
Anti-ovarian cancer 
Oestrogenic and anti-oestrogenic activities 
Anti-inflammation 
Reducing blood pressure 
Cholesterol lowering 
References 
(Suja, Jayalekshmy et al. 2004; Eklund, 
Langvik et al. 2005; Gulcin, E lias et al. 2006; 
Kancheva, Saso et al. 20 I 2) 
(Buck, Za ineddin et al. 20 11 ; McCann, 
Hootman et al. 2012) 
(Jenab and Thompson 1996; Hausott, Greger et 
al. 2003; Qu, Madi et al. 2005) 
(Mccann, Gi ll et al. 2005 ; Landberg, 
Andersson et al. 2010) 
(Bloedon and Szapary 2004; B loedon, Balikai 
et al. 2008; Prasad 2009; Peterson, Dwyer et al. 
2010) 
(Takasaki, Konoshima et al. 2000; Qu, Madi et 
al. 2005; Van Miert, Van Dyck et al. 2005; 
Zhou, Liu et al. 2009) 
(McCann, Freudenheim et a l. 2003) 
(Mazur and Ad lercreutz 2000; Aeh le, Muller et 
al. 20 11 ) 
(Hallund , Tetens et al. 2008; Baumgartner, 
Sosa et al. 201 ! ) 
(Comish, Chilibeck et al. 2009; Peterson, 
Dwyer et al. 2010) -
(Zhang, Wang et al. 2008; Fukumitsu, Aida et 
al. 20 10) 
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Figure 4.18. Structures of mammalian lignans enterolactone and enterodiol. 
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There are only a few reports on bioactivity of e1ythro-guaiacylglycerol-8-O-4 ' -
coniferyl alcohol (FKJ) and threo-guaiacylglycerol-8-O-4' -coniferyl alcohol (FK2). A 
mixture of these two molecules was cytotoxic for human colon carcinoma (HCT-116) 
and human hepatocellular carcinoma (HepG2) cell lines at 30.2 and 57.3 µg/mL (80 and 
152 µM), respectively (Lee, Song et al. 2007). These molecules were also shown to 
have a chemopreventative effect on prostate cancer by inhibition of prostate specific 
antigen (PSA) secretion (IC50, FK1=109.3 and FK2=130.5 µM) and they also 
suppressed androgen receptor (AR) expression by the prostate cancer cell line LNCaP 
cells at 100 µM. In this study it was suggested that they suppress the androgen receptor 
signalling pathway and induce apoptosis (Han, Wang et al. 2008). It is difficult to 
compare these studies to those described in this thesis since the concentrations used 
were a minimum of 16 fold higher than the highest concentrations described in this 
chapter. However, the results from the FKJ and specially FK2 rat aorta angiogenesis 
and HUVEC proliferation assays showed that decreasing the concentration from 5 x 10· 
6 M to 5 x 10·8 M resulted in higher activity. This might suggest that increasing tested 
concentrations to the high µM range might reverse the pro-angiogenic response to an 
anti-angiogenic effect. However, concentrations higher than I µM are very unlikely to 
occur in plant-derived natural products or to be detected in human plasma and tissues 
after lignin digestion (Hollman 2004; Perez-Vizcaino, Duarte et al. 2012). 
We also tested synthetic FKJ in an anti-malaria drug bioassay to investigate its 
possible inhibitory effect on Plasmodium viability. FKJ showed no effect at 
concentrations ranging from 10·4 M to 10·14 M on parasite viability compared to 
artemisinin (known anti-malaria drug) as control (data not shown). These results are 
comparable with a study conducted in 2005 in which HPLC plant (Grewia bilamellata) 
fractions containing FKJ and FK2 (mix) showed no antimalarial activity against 
P.faciparum (Ma, Zhang et al. 2006). 
ln conclusion, it has been demonstrated that two lignin precursors, e,ythro-
guaiacylglycerol-8-O-4' -coniferyl alcohol (FKJ) and threo-guaiacylglycerol-8-O-4 ' -
coniferyl alcohol (FK2), possess pro-angiogenic activity in an animal model. The 
cellular mode of action of these molecules was then investigated by studying their effect 
on endothelial cell proliferation, migration, tube formation and adhesion to ECM 
components. It was found that the compounds enhanced endothelial cell proliferation 
and endothelial cell tube formation on an artificial ECM. These activities suggest that 
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these molecules have bFGF like stimulatory activity and may enhance angiogenesis via 
FGF signalling pathways. 
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Chapter 5 
Identification of Pro-angiogenic Flavonoids, 
Their Structural Activity Relationship and 
Cellular Mode of Action 
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5.1. Introduction 
Flavonoids are polyphenolic plant substances commonly found in the human diet 
especially in fruits , vegetables and beverages such as tea and red wine (Table 1.1) 
(Aheme and O'Brien 2002). Flavonoids are implicated in positively influencing a 
number of human conditions and disease by their anti-tumour, anti-inflammatory, anti-
microbial and anti-oxidant activities (Ren, Qiao et al. 2003). However, the bioactivities 
of these compounds have been mostly studied at high concentrations (> 1 ~tM) in both 
in vitro and in vivo experiments and these concentrations have not been reported to be 
physiologically relevant. Therefore, reports on flavonoid structure activity relationship 
using high flavonoid concentrations (Middleton, Kandaswami et al. 2000; Havsteen 
2002; Monasterio, Urdaci et al. 2004; Touil , Fellous et al. 2009; Lam, Alex et al. 2012) 
have to be interpreted with this in mind. 
In this chapter, the pro-angiogenic activity of flavonoids at physiological 
concentrations (sub µM to mid nM levels) has been investigated first using an in vitro 
rat aorta pro-angiogenesis assay. The structural features of flavonoids that mediate their 
effects on angiogenesis were also investigated. Moreover, two flavonoids, genistein and 
naringenin, which have been found in the literature te be anti-angiogenic at 
concentrations above I µM, were found to be pro-angiogenic at lower concentrations. 
The bioactivity of these and other flavonoids was examined across a wide concentration 
range (5 x 10·6 to 5 x 10·12 M) that included concentrations shown to be present in 
human plasma. The cellular mode of action of these flavonoids was then studied using 
in vitro endothelial assays including cell proliferation, migration, tube formation and 
adhesion to ECM components. 
5.1.1. ~etabolism and absorption of flavonoids 
Flavonoid glycosides are the predominant dietary source of flavonoids (Walle, 
Browning et al. 2005), although flavonoids from teas (also called tea flavonoids) occur 
as aglycones (Table 1.1) (Lee, Lambert et al. 2004; Walle 2004). Flavonoid glycosides 
are hydrolysed by the acidic conditions in the stomach and the resulting aglycones are 
absorbed into the circulatory system mainly from the small (Passamonti, Terdoslavich 
et al. 2009; Crozier, Del Rio et al. 2010), but also from the large intestine (Erlund, 
Meririnne et al. 2001) (Fig. 5.1). However, flavonoid glycosides such as genistein-7-O-
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glucoside or quercetin-4'-O-glucoside can be hydrolysed to genistein and quercetin, 
respectively, in the oral cavity and absorbed by the oral epithelial cells (Walle, 
Browning et al. 2005). 
Generally, the transport of flavonoids across the alimentary membranes is facilitated 
by both ATP-dependent pumps and ATP-independent transporters (Passamonti, 
Terdoslavich et al. 2009). In the small intestine, flavonoid-O-~-D-glycosides that 
survive passage through the stomach may be hydrolysed by lactase-phlorizin hydrolase 
(LPH) in the brush border of the epithelial cells or by a cytosolic ~-glycosidase (CBG) 
within the epithelial cell. In order for CBG-catalysed hydrolysis to occur, the polar 
glycosides must be transported into the epithelial cells, possibly with the involvement of 
the active sodium-dependent glucose transporter SGL Tl and further hydrolysed 
intracellularly (Day, DuPont et al. 1998; Gee, DuPont et al. 2000). The aglycones 
released in the brush border may enter the epithelial cells by passive diffusion as a result 
of their increased hydrophobicity (Day, Canada et al. 2000) . Thus, there are two 
possible routes by which the glycoside conjugates are hydrolysed and the resultant 
aglycones appear in the epithelial cells, namely "LPH/diffusion" and "transport/CBG" 
(Crozier, Del Rio et al. 2010). In addition, it has been hypothesised that any remaining 
flavonoid glycosides may be hydrolysed by the gastrointestinal microflora in the distal 
part of the small intestine or the large intestine (Fig. 5. I) (Erlund, Meririnne et al. 
2001). 
After the aglycones enter the cellular environment they may be conjugated with 
glucuronic acid, sulphate and/or methylated during first-pass metabolism in the 
intestinal wall or in the liver. The enzymes responsible for these metabolic processes 
are UDP-glucoronosyltransferase, sulfotransferases and methyltransferases. In vitro 
studies of the bioactivity of these conjugated metabolites indicated that they are less 
active or totally inactive compared to the aglycones. However, the ~-glucuronidase 
enzyme found in the vascular walls is able to hydrolyse the glucuronide conjugates 
allowing uptake of the aglycone by different tissues (Perez-Vizcaino, Duarte et al. 
2012). 
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5.1.2. Bioavailability of flavonoids 
Bioavailability is defined as the proportion of unchanged administered substance that 
reaches the systematic circulation (Passamonti, Terdoslavich et al. 2009). Flavonoids 
are not synthesised in animal cells, so their presence in animal tissues is derived entirely 
from the ingestion of plants or their derived products (Middleton, Kandaswami et al. 
2000; Mennen, Sapinho et al. 2008). However, the level of dietary tlavonoids varies 
greatly between individuals and countries, with the lowest average intake (2.6 mg/day) 
reported in Finland and the highest intake (68.2 mg/day) in Japan (Nijveldt, van Nood et 
al. 2001). 
The first barrier to the absorption of tlavonoids is the intestinal epithelium and 
enterocytes. Compounds with a relative molecular mass of more than 500 and able to 
form hydrogen bonds, are generally unable to cross biological membranes by passive 
diffusion (Lipinski, Lombardo et al. 2001) and thus the ingested glycosylated 
flavonoids, the major flavonoid component, are poorly absorbed at the gastro-intestinal 
level. Those that are absorbed into the blood stream then face the additional barriers of 
the cell plasma membranes of peripheral tissues. This is confirmed by a number of 
studies, showing that flavonoid bioavailability is mostly < l %,of the administered dose 
(Kris-Etherton, Lefevre et al. 2004). In the other words, the intestinal absorption of 
fl avonoids can be high; however, the plasma concentration of any individual molecule 
rarely exceeds 1 µM after the consumption of 10-100 mg of a single compound 
(Scalbert and Williamson 2000) . 
Thus although the flavonoid aglycones have a well demonstrated in vitro biological 
activity as antioxidants, anti-inflan1J11atory, anti-proliferative and anti-angiogenic agents 
these studies have been conducted at concentrations ranging from than 25 µM to 200 
µM (Rice-Evans 2004; Comalada, Ballester et al. 2006). Therefore, these activities are 
unlikely to be relevant in vivo as the concentration of flavonoids in plasma and tissues 
following oral ingestion is in the nM to µM range (i.e., less than 1 µM for normal diet) 
(Hollman 2004; Williamson and Manach 2005; Crozier, Del Rio et al. 201 0; Perez-
Vizcaino, Duarte et al. 2012). 
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Figure 5.1. Possible routes for absorption and excretion of dietary flavonoids in 
humans. 
Dietary _flavonoids (glycosides) are mostly hydrolysed and then absorbed by the body from the small 
intestine as aglycones. Remaining glycosides wi ll be carried to the colon where they may be hydrolysed 
by the endemic microflora. Absorbed flavonoids can be metabolised to glucuronides or sulphates and/or 
methylated in the epithelial cells of the gut and in the liver for circulation around the body or for excretion 
into the intestine via the bi le duct. The circulating _conjugates can be hydrolysed for uptake into various 
tissues or excreted via the kidneys. Metabolism of the flavonoid skeleton to water soluble phenolic acids 
can occur in the tissues (excreted via the kidney) or in the gut. Glycosides (---+), aglycones (---+), 
glucuronides/sulphates and aglycones (---+ ), phenolic acids and undigested glycosides (---+ ). Adapted from 
(Scalbert and Williamson 2000). 
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Thus, the concentrations of individual flavonoids and their biologically active 
conjugates may not be high enough after occasional intake to explain their health 
benefits. However, low concentrations may not necessarily indicate lack of biological 
activity for a highly potent substance. Moreover, accumulation may occur with regular 
dietary intakes (half-lives from 8-24 hours) , which may result in sufficiently active 
flavonoid concentrations being achieved (Nijveldt, van Nood et al. 2001; Perez-
Vizcaino, Duarte et al. 2012). 
5.1.3. Bioavailability of naringenin 
Naringenin is a flavanone, commonly found in citrus fruits and tomatoes and mainly 
occurs as glycosides such as naringenin-7-rharnnoglucoside (naringin) and naringenin-
7-O-glucoside (Krause and Galensa 1992; Erlund, Meririnne et al. 2001; Bugianesi, 
Catasta et al. 2002; Yamamoto, Yoshimura et al. 2004). Naringin is the predominant 
flavanone in grapefruit ( Citrus paradisi) (up to 10% of the dry weight/ 100-500 mg/I) 
and is responsible for the bitterness of grapefruit juices (Ortuno, Garciapuig et al. 1995; 
Manach, Scalbert et al. 2004; Jagetia, Jagetia et al. 2007). 
Naringenin glycosides ingested with food are metabolised- by the human intestinal 
microflora to the aglycone naringenin (Felgines, Texier et al. 2000; Matsumoto, Ikoma 
et al. 2004). Citrus flavonoids have been reported to be anti-inflammatory, anti-
carcinogenic, cholesterol lowering and neuro-protective (Benavente-Garcia, Castillo et 
al. 1997; Montanari, Chen et al. 1998; Lee, Jeong et al. 2001; Heo, Kim et al. 2004; 
Galluzzo, Ascenzi et al. 2008; Mulvihill and Huff 2010). In addition, naringenin is a 
phyto-oestrogen and, like certain isoflavones, can bind to oestrogen receptors (Harris, 
Besselink et al. 2005) or inhibit aromatase activity, the rate limiting enzyme in the 
conversion of androgens to oestrogens (Edmunds, Holloway et al. 2005). Analysis of 
plasma and urine showed only the presence of the naringenin aglycone and the 
sulfoconjugated derivative (90%) and also glucuronides (Felgines, Texier et al. 2000; 
Erlund, Meririnne et al. 2001; Gardana, Guarnieri et al. 2007). 
In a study conducted by Erlund et al. in 2001 showed that plasma naringenin 
concentration was measured after a baseline period (2 weeks), on a low vegetable diet 
(5 weeks, containing low amounts of vegetables and fruit, and no citrus) and a high 
vegetable diet (5 weeks, containing high amount of vegetables and fruit, including 
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moderate amounts of citrus) (Erlund, Meririnne et al. 2001). The daily baseline intake 
of naringenin was found to be 3 mg while the high vegetable diet provided 29 mg of 
naringenin and the low vegetable diet contained no fl avanones. The plasma naringenin 
concentrations for the low and high vegetable diet were below the limit of detection and 
1.129 x 10·7 M ( I 12.9 nM), respectively. Later, these results were confirmed by 
Gardana et al. in 2007 and it was shown that the maximum naringenin concentration in 
plasma was 1.25 x 10·7 M (125 nM), 5 hours after taking 300 mL of orange juice and 
was undetectable in plasma after 24 hours(Gardana, Guarnieri et al. 2007). The plasma 
concentrations (ng/mL) were also comparable with those found in two other studies 
(Manach, Morand et al. 2003; Manach, Williamson et al. 2005). 
Plasma and urine studies showed that naringenin can be detected within 2-4 hours of 
oral administration. However, after 5 hours there was found to be a second increase in 
plasma naringenin levels corresponding to naringenin released and absorbed from the 
glycoside (naringin; naringenin-7-rhamnoglucoside) in the large intestine (Felgines, 
Texier et al. 2000; Gardana, Guarnieri et al. 2007). These studies indicated that the 
fl avanone did not accumulate in plasma, however, distribution and accumulation of 
flavanones in other tissues could not be ruled out, because compounds taken into cells 
could be released back into the bloodstream at concentrations below the limit of 
detection of the analytical method, or as metabolites or degradation products. 
5.1.4. Bioavailability of genistein 
The isoflavones, genistein, daidzein and glycitin (8-ring attached to C3 rather than 
C2 position as in other flavonoids) have a very limited distribution in the plant kingdom 
being found only in leguminous species (Kaufman, Duke et al. 1997) mostly as the 
polar, water soluble 6-O-~-glucosides, -acetylglucoside or -malonylglucoside 
conjugates (Coward, Smith et al. 1998; King and Bursill 1998; Setchell 2000; Rice-
Evans 2004). Worldwide, soybean (Glycine max) is the most common dietary source of 
isoflavones. However, they also occur in low levels in black beans (Phaseolus vulgaris) 
and green peas (pisum sativum). 
After ingestion, the isoflavone glucosides are hydrolysed by both intestinal mucosa] 
and bacterial ~-glucosidases releasing the aglycones which are then either absorbed 
directly or further metabolised by the intestinal microflora in the large intestine into the 
130 
Chapter 5 
isoflavonoid microbial metabolites, dihydrodaidzein, dihydrogenistein, 
dihydroglycitein, O-desmethylangolensin, equol, 6-hydroxy-O-desmethylangolensin, 5'-
methoxy-O-desmethylangolensin and dihydro-6, 7, 4'-trihydroxyisoflavone (Day, 
DuPont et al. 1998; Setchell, Brown et al. 2002; Walsh 2006). 
The isoflavonoids also act as phytoestrogens and have a wide range of hormonal and 
non-hormonal activities in animals or in vitro (Cassidy, Hanley et al. 2000) suggesting 
the potential human health benefits to be derived from a diet rich in these compounds. 
They have similar chemical structure to oestrogens due to the phenolic rings and 
particularly the 4'-hydroxyl and been found to bind to oestrogen receptors (Wang, 
Sathyamoorthy et al. 1996; Zava and Duwe 1997). Genistein has shown positive results 
in treating breast cancer (Peterson and Barnes 1991 ; Ju, Doerge et al. 2002; Du, Yang et 
al. 2012), modulating angiogenesis by inhibiting tyrosine kinases and VEGF expression, 
release and activation (Akiyama, Ishida et al. 1987; Fotsis, Pepper et al. 1993; Buchler, 
Reber et al. 2004; Qi, Weber et al. 2011; Yu, Zhu et al. 2012) and inhibiting cell 
proliferation (Fotsis, Pepper et al. 1995; Comalada, Ballester et al. 2006; Qi, Weber et 
al. 2011) and cell migration (Tham, Gardner et al. 1998). Using in vitro models, they 
have been tested at concentrations in the range of 25-100 µM. It has been observed that 
the plasma concentration of genistein after conswnption of single or multiple soy 
containing meal s rises slowly and reaches a maximum value of 1-5 µM after 5.5-7.5 
hours with a half-li fe of 9-11 hours and returned to undetectable levels after 24-35 hours 
(Xu, Wang et al. 1994; King and Bursill 1998; Cassidy 2006). 
Thus, the observed in vitro pharmacokinetics of genistein is important with respect to 
possible use of thi s compound in therapeutic applications. Based on the likely dail y 
intake of isoflavones, absorption from the gut, di stribution to peripheral tissues and 
excretion, it is unlikely that the . blood isoflavone concentrations, even in high soy 
consumers, would exceed 1-5 µM . The mean concentration of circulating genistein 
found in Japanese men (high consumers) was 492.7 nM compared to 33.2 nM in men 
from the UK (low consumers) (Tham, Gardner et al. 1998; Morton, Arisaka et al. 2002). 
Therefore, studying the effects of genistein at likely physiological concentrations (< 1 
µM) became the area of interest in this project. 
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5.1.5. Flavonoid properties in angiogenesis 
Flavonoids are known to have anti-carcinogenic, anti-microbial, anti-inflammatory, 
anti-allergic, anti-oxidant and anti-viral activities. They also are thought to lower the 
risk of human cardiovascular disease (Hollman and Katan 1999; Middleton, 
Kandaswami et al. 2000; Nijveldt, van Nood et al. 2001; Comalada, Ballester et al. 
2006; Lam, Alex et al. 2012). Many studies of flavonoids have shown a structure-
activity relationship (SAR), suggesting that the position and number of the hydroxyl and 
methoxyl moieties on the flavonoid A and B rings, along with the oxidation state of 
carbon 4 (C4=O), the presence of a double bond in ring C (C2-C3) and of glycosylation, 
may be important factors in conferring activity (Table 5.1) (Fotsis, Pepper et al. 1997; 
Kawaii , Tomono et al. 1999; Casagrande and Darbon 2001; Manthey and Guthrie 2002; 
Rodriguez, Yanez et al. 2002; Bagli, Stefaniotou et al. 2004; Kanadaswami, Lee et al. 
2005; Mayr, Windhorst et al. 2005). 
Flavonoids are also known to influence the otherwise tightly regulated process of 
angiogenesis. Several critical events in the process of angiogenesis have been shown to 
be inhibited by flavonoids. These include the proliferation and migration of both 
endothelial cells and smooth muscle cells from the vascular wall. In addition, 
flavonoids are also known to inhibit the expression of both VEGF and MMP-2, which 
are important partners in the angiogenic process (Fotsis, Pepper et al. 1997; Paper 1998; 
Benavente-Garcia and Castillo 2008). 
The presence of the C2-C3 double bond on the C ring, conjugated with the 4-oxo 
function, has been shown to be a critical structural feature for the anti-proliferative 
activity offlavonoids (Rodriguez, Yanez et al. 2002; Comalada, Ballester et al. 2006). 
Subsequent studies showed that the presence of three or more hydroxyls in any of the 
rings of the flavonoid skeleton also significantly increased the anti-proliferative activity 
observed in Bl 6Fl 0 melanoma cell cultures (Martinez, Yanez et al. 2003). However, in 
comparing luteolin (flavone) with quercetin (flavonol) (quercetin has an additional 3-
hydroxy; see Table 1.1), in different cell lines, it seems the 3-hydroxylation does not 
confer a greater anti-proliferative activity (Casagrande and Darbon 2001; Manthey and 
Guthrie 2002; Rodriguez, Yanez et al. 2002). 
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Methylation of the hydroxyls does not reduce the anti-proliferative capacity and even 
appears to increase it, because the activity shown by 7-3'-dimethylhesperetin (2 
methoxyls) was higher than that shown by its homologues, hesperetin (I methoxyl) and 
eriodictyol (no methoxyls; see structures in Table l. l ), suggesting that the presence of a 
methoxyl group in position C4 may be related to greater cytostatic activity (Benavente-
Garcia and Castillo 2008). Furthermore, the high anti-proliferative effects oftangeretin 
( 4 methoxyls on the A ring and one on the C ring; Table 1.1) in many cancer cell lines 
(Hirano, Abe et al. 1995; Manthey and Guthrie 2002; Kanadaswami, Lee et al. 2005) 
shows being less polar and having a planar structure may play a critical role in the 
biological activity, enhancing flavonoid permeability through biological membranes and 
its binding properties (Manthey and Guthrie 2002). 
The in vivo structure-activity relationship analysis indicated that a flavonoid with a 
methoxylated group at the C3' (C3'-OCH3) position possesses a stronger anti-
angiogenic activity, whereas the absence of a methoxylated group at the CS position 
results in lower lethal toxicity in addition to enhancing the anti-angiogenic activity. 
Also, methylation of the OH groups at the C4', C5 , C6 and/or C7 positions may increase 
the anti-angiogenic activity (Lam, Alex et al. 2012). 
Naringin (naringenin-7-O-glycoside) in comparison with naringenin displayed no 
detectable anti-angiogenic activity at concentrations from 3 to 100 µM , in vitro and in 
vivo. This suggests that glycosylation at the C7 position is not favourable for an anti-
angiogenic effect (Lam, Alex et al. 2012). However in another study, naringenin 
glucosides showed inhibitory angiogenic activity by blocking VEGF secretion, with 
naringenin being inactive (Schindler and Mentlein 2006). 
The concentration of the flavonoids tested in these in vivo and in vitro assays were 
mostly at the level of 20-100 µM which is much higher than plasma flavonoid 
concentrations. 
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Table 5.1. Structure-activity relationship of some structural motifs in flavonoids. 
Structural motifs Anti-angiogenesis Anti-proliferation Anti-Inflamma tion Anti-oxid an t Cytotoxicity 
y y y y y 
(Fotsis, Pepper et a l. (Kawaii, Tomono et (Comalada, Ballester (Ratty and Das (Schindler and 
C2-C3 double bond 1997; Schindler and al. 1999; Rodriguez, et al. 2006) I 988; Mathiesen, Mentlein 2006; 
conjugated with Mentlein 2006) Yanez et al. 2002 ; Malterud et al. Touil, Fellous et a l. 
C4~O Comalada, Ballester 1997; Sil va, Santos 2009) 
et al. 2006) et al. 2002) 
y y y y 
(Fotsis, Pepper et al. (Comalada, Ballester (Cao, Sofie et al. (Beutler, Hamel et 
C3'-OH,C4'-OI-I 1997) et al. 2006) 1997; Benavente- al. 1998; 
(catechol structure) Garcia and Castillo Monasterio, Urdaci 
2008) et al. 2004; Tou il , 
Fellous et al. 2009) 
y y y 
(Comalada, Ballester (Cao, Sofie et a l. (Touil , Fell ous et al. 
C4 '-OI-I et al. 2006) 1997; Benavente- 2009) 
Garcia and Casti llo 
2008) 
y NE NE y y 
(Fotsis, Pepper et al. (Kawaii , Tomono et (Comalada, Ballester (Ratty and Das (Touil, Fellous et al. 
C3 -OH 1997) al. 1999; Manthey and et al. 2006) 1988; Burda and 2009) Guthrie 2002; Oleszek 200 I; 
Rodriguez, Yanez et Silva, Santos et al. 
al. 2002) 2002) 
y 
C6-OI-I (Toui l, Fellous et al. 
2009) 
y N 
(Lam, Alex et al. (Dugas, Castaneda-
C3'-OCl-1 3 20 12) Acosta et al. 2000; 
Burda and Oleszek 
2Q0I) 
y N 
(Lam, Alex et al. (Dugas, Castaneda-
C4'-OCH3 20 12) Acosta et a l. 2000; 
Burda and Oleszek 
200 1) 
y N 
(Lam, Alex et al. (Dugas, Castaneda-
CS-OCI-13 20 12) Acosta et al. 2000; 
Burda and Oleszek 
200 1) 
y N 
(Lam, Alex et al. (Dugas, Castaneda-
C6-OCH, 20 12) Acosta et al. 2000; 
Burda and Oleszck 
200 1 
y N 
(Lam, Alex et al. (Dugas, Castaneda-
C7-OCH3 2012) Acosta et al. 2000; 
Burda and O leszek 
2001) 
y y N 
(Lam, Alex et al. (Kawaii, Tornono ct (Dugas, Castaneda-
C8-OCI-13 
20 12) al. 1999) Acosta et al. 2000; 
Monasterio, Urdaci 
et al. 2004; Lam, 
Alex et al. 20 12) 
N N 
Glycosylation at C7 (Lam, Alex et al. (Touil, Fellous et al. 
20 12) 2009) 
Flavonoids backbone and some structures are depicted in Figure 1.3 and Table 1. 1. Y (positive effect), N (negative effect), 
NE (no effect) 
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5.2. Research aims 
Flavonoids are well studied as anti-tumour agents. They are thought to act via their 
anti-angiogenic and anti-proliferative activities. However, most experiments have been 
performed in vitro and also with high concentrations of compounds. The concentrations 
used in these studies are not comparable with the in vivo conditions when one considers 
the bioavailability of flavonoids (after ingestion) in plasma and tissues. This chapter 
focuses on the angiogenic modulating activity of flavonoids at their likely in vivo 
concentrations as well as investigating the structure activity relationship to identify 
important structural motifs involved in angiogenesis inhibition/enhancement. 
5.3. Research objectives 
1) Identify pro-angiogenic flavonoids using rat aorta pro-angiogenesis bioassay 
2) Investigate the pro-angiogenic activity of flavonoids at concentrations 
approximating human plasma concentrations to assess their possible positive 
influence on wound healing and cardiovascular disease. 
3) Determine the structure-relationship activity including the effect of C2-C3 
double bond, phenolic rings (A, B or C), glycosylation at C7, OH groups on A 
and Bring, and methoxylated OH groups on pro-angiogenic activity. 
4) Determine the cellular mode of action of flavonoids, naringenin and genistein, 
with pro-angiogenic activity at concentrations close to in vivo human plasma 
)evels. 
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5.4. Results 
5.4.1. In vitro rat aorta pro-angiogenesis bioassay of flavonoids to screen for the 
most pro-angiogenic compounds 
As described in chapter 4, the rat aorta angiogenesis bioassay has been used in the 
Parish laboratory to screen for compounds and other small molecules that could either 
enhance or inhibit the formation of new capillaries (Parish, Freeman et al. 1999). ln 
order to screen for pro-angiogenic activity, the rat ao11a ring bioassay was performed 
using medium containing 5% HIFCS (as in Chapter 4). These culture conditions 
resulted in sub-optimal vessel outgrowth (approximately 60% vessel occupancy after 7 
days culture), which enabled both the stimulatory and inhibitory effects of test 
compounds on angiogenesis to be measured in the one assay. In this thesis the assay 
was quantified manually by measuring the relative density and the number of new 
vessels sprouted from the aorta ring in the field of view, which is represented as 
percentage growth. 
To investigate the relation between the structure and pro-angiogenic activity of 
flavonoids, eighteen flavonoids were chosen based on structur-al features including, the 
substituent patterns of the A and C rings, the presence and absence of the C2-C3 double 
bond, the number and position of hydroxyl and methoxyl groups on the A and B ring 
(Table 5.2) and their demonstrated biological activity. These were then screened for 
activity with an in vitro rat aorta bioassay at 5 x 10·7 Mand 5 x 10·3 M (Fig. 5.2). These 
concentrations were selected to represent the levels of flavonoids found in plasma and 
tissue (10-6 M to 10·9 M) following oral ingestion of a normal diet (Hollman 2004; 
Williamson and Manach 2005). 
Seven flavonoids (genistein, 7-hydroxycoumarin, naringenin, dihydroquercetin, 
dihydrokaempferol, flavanone and naringenin-7-O-glucoside) approached significant 
pro-angiogenic activity at both 5 x 10·7 M ~nd 5 x 1 o·8 M in more than three individual 
tests. They were chosen for further investigation. These flavonoids were then tested for 
pro-angiogenic activity in the presence of the endogenous growth factor bFGF at 12.5 
ng/mL (as done in Chapter 4) and demonstrated similar enhancement in the growth of 
new capillaries at 5 x 10·7 M (Fig. 5.3) but only naringenin, dihydrokaempferol and 
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genistein approached significant enhancement in pro-angiogenic activi ty at 5 x 10-8 M 
(Fig. 5.4). 
The anti-angiogenic activity of genistein (1-250 µM) and the anti-tumour effect of 
naringenin (I 0, I 00 and 200 µM) have been reported previously (Fotsis, Pepper et al. 
1995; Manthey and Guthrie 2002; Buchler, Reber et al. 2004; Sasamura, Takahashi et 
al. 2004; Zhang, Du et al. 2009). Therefore, genistein, naringenin and five other 
tlavonoids were tested with in the in vitro pro-angiogenesis assay at 5 x 1 o-6 M (Fig. 
5.5). No significant pro-angiogenic activity was observed for flavonoids tested at 5 x 
10-6 M and interestingly genistein at 5 x 10-6 M inhibited the angiogenesis process 
although this did not reach significant levels (unpaired t-test, P = 0.0998 at day 7). 
However, in our hands, naringenin showed elevated pro-angiogenic response for 5 x 1 o-
6 M in five out of seven tests and in two tests it reached significant levels. 
In order to compare our findings to the literature, anti-angiogenic activity of 
genistein at 100 and 200 µM was assayed by the in vitro anti-angiogenesis rat aorta 
bioassay performed using mediw11 containing 20% HIFCS (Fig. 5.6) and it 
demonstrated a very significant anti-angiogenic activity at both 100 and 200 µM with 
the stronger inhibition effect at 200 µM . Both genistein and naringenin were tested for 
pro-angiogenic activity by titrating the angiogenic effect at concentrations from 5 x I o-6 
M to 5 x 10-12 M. Genistein, as expected, showed anti-angiogenic activity at the highest 
concentration tested (5 x 10-6 M) and demonstrated significant stimulation of 
angiogenesis at 5 x 10-7 M to 5 x 10-9 M (Fig. 5.7). Interestingly for naringenin, 
angiogenesis was stimulated at most concentrations tested from 5 x I o-6 M to 5 x 10-12 
M and this effect reached the significant levels from 5 x 10-9 M and 5 x 10-IO M with 
maximal effect at 5 x 10-9 M, p :S 0.01 (Fig. 5.8). 
Seven chosen tlavonoids and specifically genistein and naringenin were then selected 
to study the cellular mode of action. 
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Table 5.2. Chemical structures of eighteen flavonoids screened in the in vitro rat 
aorta ring pro-angiogenesis assay. 
Flavones Flavonols and Dihydroflavonols Isoflavonoids 
-w· -#- "' 1"' 0 I /2 1: 
'" 
0 o......,o,, 
Apigenin Quercetin Biochanin A 
(J(" w- "' 0 "°W "' I I ':::: . OH "' I ,,,,;:. OH '" 0 I "' /, 
'" 
°" 0 
Acacetin Dihydroquercetin (DHQ) Genistein 
~;r· ~fY- % "' 0 "' '" 0 "' /2 
4',7-Dihydroxyflavone (DHF) Kaempferol lsoflavone 
Flavanone 
((~ a'" 
"'W/ "'W "'U?u I ,;, I /2 '" - /2 "' 0 I,✓.;:: OH 
'" 0 o, 0 
Naringenin Dihvdrokaempferol (DH]() Daidzein 
Others 
r 
.Jf ·woe ,,✓'% "' . '" /2 "' 1/, , I /2 
'" 0 
Hesperetin 2,5-Dihydroxy-1,4-benzoquinone 7-Methoxyisoflavone 
0 
"°U)' CQ/ 
/2 /, /, 
0 
Flavanone 7-Hydroxycoumarin irw(Y "° , ~ I 
°" 0 
'" 
N aringenin-7-0-glucoside 
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Figure 5.2. Screening for pro-angiogenic activity of flavonoids in the in vitro rat 
aorta assay. 
. Structure pro-angiogenic activity relationship of eighteen flavonoids was screened with an in vitro rat 
aorta bioassay at concentrations of 5 x 10·7 and 5 x 10·8 M. Data are expressed as a percentage of aorta 
vessel outgrowths observed on days 5 (A), 6 (B) and 7 (C). Data analysis was performed by Student-
Newman- Keu ls test after one-way ANOV A comparing each group to control in each treatment. Error 
bars represent SEM (n=6). Two-way ANOV A ana lysis was performed comparing 5 x I 0·1 M and 5 x I o-8 
M concentration on day 5, 6 and 7. No significant difference was observed. 
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Figure .5.3. Pro-angiogenic activity of flavonoids at 5 x 10-7 M ± bFGF in the in 
vitro rat aorta assay. 
Effect. of seven chosen flavonoids was tested at 5 x 10-7 M in pro-angiogenesis medium, Ml99 
supplemented with 5% HIFCS (mediwn) with and ·without the mitogen bFGF (12.5 ng/mL). Control 
cultures ,contained the same diluent dilution as the test compounds. Data are expressed as a percentage of 
aorta vessel outgrowths observed on days 5, 6 and 7. Data analysis was performed by Student-Newman-
Keuls test after one-way ANOV A comparing each group to control in each treatment. Error bars 
represent SEM (n~6). *, P <: 0.05 , ** , <: 0.01, ***, <: 0.001. No significant effect was observed using 
two-way ANOVA analysis between compounds treated with medium and medium+bFGF (12.5 ng/mL) 
treatments on day 5, 6 and 7. 
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Figure 5.4. Pro-angiogenic activity of flavonoids at 5 x 10·8 M ± bFGF in the in 
vitro rat aorta assay. 
Effect of seven chosen flavonoids was tested at 5 x 10·' M in pro-angiogenesis medium, M 199 
supplemented with 5% HTFCS (medium) with and without the mitogen bFGF (12.5 ng/mL). Control 
cultures contained the same diluent dilution as the test compounds. Data are expressed as a percentage of 
aorta vessel outgrowths observed on days 5, 6 and 7. Data analysis was performed by Student- Newman-
Keuls test after one-way ANOV A comparing each group to control in each treatment. Error bars 
represent SEM (n=6). *, P :S 0.05, **, :S 0.0 I, ***, :S 0.00 I. Two-way AN OVA analysis was performed 
comparing medium and medium+bFGF (12.5 ng/mL) treated compounds on day 5, 6 and 7 and only 
naringenin showed significant difference on days 6 and 7, P :S 0.05. 
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Figure 5.5. Pro-angiogenic activity of flavonoids at 5 x 10-6 M in the in vitro rat 
aorta assay. 
Effect of seven chosen flavonoids was tested at 5 x 10·• M in pro-angiogenesis medium, M 199 
supplemented with 5% HTFCS. Control cultures contained the same diluent dilution as the test 
compounds. Data are expressed as a percentage of aorta vessel outgrowths observed on days 5, 6 and 7. 
Data analysis was perfonned by Student- Newman-Keuls test after one-way ANOV A comparing each 
group to control in each treatment. Error bars represent SEM (n=6). No significant effect was observed. 
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Figure 5:6. Anti-angiogenic activity of genistein at 100 and 200 µM in the in vitro 
rat aorta assay. 
Effect of genistein was tested at I 00 x Io·• M and 200 x Io·• M in anti-angiogenesis medium, M 199 
supplemented with 20% HIFCS. PI-88 has clinically proven anti-angiogenic activity and was used as a 
positive control. Control cultures conta ined the same diluent di lution as the test compounds. Data are 
expressed as a percentage of aorta vesse l outgrowths observed on day 5. Data ana lysis was performed by 
Student-Newman- Keuls test after one-way ANOV A comparing each group to control in each treatment. 
***, P -S 0.001. 
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Figure 5,7. Pro-angiogenic activity of genistein at 5 x 10-6 M to 5 x 10-12 Min the in 
vitro rat aorta assay. 
Effect of genistein was tested at 5 x I0.6 M to 5 x I0"12 M , in pro-angiogenesis medium, M 199 
supplemented with 5% HlFCS. Control cultures contained the same diluent dilution as th e test 
compounds. Data are expressed as a percentage of aorta vessel outgrowths observed on days 5, 6 and 7. 
Data analysis was performed by Student- Newman- Keuls test after one-way ANOV A comparing each 
group to control in each treatment. Error bars represent SEM (n=6). *, P -S 0.05, **, -S 0.01 , *** , P -S 
0.001. 
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Figure 5.8. Pro-angiogenic activity of naringenin at 5 x 10-6 M to 5 x 10-12 M in the 
in vitro rat aorta assay. 
Effect of naringenin was tested at 5 x 10·• M to 5 x 10· 12 M, in pro-angiogenesis medium, MI99 
supplemented with 5% HJFCS. Contro l cultures contained the same di luent dilution as the test 
compounds. Data are expressed as a percentage of aorta vessel outgrowths observed on days 5, 6 and 7. 
Data analysis was performed by Student- Newman-Keul s test after one-way ANOVA comparing each 
group to control in each treatment. Error bars represent SEM (n=6). *, P S 0.05 , **, S 0.01. 
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5.4.2. Effects of chosen flavonoids on endothelial cell proliferation 
In order to determine the effect of the seven chosen flavonoids and in particular 
naringenin and genistein, on cell proliferation, in vitro HUVEC proliferation assays 
were employed based on 3H-thymidine incorporation. In some of the proliferation 
experiments bFGF was added to assess whether or not the test compounds influenced 
the mitogenic activity of bFGF. Optimisation of the bFGF concentration required for 
the proliferation experiments was carried out on serum-starved confluent HUVEC. As 
explained in chapter 4, a 12.5 ng/mL bFGF concentration appeared to be sufficient to 
induce HUVEC cell proliferation and was optimal for detecting enhanced proliferation 
by the test compounds. 
Initially, all seven chosen flavonoids were tested at 5 x 10·7 M and 5 x 10·8 M ± 
bFGF for their effect on the proliferation of serum-starved confluent HUVEC (Fig. 5.9). 
The results showed that in the absence of bFGF, naringenin (5 x 10·7 M), 
dihydrokaempferol (5 x 10·8 M), dihydroquercetin (5 x 10·7 M), 7-hydroxycoumarin (5 
x 10·8 M) and flavanone (5 x 10·8 M) could enhanced cell proliferation. The 
introduction of bFGF into the system at a concentration of 12.5 ng/mL, resulted in an 
overall increase in cell proliferation. However, significant cell proliferation beyond that 
of the control was again observed for naringenin, 7-hydroxycoumarin and fla~anone. 
Further experiments were performed using naringenin and genistein at 5 x I 0-6 M to 
5 x 10·12 M using serum-starved confluent HUVEC ± bFGF (12.5 ng/mL). These 
experiments confirmed the results from the initial experiments for naringenin and 
genistein. · A much stronger proliferative response was observed with naringenin and it 
reached significant levels in the absence (5 x 10·6, 5 x 10·7, 5 x 10·8 and 5 x 10·9 M) and 
presence of bFGF (5 x 10·6 and 5 _x 10·7) (Fig. 5.10). These activities are comparable 
with the elevated pro-angiogenic activity of naringenin in the in vitro rat aorta assay. 
The results indicated that genistein in the absence of bFGF, at 5 x 10·7 M and 5 x 10·8 M 
did not significantly enhance cell proliferation. Interestingly, approached and reached 
statistically significant cell proliferation inhibition was observed at 5 x 10·6 M in the 
absence and presence of bFGF, respectively. The inhibitory effect did not reach 
significance for the rest of the genistein concentrations tested in the absence and 
presence ofbFGF (Fig. 5.11). 
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Figure 5.9. HUVEC proliferation assay of chosen tlavonoids at S x 10-7 M and S x 
10-8 M. 
Effect of seven chosen flavono ids at 5 x 10·7 M and 5 x 10·• M concentrations on confl uent serum-
starved HUVEC proliferation in serum free media "(SFM) with and without the mitogen bFGF ( 12.5 
ng/mL). Control cultures contained the same diluent dilution as the test compounds. Ce ll proliferation 
was measured as 3H thymidine incorporation after 24 hours incubation. Data analysis was performed by 
Student-Newman- Keuls test after one-way ANOY A comparing each group to control in each treatment. 
Error bars represent SEM (n~6). *, P '.S 0.05, **, '.S 0.01. A two-way ANOVA data analysis showed 
significant difference for all tested concentrations comparing their effect in SFM to SFM+bFGF ( 12.5 
ng/mL) treatments, P :S0.000 I. 
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Figure 5.10. HUVEC proliferation assay in the presence of naringenin. 
Effect of naringenin at concentrations from 5 x 10-6 M to 5 x 10-12 M, on confluent serum-starved 
HlNEC proliferation in serum free media (SFM) with and without the m1togen bFGF (12.5 ng/mL). 
Control cultures contained the same diluent dilution as the test compounds. Cell proliferation was 
measured as 3H thymidine incorporation after 24 hours incubation. Data analysis was performed by 
Student-Newman-Keuls test after one-way ANOV A comparing each group to control in each treatment. 
Error bars represent SEM (n~6). *, PS 0.05 , **, S 0.01. A two-way ANOVA data analysis showed 
significant difference for all tested concentrations comparing their effect in SFM to SFM+bFGF (12.5 
ng/mL) treatments, P S0.0001. 
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Figure 5.11. HUVEC proliferation assay in the presence of genistein. 
Effect of geni stein at concentrations from 5 x Io-• M to 5 x I 0- 12 M, on confluent serum-starved 
HUVEC proliferation in serum free med ia (SFM) with and witbout the mitogen bFGF ( 12.5 ng/mL). 
Control cultures contained the same diluent dilution as the test compounds. Cell proliferation was 
measured as 3H thymidine incorporation after 24 hours incubation. Data analys is was performed by 
Student- Newman- Keul s test after one-way ANOV A comparing each group to control in each treatment. 
Error bars represent SEM (n=6). *, P S 0.05. A two-way ANOY A data analysis showed significant 
difference for all tested concentrations comparing their effect in SFM to SFM+bFGF (12.5 ng/mL) 
treatments, P S0.000 l. 
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5.4.3. Effect of chosen flavonoids on endothelial cell migration (wound healing 
assay) 
As mentioned in chapter 4, cell migration was determined using a "wound healing" 
assay. The effect of the test compounds on the recovering wound was measured at 2 
hour intervals with confluent monolayers ofHMEC in 96-well plates. The results were 
then expressed as percentage wound confluence relative to the initial wound width. 
The application of the chosen flavonoids, naringenin-7-O-glucoside, 
dihydrokaempferol , dihydroquercetin, 7-hydroxycoumarin and flavanone at 5 x 10·6 M 
(Fig. 5.12), 5 x 10·7 M (Fig. 5.13) and 5 x 10·8 M (Fig. 5.14) concentrations, made no 
significant difference to the rate ofHMEC wound healing compared to control cultures. 
The effect of naringenin and genistein on HMEC wound recovery was determined 
separately at concentrations from 5 x 10·6 M to 5 x 10·12 M. Again no statistically 
significant effect on wound recovery was observed for either naringenin (Fig. 5.15) or 
genistein (Fig. 5.16). 
In conclusion, none of the flavonoids, at the tested concentrations, exerted any 
significant influence on the rate of wound healing of HMEC mono layer. 
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Figure 5.12. Effect of chosen flavonoids at 5 x 10·6 M on HMEC wound healing 
assay. 
Effect of chosen flavonoids at 5 x 10·• Mon wound recovery was measured as % wound confluence 
from O to 26 hours relative to the initial wound marks. Control cultures contained the same diluent 
dilution as the test compounds. Data analysis was performed by one-way and two-way ANOV A, 
comparing each group to control and other groups. Error bars represent SEM (n= 12). No significant 
difference in cell adhesion was observed. 
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Figure 5.13. Effect of chosen flavonoids at 5 x 10-7 M on HMEC wound healing 
assay. 
Effect of chosen flavonoids at 5 x 10-7 Mon wound recovery was measured as% wound confluence 
from O to 26 hours relative to the initial wound marks. Control cultures contained the same diluent 
dilution as the test compounds. Data analysis was performed by one-way and two-way ANOVA, 
comparing each group to control and other groups. Error bars represent SEM (n~ 12). No significant 
difference in cell adhesion was observed. 
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Figure 5.14. Effect of chosen flavonoids ·at 5 x 10-8 Mon HMEC wound healing 
assay. 
Effect of chosen flavonoids at 5 x I 0-8 M on wound recovery was measured as % wound confluence 
from 0 to 26 hours relative to the initial wound marks. Control cultures contained the same diluent 
dilution as the test compounds. Data analysis was performed by one-way and two-way ANOV A, 
comparing each group to control and other groups. Error bars represent SEM (n= 12). No significant 
difference in cel l adhesion was observed. 
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Figure 5.15. Effect of naringenin on HMEC wound healing assay. 
Effect of naringenin at concentrations from 5 x 10-6 M to 5 x 10-12 M on wound recovery was 
measured as% wound confluence from O to 26 hours relative to the initial wound marks. Control cultures 
contained the same di luent dilution as the test compounds. Data analysis was performed by one-way and 
two-way ANOV A, comparing each group to control and other groups. Error bars represent SEM (n= 12). 
No significant difference in cell adhes ion was observed. 
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Figure 5.16. Effect of genistein on HMEC .wound healing assay. 
Effect of genistein at concentrations from 5 x 1 o·6 M to 5 x 10·12 M on wound recovery was measured 
as % wound confluence from O to 26 hours relative to the initial wound marks. Control cultures 
contained the same diluent dilution as the test compounds. Data analysis was performed by one-way and 
two-way ANOVA, comparing each group to control and other groups. Error bars represent SEM (n~J2). 
No significant difference in cell adhesion was observed .• 
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5.4.4. Effects of naringenin and genistein on endothelial cell differentiation (tube 
formation assay) 
As described in chapter 4, the in vitro formation of capillary-like tubes by endothelial 
cells on an appropriate basement membrane matrix is a powerful method to screen for 
various factors that promote or inhibit angiogenesis (Arnaoutova and Kleinman 2010). 
To determine the effect of naringenin and genistein on endothelial cell tube 
formation, in vitro HUVEC tube formation assays on a Matrigel plug were employed. 
HUVEC ( 4 x l 04 cells/well) were cultured on a Matrigel plug in 96 well plates and 
incubated at 37 °C in an IncuCyte incubator and observations were recorded every 2 
hours. 
Tube formation was evident after 2 hours of culture, and became complete in 12-18 
hours (Fig. 4.4). Cells lost their connections and started to die after 18 hours culture. 
Different stages in tube formation in control cultures and cultures treated with 
naringenin and genistein at concentrations from 5 x 10·6 M to 5 x 10·12 M were 
compared. 
Semi-quantitative analysis using the IncuCyte software and the NIH ImageJ software 
was established to measure the capacity of test compounds to induce or inhibit tube 
formation by quantifying the percentage of denuded area, the number of sprouting cells 
at earlier time points (4 hours incubation), the number of tubes and the total tube length 
at later time points (6 hours incubation). 
The results showed that naringenin could enhance tube formation at a concentration 
of 5 x 10:7 M for all the characteristics tested but no significant effect was observed for 
the other tested concentrations (Fig. 5.17 and 5.18). Interestingly, genistein inhibited 
tube formation at 5 x I o·6 M by significantly reducing the number of tubes and sprouts, 
denuded area percentage (Fig. 5.19 and 5.20). 
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Figure 5.17. Effect of naringenin on HUVEC tube formation assay on Matrigel. 
Effect of naringenin, at a concentration of 5 x I 0·7 M on HlNEC tube formation was observed from 0 
to 24 hours. Control cultures contained the same diluent dilution as the test compounds. 
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Figure 5.18. Effect of naringenin on HUVEC tube formation assay on Matrigel. 
Effect of naringenin, at concentrations from 5 x 10·6 M to 5 x 10·12 M, on HUY EC tube formation was 
measured, as percentage denuded area (A), number of sprouting cells (B), number of tubes (C) and total 
tube length (D). Parameters shown in (A) and (B) were measured after 4 hours culture and in (C) and (D) 
after 6 hours culture. Control cultures contained the same diluent dilution as the test compounds. Data 
analysis was performed by Student- Newman-Keuls test after one-way ANOV A comparing each group to 
control in each treatment. Error bars represent SEM (n=6). *, P :S 0.05 , **, :S 0.01. 
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Figure 5.19. Effect of genistein on HUVEC tube formation assay on Matrigel. 
Effect of geoistein, at a concentration of 5 x 10-6 M on HUVEC tube formation was observed from 0 
to 24 hours. Control cultures contained the same diluent di lution as the test compounds. 
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Figure 5.20. Effect of genistein on HUVEC tube formation assay on Matrigel. 
Effect of genistein, at concentrations from 5 x I o-6 M to 5 x I 0· 12 M, on HlNEC tube formation was 
measured, as percentage denuded area (A), number of sprouting cells (B), number of tubes (C) and total 
tube length (D). Parameters shown in (A) and (B) were measured after 4 hours culture and in (C) and (D) 
after 6 hours culture. Control cultures contained the same diluent di lution as the test compounds. Data 
analysis was performed by Student-Newman- Keuls test after one-way ANOV A comparing each group to 
control in each treatment. Error bars represent SEM (n~6). •, P :S 0.05, **, :S 0.0 I. 
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5.4.5. Effect of naringenin and genistein on endothelial cell adhesion (Rose Bengal 
assay) 
As described in chapter 4, cell adhesion to ECM components fibronectin and 
vitronectin was determined by using a Rose Bengal adhesion assay and endothelial cells 
(HMEC). Optimisation of the fibronectin and vitronectin concentrations required to coat 
microwells for maximal cell adhesion are depicted in Fig. 4.11. The coating 
concentrations of fibronectin and vitronectin were established as IO and 5 µg/mL, 
respectively, where sub-optimal cell binding was observed. These conditions are 
optimal for detecting either enhancement or inhibition of cell adhesion. 
The ability of naringenin and genistein to affect the adhesion of HMEC to 
immobilised fibronectin was tested at concentrations ranging from 5 x I o-6 M to 5 x lo· 
12 M, after 30 minute and 60 minute incubations. The results showed that naringenin 
had no significant effect on HMEC binding to fibronectin after either 30 or 60 minutes 
incubation (Fig. 5.21). Similar cell adhesion experiments were performed using 
genistein. Genistein showed a slight effect in cell binding only at 5 x 10·7 M and after 
60 minutes incubation (Fig. 5.22). 
Experiments using synthetic FKl in the HMEC adhesion assay in chapter 4 showed 
that HMEC adhere much more slowly to immobilised vitronectin than fibronectin. 
Therefore, monitoring the first 30 minutes of cell-vitronectin binding when cell 
attachment occurs is very critical. Thus, the experiments were performed based on a 
time course covering 2.5 to 25 minutes. The results demonstrated that both naringenin 
(Fig. 5.23) and genistein (Fig. 5.24) had no significant effect on adhesion of HMEC to 
vitronectin. 
Overall, the results demonstrated that the pro-angiogenic activity of naringenin (5 x 
I o-6 M to 5 x 10·12 M) and genistein (5 x 10·7 M to 5 x 10·12 M) and the anti-angiogenic 
activity of genistein (5 x 10·6 M) were essentially unconnected to the adhesion of 
HMEC to fibronectin and vitronectin. 
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Figure 5.21. Effect of naringenin on fibronectin-mediated HMEC cell adhesion. 
Effect of naringenin at concentrations from 5 x I o·6 M to 5 x I 0· 12 M, on cell adhesion was measured 
atfter 30 minutes (A) and 60 minutes (B) incubation as optical density of Rose Bengal staining of 
adherent ce ll s. Data analysis was performed by Student-Newman-Keuls test after one-way ANOVA 
comparing each group to control in each treatment. Error bars represent SEM (n=6). No significant 
difference in cell adhesion was observed. 
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Figure 5.22. Effect of genistein on fibronectin-mediated HMEC cell adhesion. 
Effect of genistein at concentrations from 5 x 1 o-6 M to 5 x I 0- 12 M on cell adhes ion was measured 
after 30 minutes (A) and 60 minutes (B) incubation as optical density of Rose Bengal staining of adherent 
cells. Data analys is was performed by Student- Newman- Keuls test after one-way ANOV A co mpari ng 
each group to control in each treatment. Error bars represent SEM (n~6). No significant difference in 
cel l adhesion was observed. 
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Figure 5.23. Time course of effect of naringenin on vitronectin-mediated HMEC 
cell adhesion. 
Effect of naringenin, at concentrations from 5x 10·6 M to 5x !0"12 M, on cell adhesion was measured, 
using plates coated with 5 µg/rnL vitronectin and following 2.5-25 minute incubation, as optical density 
of Rose Bengal staining of adherent cells. Data analysis was performed by one-way and two-way 
ANOVA, comparing each group to control and other groups. Error bars represent SEM (n=4). No 
significant difference in cell adhesion was observed. 
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Figure 5.24. Time course of effect of genistein on vitronectin-mediated HMEC cell 
adhesion. 
Effect of geni stein, at concentrations from 5x I0-6 M to 5x 10·12 M , on cell adhes ion was measured, 
using plates coated with 5 µg/mL vitronectin and following 2.5-25 minute incubation, as optical density 
of Rose Bengal staining of adherent cells. Data analysis was performed by one-way and two-way 
ANOVA, comparing each group to control and other groups. Error bars represent SEM (n~4). No 
significant difference in cell adhesion was observed. 
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5.5. Discussion 
Flavonoids belong to a large family of natural polyphenolic compounds that are 
commonly found in the human diet especially in fruits , vegetables and beverages such 
as tea and red wine (Aheme and O'Brien 2002). Flavonoids have been studied for a 
variety of biological activities in humans including their anti-allergic, anti-
inflarnmatory, anti-microbial and anti-oxidant activities as well as their preventive 
effects on cancer and cardiovascular disease (Ren, Qiao et al. 2003). 
Compounds used to treat cancer are usually designed either to be cytotoxic or are 
directed at starving the tumour of its blood supply through their anti-vascular or anti-
angiogenic effects. However, these effects, especiall y for flavonoid s, have often been 
studied at un-physiologically high concentrations in both in vitro and in vivo 
experiments and their structure activity relationship has remained poorly defined for 
their biological effects at physiologically concentrations (Middleton, Kandaswami et al. 
2000; Havsteen 2002; Monasterio, Urdaci et al. 2004; Touil, Fellous et al. 2009; Lam, 
Alex et al. 2012). 
Regarding the positive effects of flavonoids on preventing ischemic stroke and 
coronary heart di sease, the pro-angiogenic effect of flavonoids are of interest in this 
thesis. The purpose of this work therefore, was to identify the pro-angiogenic activity 
of the two most anti-angiogenic and bioactive flavonoids , genistein and naringenin, at 
concentrations that encompass those found in human plasma (5 x 1 o·6 M to 5 x 10·12 M) 
and to study their cellular mode of action in angiogenesis in addition to determining 
some structural motifs of flavonoids required for their pro-angiogenic activity. An in 
vitro rat aorta pro-angiogenesis assay was employed to screen for the pro- and anti-
angiogeni~ activity of the test compounds. Although in vitro angiogenesis assays can 
be carried out rapidly and can provide initial valuable information, a large number of 
assays are required to counter the considerable degree of variability inherent in 
biological assays. 
Initially, a series of eighteen flavonoids were screened with the in vitro rat aorta pro-
angiogenesis bioassay at concentrations of 5 x 10·7 and 5 x 10·8 M which, as discussed 
earlier, are more likely to represent the physiological plasma concentrations derived 
from a normal diet. 
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The structural elements of the flavonoids which seem to be critical for their pro-
angiogenic activity include the C4-oxo (C4=O) functional group conjugated with the 
C2-C3 double bond (Fotsis, Pepper et al. 1997; Schindler and Mentlein 2006) as found, 
for example, in the flavones (e.g., apigenin), isoflavones (e.g., genistein) and flavonols 
(e.g., quercetin) (Table 1.1 and 5.2). Interestingly, genistein with a C2-C3 double bond 
and naringenin without this bond both enhanced the angiogenesis activity at 5 x 10-7 M 
and 5 x 10-8 M (Fig. 5.2). To our knowledge this is the first time that these flavonoids 
have been tested at physiological concentrations (µM range and under) in a pro-
angiogenesis assay. 
The anti-angiogenic activity of genistein (1-250 µM) and the anti-tumour effect of 
naringenin (10,100 and 200 µM) has been reviewed for concentrations higher than 1 
µM (Fotsis, Pepper et al. 1995; Manthey and Guthrie 2002; Buchler, Reber et al. 2004; 
Sasamura, Takahashi et al. 2004; Zhang, Du et al. 2009). Therefore, genistein, 
naringenin and five other flavonoids were selected for testing with the in vitro pro-
angiogenesis assay at 5 x 10-6 M (Fig. 5.5). Interestingly none of the tested flavonoids 
showed significant pro-angiogenic activity. The notable point was that genistein showed 
anti-angiogenic activity at 5 x 10-6 M, and most interestingly enhanced angiogenic 
activity at 5 x 10-7 M and 5 x I o-8 M, which shows dose dependent activity for this 
flavonoid. 
Because of the difference in the angiogenic activity of genistein, at 5 x 1 o-6 M 
compared to 5 x 10-7 M and 5 x I o-8 M, and to examine whether genistein can inhibit 
angiogenesis at high µM concentrations, as reported in many other studies (Fotsis, 
Pepper et al. 1993 ; Fotsis, Pepper et al. 1995; Buchler, Reber et al. 2004; Banerjee, Li et 
al. 2008), it was tested in the in vitro anti-angiogenesis rat aorta assay at 1 x 10-4 M and 
2 x 10-4 M and shown to have a very significant dose dependent angiogenesis inhibitory 
effect which confirmed the observations reported previously (Fig. 5.6). 
Seven selected pro-angiogenic flavonoids were also further tested for pro-angiogenic 
effects at 5 x 10-7 Mand 5 x 10-8 M, with or without additional bFGF (12.5 ng/mL), to 
assess the effect of flavonoids on bFGF-stimulated angiogenesis. The results showed 
that adding extra bFGF did not have any positive effect on pro-angiogenic activity and 
the tested compounds showed more significant activity in the absences of extra bFGF 
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demonstrations that the 5% HIFCS used in the rat aorta pro-angiogenesis assay has 
enough bFGF to support the activity oftest compounds (Fig. 5.3 and 5.4). 
The C3-OH and C2-C3 double bond (flavanol) structural features, which were 
reported to have a positive effect on the anti-angiogenic activity (Fotsis, Pepper et al. 
1997), were confinned in our tests since quercetin and kaempferol showed no 
significant pro-angiogenic activity but the activity reached significant levels in the 
absence of the C2-C3 double bond in dihydroquercetin and dihydrokaempferol. 
Another example of this was found with apigenin and naringenin, with naringenin 
lacking the C2-C3 double bond and exhibiting significantly enhanced pro-angiogenic 
activity compared to apigenin (Schindler and Mentlein 2006). Also, when comparing 
the activity of isoflavone and 7-methoxy isoflavone, a positive effect of C7-OCH3 on 
anti-angiogenic activity was demonstrated (Lam, Alex et al. 2012). 
In our tests, generally acacetin with C7-OH, CS-OH and a methoxy group at C4' 
(C4'-OCH3) showed more pro-angiogenic activity (only at 5 x 10"7M) compared to 
apigenin with C7-OH, CS-OH and C4'-OH (Fig. 5.2). These data suggest that C7-OH 
may enhance angiogenesis when it is accompanied by a methoxy group at C4' on the 
flavonoid B ring. Moreover, the angiogenic effect of OH groups at C3' and C4' was 
investigated by comparing the pro-angiogenic activity of dihydroquercetin (C3'-OH and 
C4'-OH) with dihydrokaempferol (C4'-OH). The positive effect of (C3'-OH and C4'-
OH) on the anti-angiogenic activity was confirmed when dihydroquercetin showed less 
pro-angiogenic activity compared to dihydrokaempferol (Fotsis, Pepper et al. 1997). 
In our experiments, glycosylation at C7 had no significant effect on the pro-
angiogenic activity of naringenin and naringenin-7-O-glucoside, consistent with the 
results of Lam that glycosylation does not affect the anti-angiogenic activity of high 
concentrations of flavonoids (Lam, Alex et al. 2012). 7-hydroxycoumarin with two 
phenolic rings and 2, 5-dihydroxy-1 ,4-benzoquinon with one phenolic ring were tested 
as a model for A and C, and C phenolic rings in a flavonoid structure, respectively. The 
significant pro-angiogenic activity of these two compounds shows the importance of 
both A and C phenolic rings in pro-angiogenic activity; although, 7-hydroxycoumarin 
showed slightly greater pro-angiogenic activity. 
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As angiogenesis is a complex and highly regulated process, several in vitro assays 
modelling major steps in this process have been employed to investigate the mode of 
action of naringenin and genistein and five other pro-angiogenic flavonoids (dihydro 
quercetin, dihydro kaempferol , ?-hydroxy coumarin, naringenin-7-O-glucoside, 
flavanone). The steps involved in angiogenesis, including cell proliferation, migration 
and tube formation, can be studied in vitro and these steps represent possible 
intervention targets for these angiogenesis modifying compounds (Auerbach, Lewis et 
al. 2003). 
Initially, cell proliferation assays were conducted using serum-starved HUVEC in the 
presence and absence of bFGF (12.5 ng/mL). The rationale behind using bFGF, a 
potent mitogenic and pro-angiogenic growth factor, was to explore whether the test 
compounds can modify the mitogenic activity of bFGF. Sub-optimal concentrations of 
bFGF (12.5 ng/mL) were used (as in Chapter 4) to permit the enhancing or inhibiting 
effects of test compounds to be measured. Naringenin showed significant elevation in 
endothelial cell proliferation without bFGF and when adding bFGF, naringenin, 7-
hydroxycoumarin and flavanone showed significant enhancement in cell proliferation at 
5 x 10·7 M or 5 x 10·8 M (Fig. 5.9). These results are comparable with a study 
performed by Comalada, suggesting the absence of the C2-C3 double bond reduced the 
anti-proliferative effect of flavonoids used at high concentrations (Comalada, Ballester 
et al. 2006). 
In separate experiments using naringenin at concentrations from 5 x 10·6 M to 5 x 
10·12 M, significant mitogenic effects at concentrations from 5 x 10·6 M to 5 x 10-9 M, 
in the absence or presence of bFGF were observed which suggests a strong mitogenic 
effect ofnaringenin on endothelial cells (Fig. 5.10). In contrast, genistein in a similar 
test significantly inhibited HUVEC cell proliferation in the presence and absence of 
bFGF at 5 x 10·6 Mand showed no significant enhancement of proliferation at 5 x 10·7 
M and 5 x 1 o-8 M (Fig. 5.11 ). Also, in the presence of bFGF, the proliferative activity 
of genistein was less than the control for all tested concentrations which confirms the 
previous results showing genistein inhibits bFGF stimulated proliferation by inhibiting 
bFGF activity through attenuation of the activity of tyrosine kinases (Fotsis, Pepper et 
al. 1993; Fotsis, Pepper et al. 1995). Significantly enhanced proliferation induced by 
naringenin is comparable with the enhancement of angiogenesis by naringenin at almost 
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all concentrations tested and the anti-proliferative activity of genistein supports the 
results of inhibition of the overall process of angiogenesis by genistein at 5 x 10-6 M. 
However, additional studies revealed that naringenin can significantly inhibit 3T3 
mouse fibroblast proliferation (non-EC) at 5 x 10-6 M and 5 x 10-7 M in a dose 
dependent manner (Fig. 5.25A). It seems, therefore, that the effects of naringenin on 
cell proliferation are cell type-specific. Also, genistein showed approached statistically 
significant inhibition of 3T3 mouse fibroblast proliferation at 5 x 10-6 M (Fig. 5.25B). 
These results are compatible with studies claiming naringenin and genistein as anti-
proliferative agents on cancer cell lines (Fotsis, Pepper et al. 1995; Shao, Alpaugh et al. 
1998; Elattar and Virji 2000; Manthey and Guthrie 2002; Banerjee, Li et al. 2008; 
Zhang, Du et al. 2009; Qi, Weber et al. 2011). 
In our study, none of the tested flavonoids showed significant enhancement or 
inhibition of endothelial cell migration/wound healing responses on a wounded 
confluent HMEC monolayer. Also, naringenin and genistein did not affect HMEC cell 
adhesion to the ECM components fibronectin and vitronectin. Interestingly, genistein 
could inhibit HUVEC tube formation at 5 x 10-6 M while naringenin could enhance this 
activity at 5 x 10-7 M. 
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Chapter 5 
Effect of naringenin and genistein on 3T3 mouse fibroblast 
proliferation assay. 
Effect of naringenin (A) and genistein (B) at concentrations from 5 x 10·• M to 5 x 10· 12 M on 
confluent s·erum-starved 3T3 mouse fi broblast pro li fera ti on in serum free media (SFM) with and without 
the mitogen bFGF (12.5 ng/mL). Control cultures contained the same diluent dilution as the test 
compounds. Cell proliferation was measured as 3H thymidine incorporation after 24 hours incubati on. 
Data analys is was performed by Student-Newman-Keu ls test after one-way ANOY A comparing each 
group to control in each treatment. Error bars represent SEM (n- 6). ***, S 0.00 1. A two-way ANOVA 
data analysis showed significant difference for all tested concentrations comparing their effect in SFM to 
SFM+bFGF (12.5 ng/mL) treatments, P S0.000 1. 
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In previous studies, the ability of genistein to inhibit bFGF induced endothelial cell 
migration was reported by Fotsis; however, the concentrations used were un-
physiological at 100 µM (Fotsis, Pepper et al. 1995). Genistein, has also been reported 
to induce cell-integrin (fibronectin) interactions and to decrease the rate of metastasis in 
prostate cancer 2 hours after adding 20-50 µM and 3 days after adding 1 µM of 
genistein, respectively (Bergan, Kyle et al. 1996; Lakshman, Xu et al. 2008; Pavese, 
Farmer et al. 2010). Inhibition of endothelial cell tube formation by genistein also has 
been reported but again this was at an un-physiological concentration of 150 µM 
(Fotsis, Pepper et al. 1993; Fotsis, Pepper et al. 1995). 
Naringenin has been reported in a number of studies to inhibit cell proliferation in a 
variety of cell types, but the effect of naringenin on cell migration and tube formation 
has not been explored in depth previousely. It has been shown that naringenin can 
inhibit the migration of Dictyostelium cells (a model for identifying cellular processes in 
health and disease including cell migration (Egelhoff and Spudich 1991) at 50 µM 
(Russ, Martinez et al. 2006). Oral administration of naringenin (I 00 mg/kg) in mice 
with breast cancer significantly decreased the number of lung metastatic colonies 
compared to control groups (Qin, Jin et al. 2011). However, naringenin had no effect 
on colon epithelial cell migration in a non-tumourigenic cell line at 1, 50 and 300 µM 
(Fenton and Hord 2004). There has been little work done on the effect ofnaringenin on 
integrin-ECM interactions but naringenin has been shown to possess anti-fibrotic 
properties by decreasing ECM expression in rat hepatic stellate cells and fibrotic 
progression at 50 µM (Liu, Wang et al. 2006). Another study showed that naringenin 
can inhibit ECM production by nasal polyp-derived fibroblasts at 40 µM (Jung, Park et 
al. 2012) and it has also been shown that oral administration of 10 µM of naringenin 
(plasma \evels 2-6 µM) for 21 days can significantly decrease the metastatic frequencies 
of B16-Fl0 melanoma cells by enhancing cell-cell and cell-ECM adhesion (Lentini, 
Forni et al. 2007). 
In conclusion, the results obtained with an in vitro rat aorta pro-angiogenesis assay 
and 18 flavonoids demonstrated that some of the flavonoids exhibited either pro- or 
anti-angiogenic activity at physiological concentrations (5 x 10·7 M and 5 x 10·8 M). 
We also confirmed the critical effect of the C2-C3 double bond conjugated with C4=O 
on anti-angiogenic activity. Also, positive effects of C3'-OH and C4'-OH, C7-OCH3 
and C3-OH on anti-angiogenic activity were demonstrated, especially when these 
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structural motifs are combined with the C2-C3 double bond. The isoflavonoid, 
genistein, inhibited in vitro angiogenesis at 5 µM and exhibited pro-angiogenic activity 
at sub-µM concentrations (5 x 10-7 M and 5 x 10-s M). The anti-angiogenic effect of 
genistein at 5 x I o-6 M was supported by the observed anti-proliferative and inhibition 
of tube formation activities. In contrast, the flavanone, naringenin, enhanced pro-
angiogenic activity at 5 x 10-7 M to 5 x 10-11 M. This activity was supported by its 
strong mitogenic activity, with or without bFGF (12 .5 ng/mL), on HUVEC and its 
ability to enhance HUVEC tube formation at 5 x 10-7 M. 
The key conclusion from these findings is that some dietary flavonoids may exhibit 
pro-angiogenic activity at their physiological plasma concentrations. Thus, a normal 
diet containing a moderate level of vegetables and fruit may result in therapeutic 
angiogenesis which could help ischemic conditions such as stroke and heart disease. 
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174 
Chapter 6 
6.1. Final discussion 
Plant natural products and their derivatives continue to be invaluable sources of 
therapeutic agents to enhance human health and to treat disease (Koehn and Carter 
2005). This thesis has identified new potential therapeutics that regulate angiogenesis. 
The process of angiogenesis involves the formation of new blood vessels from pre-
existing blood vessels. Angiogenesis is a tightly controlled process and either excessive 
or insufficient angiogenesis has been associated with many diseases. For example, 
excessive angiogenesis contributes to tumour progression, psoriasis, blindness induced 
by age-related macular degeneration (AMD) and arthritis (Folkman 2000; Carmeliet 
2003; Folkman 2007). On the other hand, insufficient angiogenesis leads to 
physiological conditions including hypertension, impaired wound healing (Tonnesen, 
Feng et al. 2000; Bao, Kodra et al. 2009) and various ischemic conditions such as 
cardiovascular disease (Pandya, Dhalla et al. 2006) and stroke (Beck and Plate 2009; 
Font, Arboix et al. 2010). 
In 1971 Folk.man introduced the concept of "anti-angiogenesis" as a therapeutic 
strategy and since then a diverse and extensive range of anti-angiogenic molecules have 
been isolated, identified and tested in clinical trials (Pezzuto -1997; Newman 20 I I). 
However, pro-angiogenic drugs are less well researched and only a limited number have 
been studied in clinical settings. Therefore, the aim of this research was to screen for 
natural products with pro-angiogenic activity·using an activity-guided bioassay strategy 
to purify and isolate sufficient material to enable their identification and to study their 
cellular mode of action using human cell lines in a series of in vitro angiogenesis 
assays. 
There is a substantial body of correlative studies associating the consumption 
soybeans (Glycine max) with a number of health benefits (Barnes 1998; Tham, Gardner 
et al. 1998). Soybeans are a rich source of tlavonoids with anti-oxidant and 
phytoestrogen properties and preliminary studies in the Djordjevic and Parish 
laboratories had indicated that they may also be a source of compounds with the ability 
to either enhance or inhibit angiogenesis to different extents (Du Fall 2009). Therefore, 
the work described in this thesis was directed at isolating and identifying these active 
components from soybean xylem sap and studying their cellular mode of action. It was 
also decided to examine the pro-angiogenic activity and structure-activity relationship 
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of a selection of tlavonoids, including naringenin and genistein, that also occur in 
soybeans but to test these at concentrations likely to be achieved in plasma following 
dietary consumption. 
6.2. Major research findings of this thesis 
6.2.1. Screening, fractionation and structural elucidation of compounds from 
soybean xylem sap that promote angiogenesis 
Soybeans were cultured under several regimes and the relative abundance of 
substances in the fractionated xylem sap material was found to be quite varied. As a 
subtropical plant, ideal growth conditions in glasshouses were limited to the warmer 
months with a long day length. The optimisation of the yield of pro-angiogenic 
materials was not systematically pursued but, generally, the more robust the plants 
grew, the higher the relative yield of xylem sap and pro-angiogenic activity. Plants 
fertilised with 10 mM KNO3 produced a higher abundance of angiogenic-active 
metabolites than plants that relied on symbiotic nitrogen fixation as the major source of 
organic nitrogen (Fig. 3.3A and 3.3B). The successive use of 10 kDa and 3 kDa 
molecular weight spin filters and HPLC in combination with an in vitro rat aorta 
bioassay was used to size fractionate the material and guide the collection of three 
fractions (FKl , FK2 and P6) from xylem sap (Fig. 3.3). However, P6 appeared to be of 
low and variable abundance and poor stability. In contrast, approximately 400 µg of 
FKl and FK2 was obtained following semi-preparative HPLC (C1 8) (Fig. 3.7). 
Structural elucidation using NMR (1H and 13C) and high resolution accurate mass 
LC/MS, showed the pro-angiogenic compounds to be erythro-guaiacylglycerol-8-O-4'-
coniferyl_ alcohol (FKl) , and threo-guaiacylglycerol-8-O-4'-coniferyl alcohol (FK2) 
(Fig. 3.10 and 3.1 l and Table 3.2 and 3.3). 
FKl and FK2 are both lignans and are derived from the free radical dimerisation of 
monolignols which are the precursors of the structural element lignin in plant secondary 
cell walls. Lignans are formed in plants firstly by the production of glycosylated 
monolignols in the cytoplasm from phenylalanine and these molecules are then 
transported through the cell membrane to the apoplast. Polymerisation is thought to 
begin after the removal of the glycosyl group (Boerjan, Ralph et al. 2003). The lignans 
isolated in this thesis are dimeric derivatives that apparently accumulate to appreciable 
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levels in the xylem sap before being polymerised to lignin. These compounds would 
therefore be expected to occur to some extent in the vascular tissue of soybeans and be 
present in leaves, stems and possibly roots. It is not known to what extent these 
compounds would occur in the edible part of soybeans (the bean). 
It is interesting to note that both FKJ and FK2 conform to the physico-chemical 
parameters outlined by Lipinski (1997) in his Rule of Five for desirable oral drug 
properties. FKJ and FK2 possessed a HBD = 4 (:S: 5), HBA = 7 (:S: 10), M, = 376 (:S: 500 
Da), logP = 1.58 (:S: 5). These values were derived using the online calculator available 
at http://www.vlsd.com/JME EditorOK.dir/run jlogp.html, accessed 2nd April 2013. 
The physico-chemical parameters of FKJ and FK2 are also in conformity with some of 
the more stringent requirements that have since been developed (see section 1.3 in 
Chapter 1), with logP = 1.58 (:S: 3), PSA = 108.6 (:S: 140 A2) (values obtained using the 
online calculator available from http://www.molinspiration.com/cgi-bin/properties, 
accessed 2nd April 2013). Although the number of rotatable bonds at 9 is clearly higher 
than desirable (:S: 3), this is the only parameter which shows a less than ideal value. 
6.2.2. Determination of the cellular mode of action of FKJ and FK2 using human 
cell lines 
In chapter 4, following the identification and structural determination of FKJ and 
FK2 from soybean, synthetic FKJ and an independently derived natural source of FK2 
(isolated from Bretschneidera sinensis) were obtained firstly to confirm their pro-
angiogenic activity and secondly, to study the cellular mechanism of their ability to 
modulate angiogenesis. The in vitro pro-angiogenesis assay (testing concentrations in 
the rang~ of 5 x 10·6 M to 5 x 10·9 M) confirmed that the newly obtained FKJ and FK2 
possess essentially identical pro-angiogenic activity to the soybean-derived compounds 
(Fig. 4.2). Interestingly, the pro-angiogenic activity increased from 5 x 10·6 M to 5 x 
10·8 M which might suggest that using higher concentrations (i.e., > µM) may not 
increase their pro-angiogenic activity as ANOV A analysis of FK2 cell proliferation 
showed a significant difference between 5 x 1 o·6 M to 5 x 1 o·8 M and 5 x 10·9 M in the 
presence ofbFGF. Moreover, as mentioned in chapter 4, both, FKJ and FK2 have been 
previously found to have cytotoxic and chemo-preventative effects on human colon 
carcinoma, human hepatocellular carcinoma and prostate cancer in the high µM range 
(80 to 150 µM) of concentrations (Lee, Song et al. 2007; Han, Wang et al. 2008). 
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Indeed, higher concentrations of FKl and FK2 may prove inhibitory or toxic, so it is 
important to determine the therapeutic range of these molecules. 
The cellular mode of action of synthetic FKl and naturally derived FK2, was 
investigated using several in vitro assays modelling the major steps in angiogenesis, 
including endothelial cell proliferation, migration, tube formation and adhesion to ECM 
components (fibronectin and vitronectin) (section 4.4.1 to 4.4.5). It was found that 
these compounds can significantly enhance HUVEC endothelial cell proliferation 
(mainly in the presence of bFGF) and HUVEC and HMEC tube formation on an 
artificial ECM, Matrigel. However, they did not affect HMEC migration and adhesion 
to fibronectin and vitronectin. Therefore, the proposed mechanism of action for pro-
angiogenic activity of these compounds is the possible potentiation of the potent 
mitogen, bFGF and its downstream signalling. 
The synthetic FKl was also tested in an anti-malaria drug bioassay but no inhibitory 
effect on Plasmodium viability at concentrations from 10·4 M to 10·14 M was found 
compared to the well-known anti-malaria drug, artemisinin. This confirms the study by 
Ma et al. (2006) who showed that an HPLC fraction containing both FKl and FK2 from 
Grewia bilamellata had no anti-malaria effect against P.faciparum (Ma, Zhang et al. 
2006). 
6.2.3. Investigate the pro-angiogenic activity and structure-activity relationship, 
at physiological concentrations, of a selection of flavonoids, including naringenin 
and genistein 
Flavonoids have been studied for a variety of beneficial biological activities m 
hwnans including prevention of cardiovascular disease and anti-angiogenic activity 
(Ren, Qiao et al. 2003) . However, these effects have often been studied at high, non-
physiological, concentrations (high µM range) in both in vitro and in vivo experiments. 
Therefore, their structure-activity relationship has remained poorly defined at 
physiological concentrations (:S 1 µM) which would result from a diet containing 
normal levels of fruit and vegetables (Middleton, Kandaswami et al. 2000; Monasterio, 
Urdaci et al. 2004; Touil, Fellous et al. 2009; Lam, Alex et al. 2012). 
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In chapter 5, 18 tlavonoids (Table 5.2) were screened with an in vitro pro-angiogenic 
bioassay at physiological concentrations ranging from 5 x 10·7 M to 5 x 10·8 M and 
seven flavonoids (naringenin, genistein, naringenin-7-O-glucoside, dihydrokaempferol , 
dihydroquercetin, 7-hydroxycoumarin and flavanone) showed consistent pro-angiogenic 
activity. A key finding of this study was that none of the tested flavonoids were pro-
angiogenic at 5 x 1 o-6 M. Moreover, the isoflavonoid, genistein, inhibited in vitro 
angiogenesis at 5 µM and enhanced pro-angiogenic activity at sub-µM concentrations 
(5 x 10·7 M and 5 x 10·8 M). The angiogenesis inhibitory effect of genistein at 5 x 10·6 
M was supported by inhibition of 3T3 mouse fibroblast proliferation (Fig. 5.25B) as 
well as HUVEC proliferation and HUVEC tube formation activities and confirmed the 
results found by Akiyama et al. , 1987 and Fotsis et al., 1993 showing that genistein 
inhibits bFGF- and VEGF-driven endothelial cell proliferation, migration, and tube 
formation (Akiyama, Ishida et al. 1987; Fotsis, Pepper et al. 1993). Naringenin 
significantly promoted angiogenesis at concentrations of 5 x 10-9 M to 5 x 10·10 M (Fig. 
5.8). The results obtained from its strong mitogenic activity on HUVEC proliferation 
and HUVEC tube formation (Fig. 5.10), provided the evidence for this flavanone's pro-
angiogenic act1v1ty. However, naringenin could significantly inhibit 3T3 mouse 
fibroblast proliferation at 5 x 10·6 Mand 5 x W-7 M (Fig. 5.25A). 
The pro-angiogenic response of a series of 18 flavonoids revealed some important 
structural motifs that were important for activity at physiological concentrations (5 x 1 o· 
7 M and 5 x 10·8 M). The results confirmed that, for anti -angiogenic activity, the critical 
effect of the C2-C3 double bond being conjugated with C4=O. Also, flavonoids with 
C3'-OH and C4'-OH, C7-OCH3 and C3-OH with the C2-C3 double bond showed anti-
angiogenic activity. All flavonoids with no C2-C3 double bond showed significant pro-
angioge~c activity, including hesperetin and the seven flavonoids mentioned above. 
6.3. Future directions 
As described in chapter 1, angiogenesis is a complex and highly regulated process. 
The studies performed in this thesis identified two groups of pro-angiogenic molecules, 
FKJ and FK2 (neolignans), and genistein and naringenin (flavonoids), each group 
appearing to have novel mechanisms of action. In order to investi gate their mode of 
action in more details and also discover the other structural related molecules that 
possess pro-angiogenic activity, further experiments are suggested. 
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6.3.1. In vivo angiogenesis bioassay 
In this thesis an in vitro rat aorta angiogenesis bioassay was employed to screen for 
compounds with pro-angiogenic activity. As mentioned in chapter I (section 1.10), in 
vitro angiogenesi s assays are the most valuable first step in identifying compounds that 
modulate angiogenesis. However, in vivo assays provide a more comprehensive insight 
as to how the test compounds might affect the angiogenic process. Therefore, in order 
to validate the in vitro angiogenesis results obtained from FKJ and FK2, and also 
genistein and naringenin at sub-µM concentrations, in vivo angiogenesis assays in 
animal models such as chick chorioallantoic membrane (CAM) and Matrigel plug 
assays could be used (Auerbach, Lewis et al. 2003). Recently, biologically-active Nod 
factor and Nod factor-like compounds were tested in an in vivo Matrigel plug assay in 
collaboration with Professor Levon Khachigian, at UNSW. In this assay, a series of 
individual Matrigel plugs containing different Nod factors were assayed against a bFGF 
containing control to confirm the in vitro pro-anti-angiogenic activity of the test 
compounds (Djordjevic, Bezos et al. 2013). It would be interesting, therefore, to extend 
our study to look at the in vivo angiogenic activity of FKJ and FK2. 
6.3.2. Studies on FK2, and FKJ and FK2 analogues 
As mentioned in chapter 4, following structural determination of soybean xylem-sap-
derived FKJ and FK2, FKJ was obtained from BOC Sciences, NY, USA and naturally 
derived FK2 (from Bretschneidera sinensis) was provided as a gift from Prof. Dr. Wei-
Dong Zhang and Dr. Shan Lei from the Second Military Medical University, Shanghai, 
China. Although, the observed angiogenic activity of FK2 was higher than FKJ (Fig. 
4.2 and 4- 3), the quantity of FK2 provided was not sufficient to complete the cellular 
mode of action studies. In theory, the 8-0-4' coupling of coniferyl alcohol could result 
in forming a total of four stereo isomers, the erythro-7S, 8S/7R, SR and threo-7R, 
8S/7S, SR. Based on the greater effects observed with FK2 it would be of interest to 
complete the cellular mode of action studies of FK2 and also to examine the individual 
stereoisomers for pro-angiogenic activity (Fig. 3.9). 
Indeed it would be interesting to test other members of the large lignin family of 
compounds (Fig. 3.13), particularly the lignans (C8-C8' dimers) which are the most 
abundant dimers in dietary food (Fig. 4.17) tUmezawa 2007) and which have been 
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shown to be converted to mammalian lignans after digestion by the microflora in the 
human large intestine (Fig. 4.18) (Heinonen, Nurmi et al. 2001). These molecules have 
already demonstrated a wide range of bioactivity in humans, including anti-breast, colon 
and prostate cancer, oestrogenic and anti-oestrogenic activities, anti-inflammatory 
activity and positi ve effects on cardiovascular disease (Table 4.2). Therefore, the 
general chemical family of lignans and neolignans are also good candidates to be 
investigated for angiogenesis modulating activity. 
6.3.4. Other active xylem sap fractions 
Previously, it was shown that xylem sap contains both anti- and pro-angiogenic 
fractions (Du Fall 2009). This was followed up in this thesis by identifying the late 
eluting pro-angiogenic fractions (Fig. 3.1 , 3.2 and 3.3). The late eluting fractions (i .e. , 
the ones containing FKI , FK2 and P6) were examined because they were relatively less 
complex chemically. The P6 pro-angiogenic fraction was only partially characterised 
due to its low abundance and unstable nature. Several other fractions eluting at earlier 
times in the HPLC fractionation were not examined further because (a) they appeared to 
co-elute with other materials and, therefore, would be more difficult to purify and (b) 
they were more hydrophilic and hence less desirable from a potential therapeutic point 
of view. Therefore the active components in these fractions remain unidentified. It is 
possible that they may represent more hydrophilic derivatives of FKJ , FK2 and/or P6, 
but this remains to be determined. Nevertheless, these active fracti ons and P6 may be 
worthy of further exploration. 
6.3.S. Molecular mode of action studies 
6.3.5.1. Investigate the possible molecular targets and mechanisms affected by 
FK1/FK2 
Having established that FKJ and FK2 can significantly enhance endothelial cell 
proliferation (mainly in the presence of bFGF) and tube formation on an artificial ECM, 
it would be valuable to elucidate their molecular mode of action and to investigate the 
pro-angiogenesis phenomenon at the genetic and regulatory level. lt is possible that 
FKJ and FK2 potentiate the potent mitogen, bFGF and its downstream signalling and 
most possibly affect MAPK/PKC (mitogenic activity) in cell proliferation and the 
181 
Chapter 6 
laminin-integrin (a6~ 1) interaction in tube formation. Also, FKJ and FK2 might 
interfere with the bFGF mechanism of regulating angiogenesis by inducing MMP-2 and 
MMP-9 to degrade the ECM in the formation of sprouts or enhancing cell-cell adhesion 
via cadherins in tube formation (Fig. 6.2). In order to investigate the possible pathways 
affected by FKJIFK2 treatment, differential gene expression analyses (e.g., real-time 
RT-PCR, microarray or RNA-Seq technologies) could be used to determine the mRNA 
content of the endothelial cells and has been used to diagnose diseases such as cancer 
(Maher, Kumar-Sinha et al. 2009). They can provide information on gene alleles, 
differently spliced transcripts, post-transcriptional mutations or modifications and gene 
fusions (Maher, Kumar-Sinha et al. 2009). 
Furthermore, at the protein level, an analysis of post-translational modifications (e.g., 
phosphorylation analysis by mass spectrometry, photo affinity labelling and protein 
microarrays) can also be employed. Briefly, phosphorylation studies are able to identify 
which proteins are being activated by a certain treatment. Photo affinity labelling 
involves labelling the small molecule with either a tag which can be used to purify the 
protein to allow subsequent identification, or a photoreactive group (e.g., an azido 
moiety) that can be used to visualise the cellular location of the interacting protein. 
Protein microarrays consist of a chip which contains a support-surface such as a glass 
slide to which specific proteins are bound. The reaction between the probe (small 
bioactive molecules typically labelled with fluorescent moiety) and the immobilised 
protein emits a fluorescent signal which can be read by a laser scanner. 
Also, at the protein level, monoclonal antibodies (mAbs) tagged with a marker (e.g. , 
enzyme in ELISA) could also be employed to follow differential expression of a target 
protein. These techniques would also allow the gene expression profiles induced by 
MAPK, PKC, and their intermediate molecules and also a6-integrin expression to be 
quantified and compared in endothelial cells cultured with and without FKJ and FK2. 
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Figure 6.2. Possible FK1/FK2 potentiation of the potent mitogen, bFGF, and its 
downstream signalling in endothelial cell. 
In thi s thesis, it is suggested that FKJIFK2 affect MAPK and PKC signalling pathways required for 
full mitogenic activity and the laminin-integrin (o6P,) interaction in tube formation. Also, they may 
induce MMP-2 and MMP-9 production/activation to degrade the ECM as well as enh ancing cell-cell 
adhesion via cadheri ns during endothelial cell tube formation. 
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6.3.5.2. Investigate the effect of FKJ/FK2 on the affinity state of integrins 
FKJ and FK2 did not affect integrin-mediated ECM adhesion using fibronectin and 
vitronectin. However, this could be because integrins are already in a high affinity state 
in the cell lines used in the assays and, therefore, it would be difficult to assess the 
effect of pro-angiogenic compounds on inducing integrin affinity. This could be 
investigated by using cell lines in which the integrins are in an inactive state such as in 
freshly isolated HUVEC or resting lymphocytes. In order to investigate the effect of 
FKJIFK2 on the conformational state of integrins, mAbs can be used to distinguish the 
active and inactive conformations of integrins. In this regard, there are two types of 
mAbs available. The first group recognises the ligand-binding site of integrins in the 
active conformation due to their ability to compete for ligand binding (ligand-mimetic 
antibodies). The second group of antibodies recognises integrins that have already 
bound their ligand (anti-CUBS, fation-and-ligand influenced Qinding ~ite) (Bazzoni 
and Hemler 1998). Further experiments might include investigating the signalling 
pathways being activated by FKJIFK2 that could result in a conformational change in 
integrins, i.e., inside-outside signalling (Fig. 6.2). 
6.4. Conclusion 
This study has successfully identified and characterised two novel pro-angiogenic 
compounds, erythro-guaiacylglycerol-8-0-4'-coniferyl alcohol (FKJ), and threo-
guaiacylglycerol-8-0-4'-coniferyl alcohol (FK2) in soybean using an activity-guided 
fractionation approach. Both FKJ and FK2 could significantly enhance in vitro 
endothelial cell proliferation and tube formation on an artificial ECM, possibly by 
potentiat[ng the potent mitogen, bFGF and its downstream signalling. 
In addition, this thesis showed that two flavonoids (genistein and naringenin) that 
have been reported to be anti-angiogenic at high concentrations possess pro-angiogenic 
activity at lower (more physiologically relevant, sub-µM) concentrations using an in 
vitro rat aorta angiogenesis assay. These flavonoids and FKJ and FK2 have the 
potential to be developed for the therapeutic treatment of aberrant angiogenesis-related 
conditions such as cardiovascular disease, ischemia, stroke, chronic wounds and 
hypertension. 
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An intriguing question that arises from the work described in this thesis is; "Why 
should the neolignans be able to influence such a crucial process as angiogenesis?" It is 
possible that Toll-like receptors (TLRs) and ,other pattern recognition receptors (PRR) 
on the vascular endothelial cells that normally recognise pathogen-associated molecular 
patterns (PAMPs) are activated by bacterially derived molecules that are structurally 
similar to the neolignans. Clearly additional work is required to investigate this 
intriguing possibility. 
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"Soul of all souls, life of all life - you are That. 
Seen and unseen, moving and unmoving - you are That. 
The road that leads to the City is endless; 
Go without head and feet 
and you'll already be there 
What else could you be? - you are That." 
Rumi 
215 
